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Abstract 
Inherited thrombocytopenias are a heterogeneous group of disorders characterised 
by abnormally low platelet counts, often with secondary qualitative defects in platelet 
function, which can be associated with abnormal bleeding. Next generation 
sequencing has only previously been employed in small-scale studies and for the 
confirmation of suspected variants. This study presents the first large-scale approach 
to fully categorise inherited thrombocytopenia. Ninety-five patients were recruited to 
the UK-Genotyping and Phenotyping (GAPP) study with inherited thrombocytopenia 
of unknown genetic aetiology. An average platelet count of 88x109/L was observed 
across all individuals. Platelet function testing revealed a secondary phenotypic 
defect in addition to the reduction in platelet count in 71% (61/86). Of the 95 patients, 
69 patients, encompassing 47 index cases, were analysed by whole exome 
sequencing. A variant with a positive prediction of pathogenicity was identified in 40% 
(19/47) of patients and overall plausible candidate variants of disease were identified 
in 69% of index cases. Subsequently an inherited thrombocytopenia specific gene 
panel was developed to serve as a pre-screen for patients prior to whole exome 
sequencing. In total, candidate variants in genes previously known to be implicated 
with disease were identified in 77% (20/26) of patients analysed. In conclusion, the 
application of a combined phenotyping and genotyping approach to patients with 
inherited thrombocytopenia is an effective and efficient means of complete diagnosis. 
It also has the added benefit of identifying novel candidate variants in genes not 
previously known to cause disease that may further our understanding of the 
processes surrounding haemostasis through subsequent functional studies. 
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1. Introduction 
Inherited thrombocytopenias (ITs) are a heterogeneous group of disorders primarily 
characterised by a sustained reduction in platelet count. Clinically they manifest as a 
bleeding diathesis with varying severity, often dependant on the gene affected by 
genetic mutation and the presence of a secondary qualitative defect in platelet 
function. The pathophysiology behind a reduction in platelet count is often situational 
and to understand the variety within the group of disorders encompassed under IT it 
is often best to address the role of the individual genes and how their function can be 
disrupted. 
1.1. Megakaryopoiesis and thrombopoiesis 
Platelets are the cellular product of thrombopoiesis and fragmentation of their 
precursor cell, the megakaryocyte. Like all blood cells, megakaryocytes are derived 
from haematopoietic stem cells (HSCs) and are formed via progressively 
differentiated progenitor cells. This follows a process known as megakaryopoiesis, 
but can be described as a section of the broader process of haematopoiesis 
(Summarised in Figure 1.1.1).  
Haematopoiesis often occurs in unique microenvironment niches within the bone 
marrow that facilitate the self-renewal of HSCs as well as the initial differentiation into 
progenitor cells. There are at least two described niches within the bone marrow; the 
osteoblastic niche and the vascular niche (Taichman 2005). The osteoblastic niche 
refers to a subsection of the bone marrow next to the endosteal bone surface which 
is lined by osteoblasts. It is thought that this close connection to osteoblasts leads to 
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Figure 1.1.1 Schematic of the main steps of megakaryopoiesis. HSC – Haematopoietic Stem Cell, CMP – Common 
Myeloid Progenitor, MEP – Myelo-Erythroid progenitor 
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reciprocal connections between the two cell types creating an environment to 
maintain a quiescent stem cell population (Arai, Hirao et al. 2004; Passegue, Wagers 
et al. 2005). In contrast, the vascular niche consists of HSCs in close proximity to 
endothelial cells from fenestrated capillaries and is thought to promote proliferation 
and differentiation (Kopp, Avecilla et al. 2005). It is this mobilisation between niches, 
then, that is the driving force behind the differentiation of HSCs to haematopoietic 
progenitors. This is indeed true for the production of megakaryocytes, as the 
chemokine-mediated interaction between megakaryocyte progenitors and sinusoidal 
bone marrow endothelial cells (BMECs) is required for eventual thrombopoiesis 
(Avecilla, Hattori et al. 2004).  
The first step for differentiation into megakaryocytes from HSCs is a commitment to 
the myelo-erythroid lineage and subsequent divergence from the myelo-lymphoid 
lineage. This first branch point in the two lineages gives rise to the common myeloid 
progenitor (CMP), a progenitor with the propensity to differentiate to 
megakaryocyte/erythrocyte or granulocyte/macrophage progenitors (Akashi, Traver 
et al. 2000). CMPs show a broad expression profile that shares similarities with both 
long and short-term HSCs with a relatively high expression of T-cell Acute 
Lymphocytic Leukaemia 1 (TAL1) but an increasing expression of the transcription 
factors Nuclear Erythroid, Factor 2 (NF-E2) and GATA binding protein 1 
(GATA1)(Akashi, Traver et al. 2000). CMPs can subsequently differentiate into one 
of the two progenitors; the megakaryocyte/erythrocyte lineage-restricted progenitors 
(MEPs) or granulocyte/macrophage lineage-restricted progenitors (GMPs). MEPs 
incorporate a number of progressively differentiated progenitor cells that retain bi-
potency and an altered expression profile with elevated GATA binding protein 2 
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(GATA2) as well as NF-E2 and GATA1 levels when compared with CMPs (Debili, 
Coulombel et al. 1996; Akashi, Traver et al. 2000).  
From this stage the commitment to the formation of megakaryocytes as opposed to 
erythrocytes is largely dependent on the expression of chemokines and transcription 
factors. One of the most important chemokines for the formation of megakaryocytes 
is thrombopoietin (TPO). Synthesised predominately in the liver, TPO is the 
megakaryocyte specific chemokine that primarily drives megakaryopoiesis and 
thrombopoiesis (Jelkmann 2001). TPO exerts its synergistic effect on megakaryocyte 
production through the homodimerisation of its receptor; the cellular homologue of 
the myeloproliferative leukaemia virus oncogene (c-Mpl), which is one of the 
definitive cell surface markers of early differentiation along the myelo-erythroid 
lineage (Kaushansky, Lok et al. 1994; Akashi, Traver et al. 2000). It works in a dose-
dependent manner, allowing for progression of HSCs to CMP and MEP progenitors 
and subsequently burst-forming unit-megakaryocytes (BFU-MKs) and colony-forming 
unit-megakaryocytes (CFU-MKs), the primitive and mature lineage specific 
progenitors, respectively (Harker, Marzec et al. 1996; Kaushansky 2008). However, 
TPO exerts an effect throughout haematopoiesis suggesting that downstream TPO-
signalling coupled with non-TPO signalling is important for the production of mature 
megakaryocytes (Solar, Kerr et al. 1998; Fox, Priestley et al. 2002). Indeed, 
alternative signalling pathways such as the SDF1/CXCR4 axis, Src family kinases, 
integrin signalling and platelet factor 4 (PF4) related signalling have also been shown 
to play a role in in vitro and in vivo megakaryopoiesis and thrombopoiesis (Yu and 
Cantor 2012).  
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Additionally, transcription factors also play a critical role in allowing lineage specific 
progression. The transcription factor Runt-related transcription factor 1 (RUNX1) acts 
a master regulator of haematopoiesis.  It plays a crucial role in the maintenance, 
proliferation and differentiation of HSCs due its localisation, transactivation and ability 
to act as a micro-RNA hub throughout haematopoiesis (North, Stacy et al. 2004; 
Dowdy, Xie et al. 2010; Rossetti and Sacchi 2013). One of the main downstream 
transcriptional targets of RUNX1 is the transcription factor PU.1 (Imperato, Cauchy et 
al. 2015). This is expressed in the myelo-lymphoid lineage in a mutually exclusive 
pattern to GATA1 which is increasingly expressed during megakaryopoiesis in the 
myelo-erythroid lineage (Arinobu, Mizuno et al. 2007). This variance in differentiation 
patterns is maintained within megakaryocyte fated progenitors due to functional 
cross-antagonism of the transcription factors Friend Leukaemia Integration 1 
transcription factor (FLI1) and Kruppel-Like Factor 1 (Erythroid) (KLF1) (Starck, 
Cohet et al. 2003). Additional transcription factors such as; ETV6, FOG1 and SRF 
with its co-factor MKL1, in tandem with the transcriptional repressor GFI1B, ensure 
maturation of the megakaryocyte by binding promoter regions in megakaryocyte 
expressed genes (Tijssen and Ghevaert 2013; Foudi, Kramer et al. 2014).  
In the production of platelets megakaryocyte precursors have to undergo two further 
steps; endomitosis and proplatelet formation. Endomitosis is the process in which 
committed megakaryoblasts develop progressively larger and become polyploid 
promegakaryocytes and then megakaryocytes with the propensity to form platelets 
(Bluteau, Lordier et al. 2009). Cells follow a normal cell cycle progressing through 
G1, S and G2 phases followed by an altered mitotic phase. It is within this adapted 
mitosis that megakaryocytes form a mid-zone in anaphase but have a deficiency in 
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cytokinesis and cleavage furrow formation (Geddis and Kaushansky 2006; Lordier, 
Jalil et al. 2008). This process is underpinned by the RUNX1-mediated silencing of 
non-muscle myosin IIB heavy chain (MYH10) at the contractile ring (Lordier, Bluteau 
et al. 2012). The net result of which is that megakaryocytes are allowed to form a 
multilobulated polyploid nucleus that follows geometric distribution from 2N to 64N. 
Such an increase in genetic content is not a necessity to shed platelets but it has 
been tied to an associated functional gene amplification (Raslova, Roy et al. 2003).  
The theory behind an increase in functional gene amplification is that it allows for 
compensation of the next step towards thrombopoiesis; proplatelet formation. 
Following nuclear polyploidisation, megakaryocytes undergo cytoplasmic maturation 
involving the formation of an invaginated membrane system (IMS). The IMS is an 
extensive complex of cisternae and tubules continuous with the plasma membrane 
(Radley and Haller 1982). As a hallmark of mature megakaryocytes, it acts a 
reservoir of membrane for the formation of proplatelets (Schulze, Korpal et al. 2006).  
As the IMS is formed it is loaded with the phospholipid, phosphatidylinositol 4,5-
bisphosphate (PI4, P-5 [2]), which associates with filamentous actin promoting 
polymerisation through Rho-like GTPases and Wiskott-Aldrich syndrome (WASp) 
family proteins (Schulze, Korpal et al. 2006). Cytoskeletal rearrangements like this 
power proplatelet formation allowing for elongation of proplatelet extensions into 
sinusoidal blood vessels (Thon, Montalvo et al. 2010).  Microtubule β1-tubulin 
polymerisation supports the growing mass of proplatelet elongations but sliding of 
overlapping microtubules utilising the motor protein dynein is essential for full 
formation (Patel, Richardson et al. 2005). Filamentous-actin (F-actin) is also present 
throughout proplatelets and forms assembly points allowing proplatelet branching 
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and bending (Italiano, Lecine et al. 1999). Not only does the cytoskeleton create the 
necessary structure to support proplatelet elongation, but it also acts as a highway 
for the transportation of granules and organelles into the budding proplatelet tips. As 
megakaryocyte precursors enter endomitosis and begin to form an IMS they also 
begin to increase production of platelet specific granules; namely alpha (α) and 
dense (δ) granules (Behnke 1968). These granules are derived from budding 
vesicles from the trans-Golgi network and are transported bi-directionally until they 
reach proplatelet tips (Behnke 1968; Richardson, Shivdasani et al. 2005). Their 
transport is facilitated by microtubules and follows the same directional pattern as 
plus end-directed microtubule motor kinesins (Richardson, Shivdasani et al. 2005).  
Once formed, proplatelets have a unique architecture allowing for platelet release 
into sinusoidal blood vessels. As mentioned previously, maturing megakaryocytes 
relocate towards the vascular niche where an altered extracellular matrix is found, 
supporting their commitment to differentiate. Localisation towards the vascular 
network also exposes megakaryocytes to increasing concentrations of blood 
components. One particular component, sphingosine 1 phosphate (S1P), guides 
proplatelet extensions into the lumen of bone marrow sinusoids through an 
increasing gradient (Zhang, Orban et al. 2012). Once extended into the vascular 
network, downstream S1P signalling, through the activation of megakaryocyte S1P 
receptors (S1pr1), leads to platelet release into the circulating blood (Zhang, Orban 
et al. 2012). Before entering the vascular network though, proplatelet extensions still 
have to break through into the lumen and this is a process thought to be mediated by 
podosomes (Schachtner, Calaminus et al. 2013). Podosome formation and stability is 
dependent on actin polymerisation via the Arp2/3 complex and WASp to create an 
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actin core (Schachtner, Calaminus et al. 2013). Upon podosome mediated 
degradation, proplatelet intrusions can reach into the vascular lumen and blood shear 
forces aid in release of proplatelet fragments from the megakaryocyte body into 
circulation (Junt, Schulze et al. 2007). 
Megakaryocytes do not release uniform platelets into circulation, however; they are 
believed to be released as a heterogeneous mix of fragments. Contained within this 
mix of fragments are discoid particles that are 2-10µm in diameter known as 
preplatelets (Thon, Devine et al. 2012). Preplatelets represent a precursor to mature 
circulating platelets and can be reversibly converted into barbell-shaped proplatelet 
structures with two platelet-sized bulbs on each end (Schwertz, Koster et al. 2010; 
Thon, Devine et al. 2012). This process is governed by the biophysical properties of 
microtubules and the subsequent abscission of barbell-shaped proplatelets to mature 
platelets is also mediated by polar located microtubule coils (Thon, Devine et al. 
2012; Thon, Macleod et al. 2012). Tight cytoskeletal regulation of platelet maturation 
in circulation ensures that platelets are formed to a uniform size, however, there is 
also a strong genetic impact on overall platelet size (Gieger, Radhakrishnan et al. 
2011).  
Following platelet release, the remaining senescent megakaryocyte nucleus, devoid 
of the majority of its cytoplasmic components, is disposed of by apoptosis and 
phagocytosis (Gordge 2005).  
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1.2. Functional role and lifespan of platelets 
Platelets, although anuclear cellular fragments, play a highly important role within 
haemostasis following vascular injury that was first described by Giulio Bizzozero 
(Brewer 2006).  
Platelets are the smallest of human blood cells with a diameter of around 2µm. They 
were first described by Max Schultze in 1865 in a study focusing on white blood cells 
(Brewer 2006). Lacking in a nucleus, platelets have a highly specialised cytoplasmic 
content that consists of a complex actin and microtubule cytoskeleton which allows 
for rapid shape change upon activation (Boyles, Fox et al. 1985). The platelet 
cytoskeleton is a spectrin mesh reinforced by a coiled microtubule tendril that sits 
beneath the plasma membrane giving platelets their discoid resting shape (Hartwig 
and DeSisto 1991; Schwer, Lecine et al. 2001). The spectrin strands are 
interconnected by actin filaments which are cross linked by “scaffolding” molecules 
such as filamin A (FLNA), filamin B (FLNB) and α-actinin (Tablin, Reeber et al. 1988). 
Also located within the unique cytoplasm is a large quantity of platelet specific 
granules. As mentioned before, platelets contain mostly α-and-dense granules; 
secretory exosomes that release varying content through membrane fusion (Reed, 
Fitzgerald et al. 2000).  α-granules are the most abundant with a highly organised 
interior structure. They contain a variety of adhesion molecules, chemokines, 
adhesive proteins, growth factors and other proteins (Harrison and Cramer 1993).  
Dense granules, named due to the presence of a highly dense core when viewed by 
electron microscopy, contain more small compound molecules such as metallic ions 
and adenosine triphosphate (ATP), guanosine triphosphate (GTP), adenosine 
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diphosphate (ADP) and guanosine diphosphate (GDP) nucleotides (Youssefian, 
Masse et al. 1997). Both granules are secreted upon activation of platelet bound 
membrane receptors through G-protein coupled signalling, the net effect of which is 
the amplification of the platelet activation pathway. 
In normal conditions, platelets follow a sentinel role, unresponsive as they circulate 
throughout the vascular network (Ruggeri and Mendolicchio 2007). Upon vessel 
injury, when the endothelial cell layer is damaged exposing the extracellular matrix to 
circulation, platelets quickly become active. Activation of platelets generally follows 
three main steps; adhesion, secretion and aggregation.  
Platelet adhesion proceeds in slightly different conditions dependant on the shear 
forces present at the site of vascular injury. In high shear conditions, exposure of 
collagen from the subendothelial layer allows association with circulating von 
Willebrand factor (VWF). VWF multimers allow for platelet capture by cross-linking 
platelet GP1B/V/IX receptor complexes (Clemetson and Clemetson 1995). Tethered 
platelets are then allowed to roll across the endothelium through endothelial P-
selectin binding to its ligand PSGL1 in addition to the GP1b/V/IX complex (Romo, 
Dong et al. 1999; Frenette, Denis et al. 2000). In low shear conditions, platelets 
adhere by binding subendothelial collagen directly, cross-linking it using the GP1a/IIa 
integrin and GPVI which leads to downstream collagen signalling and activation 
(Nieswandt and Watson 2003). 
Once adhered, activated platelets release several granular components which 
modulate the function of interacting platelets and blood cells. ADP, released from 
dense granules is predicted to be the prominent amplifier of activation (Gachet 2001). 
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Secreted ADP binds to its cellular receptors P2Y1 and P2Y12 on the platelet surface, 
mediating platelet shape change and further positive feedback loop associated 
secretion, respectively (Fabre, Nguyen et al. 1999; Remijn, Wu et al. 2002). 
Serotonin (5-HT), also located within dense granules, is a known vasoconstrictor and 
plays a procoagulant role by retaining proteins such as fibrinogen and 
thrombospondin on the platelet surface (Dale, Friese et al. 2002). α-granules, 
containing larger adhesive, coagulation and protease inhibitor proteins, are also 
secreted upon activation. The released alpha granule content aids in platelet 
activation and the clotting cascade, as well as exposing P-selectin (CD62P) on the 
platelet surface due to fusion of the granules with the plasma membrane. Exposing 
P-selectin on the cell surface has an inflammatory response mediating the binding of 
platelets to other blood cells including neutrophils, monocytes and leukocytes at the 
site of vascular injury (Furie, Furie et al. 2001; Singbartl, Forlow et al. 2001). 
After granule secretion, the next step is the aggregation of platelets to one another to 
form a haemostatic plug. This process is underpinned by the platelet receptor 
GPIIb/IIIa (αIIbβ3-integrin), linking activated platelets through fibrinogen bridges in a 
two-step process. α-granule exocytosis increases the number of GPIIb/IIIa molecules 
on the platelet cell surface allowing for binding of soluble plasma fibrinogen, while 
immobilised fibrinogen on preactivated platelets at the site of vessel injury serves as 
a substrate for circulating resting platelets. Under high shear forces, platelet 
aggregation can also occur through the bridging of VWF to the GP1b/V/IX complex 
which leads to inside-out GPIIb/IIIa signalling and the formation of stable fibrinogen 
complexes (Ruggeri 1993).  
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Once platelets begin to aggregate at the site of vascular injury, it can lead to 
receptor-mediated generation of thrombin allowing the clotting cascade to form a 
stable platelet-fibrin plug. Upon platelet activation, the constituents of the plasma 
membrane are altered so that molecules, such as phosphatidylserine (PS), are 
transported in a flip-flop movement from the inner-to-outer leaflet (Dormann, 
Kardoeus et al. 1998). Platelets utilise this process to act as a catalyst; amplifying the 
small amount of thrombin exposed by the endothelia through their own activation and 
providing a pro-coagulant surface for members of the clotting cascade to bind and 
form thrombin (Sims, Wiedmer et al. 1989). Also within this process, microvesicles 
are released due to Ca2+-mediated activation of calpain aiding in coagulation 
(Wiedmer, Shattil et al. 1990). 
An important part of platelet activation is signal transduction allowing for shape 
change to facilitate the complete formation of a platelet plug. Binding of platelet 
agonists to cell surface receptors coupled to the Gq-family of G-proteins such as; 
PAR1, PAR4, and TxA2-receptor, cause a change in intracellular messenger 
molecules. The knock on effect is a positive feedback loop, amplifying platelet 
activation and accommodating the necessary shape change required through re-
modelling of the platelet cytokskeleton to allow platelets to spread.  
Platelets do not only play a role in the haemostatic regulation in response to vessel 
injury, they are also a key modulator in a number of processes. They are also active 
components of the immune system and response, implicated in cancer, a marker of 
cardiovascular disease and the key regulator behind thrombosis where they are 
aberrantly activated in the formation of a platelet plaque (Willoughby, Holmes et al. 
2002; Smyth, McEver et al. 2009; Bambace and Holmes 2011).  
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Following activation, platelets are cleared from the circulation usually via the spleen 
or by phagocytosis. Platelets that have not undergone activation usually have a 
circulating lifespan of around 7-10 days before they are cleared in the same way. 
This lifespan is tightly regulated by an intrinsic balance between levels of pro-
apoptotic proteins versus pro-survival proteins. Bcl-XL (encoded by BCL2L1), from 
the Bcl-2 family of pro-survival proteins, is the main connection to platelet lifespan 
(Mason, Carpinelli et al. 2007). As platelets age, Bcl-XL levels diminish as the 
inherited protein from megakaryopoiesis degrades (Bertino, Qi et al. 2003). When 
levels of Bcl-XL dip below a threshold, they are insufficient to be able to suppress the 
pro-apoptotic proteins BAK and BAX leading to platelet death (Wagner, Claudio et al. 
2000). It is this degradation over time that acts as a molecular clock for platelets, 
governing their lifespan; because of this thrombopoiesis has to be tightly regulated in 
order to maintain a healthy number of circulating platelets.   
1.3. Platelet function testing 
A platelet’s function is often disrupted so that their role in haemostasis upon vascular 
injury is impaired. Several tests are currently available to test the function of platelets, 
many of which are currently used in clinical practice. Functional assays are 
continually progressing in order to achieve more accurate and efficient clinical and 
research results. 
Platelet function testing began with the development of an evaluation of bleeding 
time by the Duke procedure in 1910 (Duke 1983). Platelet function testing now 
focuses on a number of key areas including; aggregation, platelet adhesion under 
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shear stress, analysing secretion and platelet cell surface markers upon activation, 
and metabolite release.  
One of the first developed was the platelet aggregation test in platelet-rich plasma 
(PRP) known as light transmission aggregometry (LTA). Developed by Born in the 
1960s, it functions to determine the effect of agonists on platelets by analysing the 
amount of light able to pass through a sample (Born 1962). Upon activation, platelets 
will aggregate in a GPIIb/IIIa manner, converting the opaque PRP clear and 
increasing the light transmission through the sample. Although one of the first 
developed assays, it is still considered a gold standard in clinical testing and forms 
the first step in many methodologies to determine platelet function (Kottke-Marchant 
and Corcoran 2002). Many agonists are now available to test for a wide array of 
potential defects and LTA can be coupled with lumiaggregometry to simultaneously 
determine the secretion of adenine nucleotides from platelet granules by binding the 
luciferin-luciferase reagent (Holmsen, Holmsen et al. 1966). Aggregometry assays 
have also progressed beyond LTA to increase efficiency by using a 96 well plate 
format in the Optimul assay or by assessing aggregation in whole blood through 
impedance measurements in the Multiplate assay (Toth, Calatzis et al. 2006; Chan, 
Armstrong et al. 2011).  
Platelet adhesion assays under shear stress aim to determine the capabilities of 
platelets to adhere and aggregate to a coated surface under physiological conditions. 
Many groups employ their own micro-fluidic system to determine platelet adherence 
to a number of coated surfaces, predominately collagen and fibrinogen, however 
commercially available systems including the Platelet Function Analyser – PFA-100 
and the IMPACT analyser are available (Kundu, Heilmann et al. 1995; Varon, Dardik 
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et al. 1997). Both systems work on whole blood flowed or span over pre-coated 
cartridges and aim to determine the efficacy of primary haemostasis.  
To determine the function of platelet secretion and quantification of platelet cell 
surface markers, flow cytometry is often used. Flow cytometry rapidly measures 
specific characteristics of platelets and can be adapted to determine the platelet 
count in whole blood in a similar fashion to how impedance and optical counts are 
taken. It also has the added benefit of being able to determine a platelet’s response 
to agonists, namely their granular secretion upon activation, the presence of pre-
activation and the quantity of cell surface receptors which can elucidate many forms 
of platelet-related disorders.  
In physiological conditions, when platelets are stimulated, thromboxane A2 (TXA2) is 
rapidly synthesised from the metabolism of arachidonic acid (AA) and released from 
platelets at the site of vascular injury (Kehrel and Brodde 2013). TXA2 is quickly 
transformed into the inactive metabolite TXB2 in the circulation, and it is this 
metabolite that can be measured given an indication on the activation state of 
platelets as well as their response in a number of diseases (Kehrel and Brodde 
2013).  
1.4. Inherited thrombocytopenia – Symptoms, treatment and 
misdiagnosis 
Many diseases can affect the function, number and physiology of platelets. More 
often than not, alterations in platelets are as a secondary symptom to a more severe 
multisystem disorder or one affecting the immune system. In these cases, platelet 
numbers and function can crash dramatically but usually improve as the disease 
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state of the patient resolves or in response to transfusion. The clinical state of being 
thrombocytopenic is therefore a common occurrence in a hospital environment, 
however, inherited platelet based bleeding disorders are clinically rarer and 
considerably more variable in severity than acquired thrombocytopenia. Broadly 
speaking, platelet based bleeding disorders can be split into two main categories; 
platelet function disorders and disorders of platelet numbers.  
IT is a bleeding diathesis that is categorised by a reduction in platelet count that 
manifests as a clinical coagulopathy. A normal circulating platelet count in a healthy 
individual in whole blood varies between 150-450x109/L. An individual’s platelet count 
is a unique reflection on a number of genetic and environmental factors including 
age, ethnicity and gender (Whitfield and Martin 1985; Biino, Balduini et al. 2011; 
Biino, Gasparini et al. 2012). This platelet count can fluctuate within an individual but 
is largely confined to differ by less than ±50x109/L when measured. To steadily 
maintain a healthy platelet count within this range, a delicate balance between the 
production of platelets through megakaryopoiesis and thrombopoiesis and their 
consumption by activation or removal after senescence is needed. IT often arises 
when a step in this harmony is disrupted by genetic mutation.  
Clinically, IT is defined by a reduction in platelet count to less than 150x109/L 
circulating platelets in whole blood. Its presentation often varies in severity due to the 
functional effect of genetic variation as well as the presence of a secondary 
qualitative defect in platelet function. Most patients suffer from mild symptoms related 
to excessive bleeding including; petechiae, epistaxis, easy cutaneous bruising, 
periodontal bleeding following brushing and menorrhagia in women that have 
reached menarche. Patients with a more severe form of IT may present with the 
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disease from birth in addition to an abnormality affecting the immune system or 
skeleton. In some cases, the presence of IT can go undiagnosed for many years due 
to the lack of haemostatic challenge; which is more common in men due to the 
haemostatic pressures that women face through the menstrual cycle. Although many 
of the major complications of IT are mild in presentation, they can potentially be life 
threatening upon certain challenges such as child birth, major surgery or trauma. For 
this reason, many patients will not receive active treatment but will instead be 
monitored regularly and the appropriate cause of action be taken if a risk of bleeding 
is known.  
The synthetic antidiuretic hormone desmopressin (DDAVP) is the most commonly 
used therapy given prior to a planned procedure or following exposure to significant 
trauma (Cattaneo 2002). It is best administered intravenously by slow infusion over 
30 minutes up to a maximum dose of 20µg. Mimicking endogenous vasopressin, 
desmopressin acts to reduce the excretion of water as urine but also stimulates the 
release of VWF from endothelial cells by binding the V2 receptor. An increase in 
VWF release slightly shortens bleeding time in patients with a normal dense granule 
function (Rao, Ghosh et al. 1995). 
Fibrinolytic inhibitor drugs are used in a similar preventive way to desmopressin but 
show effectiveness mostly in minor operative dental and otolaryngology procedures 
(Hayward 2005). Fibrinolytic inhibitors include epsilon-aminocaproic acid and 
tranexamic acid and function to interfere with the formation of plasmin from its 
precursor plasminogen allowing prolongation of a formed clot.  
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In few cases, the excessive associated bleeding cannot be controlled prior to 
haemostatic risk, this is most often in severe cases of thrombocytopenia and a more 
active treatment plan is needed. The most commonly used active treatment is 
platelet transfusion and in ideal circumstances human leukocyte antigen (HLA)-
matched single donor platelets are used, but leukocyte-depleted blood components 
can be used. Transfusions are used sparingly to avoid alloimmunisation which may 
lead to refractoriness to therapy (Fiore, Firah et al. 2012). Therapies such as 
recombinant factor VIIIa, are reserved for serious cases when where a lack of 
responsiveness to transfusion has occurred due to alloimmunisation (Kaleelrahman, 
Minford et al. 2004).  
Recent advances in treatment has seen the use of TPO mimetics, haematopoietic 
stem cell transplantation and stem cell gene therapy, all being utilised in individual 
platelet based bleeding disorders (Locatelli, Rossi et al. 2003; Boztug, Schmidt et al. 
2010; Pecci, Gresele et al. 2010).  
Correct diagnosis of IT is crucial to be able to administer the correct treatment plan. 
Often cases of IT are misdiagnosed as immune thrombocytopenic purpura (ITP), an 
autoimmune disorder which leads to immune mediated thrombocytopenia (Bader-
Meunier, Proulle et al. 2003). ITP is categorised by either a presence of platelet 
autoantibodies causing phagocytosis and subsequent removal of platelets or T 
lymphocyte-mediated platelet lysis (Cines, Bussel et al. 2004). Platelet counts in ITP 
can crash dramatically to less than 10x109/L requiring a more intensive therapy to 
avoid significant bleeding. Initial treatment aims to create a stable platelet count and 
is usually achieved through the use of intravenous gammaglobulin, the corticosteroid 
methylprednisolone or a combination of both (Cines, Bussel et al. 2004). Both 
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treatments cause the spleen to avoid platelets tagged for removal, therefore 
maintaining the platelet count. They can be quite harsh and are associated with a 
number of side effects which may affect a patient’s wellbeing. If a stable platelet 
count cannot be achieved with either treatment, a number of other treatments 
including anti-D and recombinant factor VIIIa can be used and in worst cases, a 
splenectomy is recommended. As most treatments target the over-excessive 
clearance of platelets, they often have little-to-no effect on patients suffering from IT, 
meaning that patients can go through several unnecessary therapies that will offer no 
benefit. As such a clear distinguished diagnosis between the two diseases should be 
achieved before therapy is started. This is often difficult to determine without pre-
testing for a number of genetic mutations or by assessing how the patient responds 
to treatment, so a definitive family history and a series of platelet counts over a time 
period are crucial steps. 
1.5. Genetic causes of inherited thrombocytopenia 
In comparison to acquired ITP, ITs are relatively rare in their prevalence. Most 
recently they have been reported as being present in 2.7 per 10,000 live births, 
although their prevalence varies considerably between each individual disease. To 
date, 35 genes have been reported to cause 30 forms of IT (Table 1.5.1). Each form 
varies in its clinical presentation, severity, association with secondary symptoms and 
cause. Many groups have sought to separate the spectrum of disorders by a number 
of factors including; platelet count, mean platelet volume (MPV)/platelet size or 
presence of secondary symptoms. To better understand the functional effect of 
genetic variation it is best to consider each individual disease by how it causes a 
reduction in platelet count. As mentioned previously, many disorders are as a result 
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of a disruption to the balance of platelet production and platelet 
consumption/senescence so they will be explained in this way and shown below.
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Area of mutational 
effect 
Gene Protein Associated disease Inheritance pattern 
Megakaryopoiesis ETV6 Transcription factor ETV6 Thrombocytopenia 5 (THC5) Autosomal dominant 
 FLI1 Friend leukemia integration 1 
transcription factor 
Paris Trousseau type 
thrombocytopenia/Jacobsen (11q23 
del) 
Autosomal 
dominant/recessive 
 FYB Adhesion and degranulation-
promoting adaptor protein 
Novel thrombocytopenia Autosomal recessive 
 GATA1 Erythroid transcription factor GATA1 related disease (X-linked 
thrombocytopenia [XLT] and X-linked 
thrombocytopenia with β-
thalassemia [XLTT]) 
X-linked recessive 
 GFI1B Zinc finger protein Gfi-1b Grey Platelet Syndrome + novel 
thrombocytopenia 
Autosomal dominant 
 HOXA11 Homeobox protein Hox-A11 Amegakaryocytic thrombocytopenia 
with radio-ulnar synostosis 
Autosomal dominant 
 MECOM MDS1 and EVI1 complex locus 
 MPL Thrombopoietin receptor Congenital amegakaryocytic 
thrombocytopenia 
Autosomal recessive 
 NBEAL2 Neurobeachin-like protein 2 Grey Platelet Syndrome Autosomal recessive 
 RBM8A RNA-binding protein 8A Thrombocytopenia with absent radii Autosomal recessive 
 RUNX1 Runt-related transcription 
factor 
Familial platelet disorder and 
predisposition to AML 
Autosomal dominant 
 THPO Thrombopoietin Mild novel thrombocytopenia 
(heterozygous) 
Autosomaldominant 
Proplatelet 
formation/platelet 
production 
ACTN1 Alpha-actinin-1 Bleeding disorder, platelet-type 15 Autosomal dominant 
 ANKRD26 N/A ANKRD26-related thrombocytopenia Autosomal dominant 
 CYCS Cytochrome C CYCS-related Autosomal dominant 
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thrombocytopenia/THC4 
 DIAPH1 Rho-effector diaphanous-
related formin 1 
Novel macrothrombocytopenia with 
hearing loss 
Autosomal dominant 
 FLNA Filamin A Isolated macrothrombocytopenia X-linked recessive 
 GP1BA Platelet glycoprotein 1b alpha 
chain 
Bernard Soulier Syndrome + (Platelet 
type von-Willebrand disease – GP1BA 
only) 
Autosomal 
dominant/recessive 
 GP1BB Platelet glycoprotein 1b beta 
chain 
 GP9 Platelet glycoprotein IX 
 ITGA2B Integrin alpha-IIb Glanzmann thrombasthenia Autosomal recessive 
 ITGB3 Integrin beta-3 
 MKL1 MKL/myocardin-like protein 1 Thrombocytopenia with 
immunodeficiency 
Autosomal recessive 
 MYH9 Myosin 9 MYH9 related disease Autosomal dominant 
 PRKACG cAMP-dependant protein 
kinase catalytic subunit gamma 
Bleeding disorder, platelet-type 19 Autosomal recessive 
 SRC SRC proto-oncogene, non-
receptor tyrosine kinase 
Novel thrombocytopenia with bone 
pathologies 
Autosomal dominant 
 TRPM7 Transient receptor potential 
melastatin-like 7 channel 
Novel macrothrombocytopenia with 
atrial fibrillation 
Autosomal dominant 
 TUBB1 Tubulin beta-1 chain TUBB1-related 
macrothrombocytopenia 
Autosomal dominant 
 WAS Wiskott-Aldrich syndrome 
protein 
Wiskott-Aldrich syndrome, X-linked 
thrombocytopenia (XLT) 
X-linked recessive 
Platelet 
clearance/other 
ABCG5 ABC transporter G family 
member 5 
Thrombocytopenia associated with 
sitosterolaemia 
Autosomal recessive 
 ABCG8 ABC transporter G family 
member 8 
 ADAMTS13 A disintegrin and Thrombotic thrombocytopenia Autosomal recessive 
 26 
 
metalloproteinase with 
thrombospondin motifs 13 
purpura, Upshaw-Schulman 
syndrome 
 GNE Glucosamine (UDP-N-Acetyl)-2-
Epimerase 
GNE related myopathy with 
congenital thrombocytopenia 
Autosomal recessive 
 STIM1 Stromal interaction molecule 1 Stormorken Syndrome Autosomal dominant 
 VWF von Willebrand factor von Willebrand disease type 2B Autosomal 
dominant/recessive 
 
Table 1.5.1 Current forms of inherited thrombocytopenia and their causative genes and inheritance patterns 
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1.5.1. Disorders of megakaryopoiesis 
The commitment to differentiate and progress along the myelo-erythroid lineage in 
the formation of megakaryocytes is a highly controlled process as mentioned 
previously. The main levels of regulation are transcriptional and signalling related, 
and as such the myriad of diseases associated with a disruption in HSCs 
proliferation, differentiation and megakaryocyte maturation are often as a result of a 
disruption in these processes.  
1.5.1.1. THPO – Mild novel thrombocytopenia (heterozygous) 
As the main regulator behind megakaryopoiesis and the differentiation of HSCs to 
megakaryocytes, the presence of TPO, encoded by the gene THPO, is essential for 
platelet production. Recently, the first reported variant causative of IT was identified 
in the THPO gene (Dasouki, Rafi et al. 2013). Present in a large Micronesian family, 
with a history of death due to idiopathic aplastic anaemia, a rare frequency variant, 
c.112C>A; p.Arg38Cys, was identified by whole exome sequencing. Identified as 
R17C in the paper, the variant has only been identified once previously in the Exome 
Aggregation Consortium (ExAC) database (rs760797899) in a heterozygous state. 
The variant was homozygous in the proband suffering from aplastic anaemia, was 
absent in a related unaffected individual and, interestingly, was present in a 
heterozygous state in both parents and a non-anaemic sibling who suffered from a 
mild asymptomatic thrombocytopenia.  Overexpression of the mutant TPO in the 
UT7-TPO cell line caused a 2.5 fold decrease in proliferation at low dosage 
suggesting that mutant TPO is defective in megakaryopoiesis (Dasouki, Rafi et al. 
2013). 
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1.5.1.2. c-Mpl – Congenital amegakaryocytic thrombocytopenia 
c-Mpl, the receptor for the thrombopoietin ligand, is expressed on the cell surface of 
HSCs and megakaryocyte progenitors promoting their differentiation. Its association 
with IT was first suggested through a lack of c-Mpl mRNA in bone marrow 
mononuclear cells and an elevated serum level of TPO in a patient suffering from 
congenital amegakaryocyte thrombocytopenia (CAMT) (MIM #604498) (Muraoka, 
Ishii et al. 1997). In a subsequent study, the genomic sequence of c-Mpl was 
analysed in a 10-year old CAMT patient that revealed the presence of compound 
heterozygous inheritance of a nonsense and frameshift causing variant; 
c.556C>T;p.Q186* and c.1499delT (Ihara, Ishii et al. 1999). CAMT is a rare disorder 
expressed in infancy associated by isolated thrombocytopenia but without secondary 
associated defects. This progresses throughout childhood to a complete 
pancytopenia and bone marrow failure usually by four years of age but can occur at a 
much faster rate (Stoddart, Connor et al. 2013). To date, genetic variations have 
been identified throughout the coding region of the c-Mpl gene, however the majority 
are present in exons 1-3 (van den Oudenrijn, Bruin et al. 2000). Clinically, CAMT 
presents as a sustained reduction in platelet count to severe levels (<10x109/L in 
whole blood), however a subset of patients have counts that fluctuate above 
50x109/L, often due to missense mutations that retain partial receptor function which 
leads to a delayed onset of bone marrow failure (King, Germeshausen et al. 2005; 
Germeshausen, Ballmaier et al. 2006). CAMT remains epidemiologically rare and the 
only feasible treatment method is HSC transplantation from related carrier or 
unrelated matched donors (Frangoul, Keates-Baleeiro et al. 2010). 
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1.5.1.3. RBM8A – Thrombocytopenia with absent radii 
Thrombocytopenia with absent radii (TAR) is a syndromic disorder originally thought 
to be characterised by the inheritance of a 200kb microdeletion of chromosome 
1q21.1 (Klopocki, Schulze et al. 2007). As with CAMT, it presents from birth with a 
severe thrombocytopenia, however it is also associated with skeletal abnormalities 
where infants have bilateral absent radii but retention of the thumb (Hall, Levin et al. 
1969). Unlike CAMT however, thrombocytopenia usually improves with age over the 
first two years negating the need for drastic transplantation treatment. Recently TAR 
has been shown to be caused by the co-inheritance of a null allele, primarily the 
microdeletion on chromosome 1q21.1, and one of two rare single nucleotide 
polymorphisms (SNPs) within the RBM8A gene (Albers, Paul et al. 2012). The 
RBM8A gene encodes the Y14 protein, a subunit of the exon-junction complex which 
forms the active nonsense-mediated mRNA decay complex. The SNPs present 
within patients are either a low frequency SNP in the 5’ untranslated region (5’UTR) 
or a SNP in the first exon of RBM8A. Both variants are located in active regulatory 
domains of the RBM8A gene and reduce promoter activity in a cell specific pattern. 
This causes inefficiency in a dose dependant manner with the co-inherited null allele 
to bring levels of Y14 below a critical functional threshold (Jan 2012). The two 
regulatory SNPs also reduce binding of the transcriptional repressor EVI1 which may 
lead to aberrant downstream transcriptional regulation through defective c-Mpl 
signalling although a lack of JAK2 phosphorylation is noted in TAR patients 
(Ballmaier, Schulze et al. 1998; Albers, Paul et al. 2012). 
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1.5.1.4. HOXA11 and MECOM – Amegakaryocytic 
thrombocytopenia with radio-ulnar syntosis 
HOXA11 is a DNA binding protein characterised by the 183bp long highly conserved 
homeobox domain. Like many other homeobox domain proteins, HOXA11 is 
expressed ubiquitously in human cord blood and haematopoietic precursor cells 
(Horvat-Switzer and Thompson 2006). First described in 2000 by Thompson and 
Nguyen, a single nucleotide deletion in the third helix of the homeobox domain 
leading to a frameshift and premature stop codon was associated with 
amegakaryocytic thrombocytopenia with radio-ulnar syntosis (Thompson and Nguyen 
2000). The disorder, similar to TAR, presents with bone marrow failure, an initial 
thrombocytopenia leading to pancytopenia, and skeletal abnormalities. 
Amegakaryocytic thrombocytopenia with radio-ulnar syntosis functionally 
distinguishes itself from previous disorders due to fusion of radius and ulnar as the 
hallmark phenotype and lack of progressive improvement in platelet count over time 
(Thompson, Woodruff et al. 2001). The connection between how variants in HOXA11 
cause amegakaryocytic thrombocytopenia with radio-ulnar syntosis is yet to be fully 
established. Unlike wild type (WT) HOXA11, truncated HOXA11 lacks DNA binding 
capability in the presence of the TALE transcription factor, Meis1b (Horvat-Switzer 
and Thompson 2006). However, both WT and mutant forms of HOXA11 impair 
megakaryocyte differentiation and CD61 surface expression in vitro (Horvat-Switzer 
and Thompson 2006). 
Recently the first variants to cause amegakaryocytic thrombocytopenia with radio-
ulnar syntosis in the gene MECOM have been described (Niihori, Ouchi-Uchiyama et 
al. 2015). Three missense mutations were identified by whole exome sequencing in 
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patients without HOXA11 mutations. The mutations are clustered around the C-
terminal 8th zinc finger motif of the protein EVI1, encoded by MECOM. EVI1 is a 
transcriptional repressor that has been previously implicated to suppress expression 
of RBM8A in patients with TAR (Albers, Paul et al. 2012). It binds DNA through two 
motifs, a GATA-like motif and an E26-transformation-specific (ETS)-like motif located 
towards the C-terminus. In patients with MECOM mutants, this ETS-domain DNA 
binding ability is reduced. EVI1 also has the potential to bind a number of haemato-
specific transcription factors indicating that the cause of amegakaryocytic 
thrombocytopenia with radio-ulnar synostosis may be related to the functional 
properties of EVI1 (Laricchia-Robbio, Fazzina et al. 2006; Senyuk, Sinha et al. 2007; 
Laricchia-Robbio, Premanand et al. 2009; Niihori, Ouchi-Uchiyama et al. 2015).  
1.5.1.5. GATA1 – GATA1 related disease (XLT and XLTT) 
As mentioned previously, megakaryopoiesis is under high transcriptional regulation 
by a number of transcription factors. GATA1 which is expressed in a myelo-erythroid 
restrictive pattern defines the progression from HSCs to CMPs and subsequently 
MEPs. Mutations in GATA1 therefore reflect the shared progenitors causing 
disorders in both thrombopoiesis and erythropoiesis including; X-linked 
thrombocytopenia (XLT) with dyserythropoiesis, X-linked thrombocytopenia with 
thalassemia (XLTT) and rarely congenital erythropoietic porphyria (Ciovacco, 
Raskind et al. 2008). GATA1 is structurally defined by the presence of zinc-finger 
DNA binding domains at both the N and C terminus with the majority of the variants 
leading to disease occurring in the N-terminal zinc-finger domain (N-f) which 
facilitates GATA1’s cofactor and DNA binding capabilities. Variants are further 
refined spatially; with missense variants disrupting GATA1’s ability to bind it’s co-
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factor FOG1 solely causing XLT and variants disrupting GATA1’s DNA binding ability 
leading to XLTT (Nichols, Crispino et al. 2000; Yu, Niakan et al. 2002). Both 
disorders have phenotypic similarities; with defective megakaryocyte maturation and 
mature megakaryocyte dimorphism which leads to abnormal platelet size and shape, 
however platelet count tends to be milder in XLTT. Although inheritance is X-linked, a 
mild phenotype can occur in female heterozygotes due to skewed X-inactivation 
(Nichols, Crispino et al. 2000).  
1.5.1.6. RUNX1 – Familial platelet disorder and predisposition to 
AML 
Familial platelet disorder with predisposition to acute myelogenous leukaemia 
(FPD/AML) (MIM #601399) is an autosomal dominant disorder characterised by a 
quantitative and qualitative platelet defect and an increased risk of AML. The 
molecular genetic cause of FPD/AML was first elucidated by linkage analysis to a 
region on chromosome 21q (Song, Sullivan et al. 1999). Contained within this region 
is the master regulator of haematopoiesis, RUNX1. To date, variants have been 
identified as the genetic cause of FPD/AML throughout the coding region of RUNX1 
but a clustering of variants within the Runt homology domain are most likely 
detrimental (Johnson, Lowe et al. 2016). FPD/AML shares phenotypic similarities 
with Jacobsen syndrome; platelet counts are often mild-moderate but variable 
between individuals with the same genetic aetiology of disease and a reduction in 
dense granule secretion is often observed as a secondary qualitative abnormality 
(Stockley, Morgan et al. 2013). The major clinical complication of this disorder, 
however, is in fact not the bleeding but the propensity to develop myelodysplasia or 
leukaemia (Walker, Stevens et al. 2002). The net effect of mutation is a 
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haploinsufficiency of RUNX1, or a potential dominant-negative effect, that disrupts 
the formation of complexes with core binding factor beta (CBFB) to disrupt the 
regulation of genes necessary for HSC maintenance, maturation and differentiation 
(Hart and Foroni 2002; Jalagadugula, Mao et al. 2010). 
1.5.1.7. FLI1 – Paris Trousseau type thrombocytopenia/Jacobsen 
(11q23 del) 
Jacobsen syndrome refers to patients with a terminal deletion of the long arm of 
chromosome 11, del11q23. A large majority of patients with this syndromic disorder 
display a bleeding diathesis of reduced platelet number and a subpopulation of 
platelets that have an abnormal response to thrombin and contain giant α-granules 
(Breton-Gorius, Favier et al. 1995). This bleeding diathesis is known as Paris 
Trousseau type thrombocytopenia. The link between the hemizygotic loss of FLI1 by 
chromosomal deletion was quickly established with this bleeding diathesis due to the 
strong role of FLI1 in haematopoiesis (Raslova, Komura et al. 2004). Variants have 
since been identified in FLI1 in patients causing Paris Trousseau type 
thrombocytopenia without the presence of the 11q deletion (Stockley, Morgan et al. 
2013). Mutations are predominantly missense and phenotypically platelets present 
similarly to those affected by RUNX1 mutation as dense granule secretion is 
disrupted and expression of MYH10 is present as a biomarker of genetic variation 
(Antony-Debre, Bluteau et al. 2012; Stockley, Morgan et al. 2013). However, patients 
are also prone to secondary symptoms such as hearing loss and cataracts.  
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1.5.1.8. ETV6 – Thrombocytopenia 5 (THC5) 
Like FLI1 and SP1, ETV6 is a member of the ETS family of transcription factors and 
contains a consensus of three helixes and four beta sheets arranged in a DNA 
binding helix-loop-helix motif (Sharrocks 2001). Also like RUNX1 and FLI1, its 
involvement in the formation of myelodysplasia and leukaemia by translocation and 
chromosome segment deletion is well documented (Harrison, Moorman et al. 2005; 
Wall, Rayeroux et al. 2012). Recently however, its presence as a causative gene of 
thrombocytopenia has been identified through small scale whole exome sequencing 
of patients with unidentified thrombocytopenia and malignancy (Zhang, Churpek et 
al. 2015). These results have since been confirmed and further variants have been 
identified within the coding region clustered around the ETS domain. Variants result 
in aberrant ETV6 localisation, disruption of transcriptional repression and defective 
megakaryocyte maturation (Topka, Vijai et al. 2015; Melazzini, Palombo et al. 2016). 
As with FPD/AML, the most significant clinical complication is a predisposition to 
leukemic malignancy, however platelet count is also mildly affected but platelet size 
remains largely normal (Melazzini, Palombo et al. 2016).  
1.5.1.9. GFI1B - Novel thrombocytopenia and Grey Platelet 
Syndrome 
The transcriptional repressor GFI1B exerts its effect through epigenetic modification 
by histone recruitment. It is expressed, like many other transcription factors, early on 
during haematopoiesis in HSCs and the first stages of progenitor cells that retain 
multipotency (Moroy, Vassen et al. 2015). The main role of GFI1B, like the closely 
related GFI1, is mediated by binding DNA with zinc finger domains and recruiting 
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chromatin modulators using a 21-amino acid SNAG (Snail1/GFI) domain (Moroy, 
Vassen et al. 2015). Genetic variations tend to localise around zinc finger domains 
and lead to a phenotype similar to mutations in GATA1 (Stevenson, Morel-Kopp et al. 
2013). Indeed knock out mouse models of both genes are embryonic lethal due the 
arrest of differentiation of both megakaryocyte and erythroid lineages (Saleque, 
Cameron et al. 2002). The defining feature of GFI1B variants though is a reduction in 
platelet α-granules observable by electron microscopy. This phenotype explains the 
reduced expression of α-granule markers such as fibrinogen and P-selectin that is 
observed in patients (Stevenson, Morel-Kopp et al. 2013).  
1.5.1.10. NBEAL2 – Grey Platelet Syndrome 
The term Grey Platelet Syndrome was originally used to describe recessive platelet 
based bleeding disorders with a complete absence of platelet α-granules giving 
platelets a unique grey appearance (Raccuglia 1971). As molecular genetics has 
progressed the genetic aetiology has been attributed to homozygous or compound 
heterozygote mutations in the Neurobeachin-like 2 gene (NBEAL2) (Albers, Cvejic et 
al. 2011). This is confirmed by antisense morpholino injection into one cell stage 
zebrafish embryos that phenocopies abrogation of thrombocyte formation with the 
presence of spontaneous bleeding (Albers, Cvejic et al. 2011). The functional 
consequence of how genetic variation can lead to a reduction in platelet count and an 
absence or severe reduction in α-granules and their associated content is yet to be 
fully established however. This does though suggest a role for BEACH domain 
proteins in granule packing and formation as other BEACH domain genes have also 
been previously associated with granule deficiency disorders (Nagle, Karim et al. 
1996; Castermans, Volders et al. 2010). 
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1.5.1.11. FYB – Novel thrombocytopenia 
Genetic variations in FYB were recently identified as the likely candidate causative 
mutations behind a recessive microthrombocytopenia in a large consanguineous 
family (Hamamy, Makrythanasis et al. 2014). To date only two variants have been 
identified; c.1385_1386del and c.393G>A, both are within large families of Middle 
Eastern origin (Hamamy, Makrythanasis et al. 2014; Levin, Koren et al. 2015). FYB 
encodes adhesion and degranulation-promoting adaptor protein (ADAP), a cytosolic 
adaptor protein expressed in platelets. It has an important role in platelet activation 
through inside-out αIIbβ3 signalling and collagen induced activation through α2β1 
(Kasirer-Friede, Moran et al. 2007; Jarvis, Bihan et al. 2012). Genetic variation 
therefore affects platelet activation, but interesting platelets appear to be pre-
activated due to overexpression of P-selectin and PAC-1. Thrombocytopenia is 
thought to be as a result of a combination of increased clearance of pre-activated 
platelets and dysmegakaryopoiesis caused by actin dysregulation (Hamamy, 
Makrythanasis et al. 2014). 
1.5.2. Disorders affecting proplatelet formation/platelet release 
Most commonly genes that fall within this category function to control the 
cytoskeleton rearrangement process involved with thrombopoiesis. In the process of 
platelet production by proplatelet extension, the tight regulation of actin and tubulin 
polymerisation is crucial to ensure normal platelet release. 
1.5.2.1. TUBB1 – TUBB1-related macrothrombocytopenia 
As mentioned previously the main process regarding proplatelet extension is the 
polymerisation and subsequent sliding of microtubules. β1-tubulin, encoded by 
 37 
 
TUBB1, is the main isoform within human megakaryocytes and its expression 
underpins this process. Genetic variants in TUBB1 were first identified to have a 
positive impact on the reduction of cardiovascular risk (Freson, De Vos et al. 2005). 
Individuals with a p.Pro43Gln variant displayed reduced ATP secretion but were less 
likely to contract cardiovascular disease. Although impairing the function of platelets, 
this variant did not affect their number. It was Kunishima et al, who first identified the 
causative heterozygous variant, p.Arg318Trp, in a patient with congenital 
macrothrombocytopenia (Kunishima, Kobayashi et al. 2009). Mutated β1-tubulin is 
expressed but is unstable, forming punctate aggregates that do not form 
heterodimers with α-tubulin and are not included in microtubule assembly 
(Kunishima, Nishimura et al. 2014). This leads to a diminishment in proplatelet 
production with fewer proplatelet extensions and larger swellings around proplatelet 
tips, thought to allow the shedding of few non-uniform sized platelets into the 
circulation. The effect of TUBB1 on the formation of platelets is also noted through 
the presence of SNP markers of disease severity in alternate disorders. The 
p.Arg307His SNP is present in a large number of patients with Bernard-Souiler 
Syndrome (BSS) and is associated with an increased bleeding risk (Basciano, 
Matakas et al. 2015).  
1.5.2.2. WAS – Wiskott-Aldrich Syndrome, X-linked 
thrombocytopenia  
Like β1-tubulin, F-actin is present throughout platelets and allows proplatelet 
branching. This actin polymerisation process is promoted by nucleation factors such 
as WASp, encoded by WAS, which is selectively expressed in haematopoietic cells 
and also aids in the formation of the IMS through the WASp/WAVE pathway 
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(Schulze, Korpal et al. 2006). WASp is a multifaceted, multi-domain protein 
associated with several clinical disorders. Genetic variations follow a genotype-
phenotype correlation dependant on the functional consequence and position of 
genetic alteration (Zhu, Watanabe et al. 1997; Lutskiy, Rosen et al. 2005). Nonsense 
mutations, frameshift causing insertions/deletions and complex mutations that lead to 
a null allele often cause the more phenotypically severe Wiskott-Aldrich syndrome 
(WAS) (Wengler, Notarangelo et al. 1995). This X-linked thrombopathy first described 
in 1937 by Alfred Wiskott and later reported by Robert Aldrich (Wiskott 1937; Aldrich, 
Steinberg et al. 1954) is classified by microthrombocytopenia, eczema and 
proneness to infection characterised by defects in T and B cell function. Life 
expectancy is usually less than 10 years and patients are prone to succumb to 
haematological malignancies. On the other hand, mostly missense variants, that 
occur within the first four coding exons of WAS which encodes the EVH1/WH1 
domain, cause a slightly less severe bleeding diathesis known as X-linked 
thrombocytopenia or THC1 (Villa, Notarangelo et al. 1995). EVH1/WH1 is the binding 
site of the WASp-interacting protein (WIP) which, when constitutively bound, 
maintains the protein in a stable inactive state (Ramesh, Anton et al. 1997; Lim, 
Misra et al. 2007). Loss of this binding results in early degradation of WASp. This 
reduces effective WASp levels but function is still retained negating the lymphoid 
abnormalities associated with WAS.   
1.5.2.3. MKL1 – Immunodeficiency with thrombocytopenia 
Myocardin-like protein 1, encoded by MKL1, is a recently reported novel gene 
causative of primary immunodeficiency with a reduction in platelet count (Record, 
Malinova et al. 2015). The production of F-actin was shown to be affected by a 
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homozygous recessive mutation and the primary phenotype was a severe 
immunodeficiency but a variable mild to moderate thrombocytopenia was also 
observed (platelet counts 50-150x109/L). MKL1 elucidates an effect on the actin 
cytoskeleton through its transcriptional co-factor, serum response factor (SRF) and 
knock-out (KO) of either MKL1 or SRF in mice phenocopies thrombocytopenia and 
megakaryocyte maturation and migration dysfunction (Halene, Gao et al. 2010; 
Smith, Thon et al. 2012). 
1.5.2.4. MYH9 – MYH9-related disease 
Myosins, in particular IIA and IIB, are also involved in proplatelet formation by 
interacting with actin filaments generating contractile forces (Pertuy, Eckly et al. 
2014). Mutations in MYH9, which is translated into the heavy chain of non-muscle 
myosin IIA (NMMMHC-IIA), affect the most proximal part of platelet production in the 
budding of preplatelets and subsequent separation into platelets. A disruption in the 
Rho-Rho kinase-myosin IIA pathway leads to an absence of NMMHC-IIA reactivation 
which is needed for the induced fragmentation of proplatelets (Chen, Naveiras et al. 
2007; Chen, Boukour et al. 2013; Spinler, Shin et al. 2015). This leads to 
characteristic large platelets and a reduction in circulating platelet count both of 
which are present from birth. MYH9-related disease brings together the previously 
classified May-Hegglin syndrome, Sebastian syndrome, Fechtner syndrome and 
Epstein syndrome. Although phenotypically different, particularly in the presence of 
myosin aggregates known as Döhle-like body leukocyte inclusions, they are all 
derived from mutations in MYH9 (Seri, Pecci et al. 2003). Like with variations in 
WAS, a genotype-phenotype correlation is observed with mutations in the ATPase 
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domain more frequently associated with nephropathy and/or hearing loss as well as 
the haematological phenotype (Dong, Li et al. 2005).  
1.5.2.5. TRPM7 – Novel macrothrombocytopenia with atrial 
fibrillation 
Mg2+ causes an inhibitory effect on platelets and this role has been successfully 
utilised in the treatment of coronary artery disease (Ravn, Kristensen et al. 1996; 
Shechter 2003). Transient receptor potential melastatin-like 7 channel (TRPM7) is a 
ubiquitously expressed cation channel with a fused alpha kinase domain. TRPM7 is 
permeable to extracellular Mg2+ and negatively gated by intracellular Mg2+, and as 
such PF4 specific deletion of TRMP7 is rescued by Mg2 supplementation (Paravicini, 
Chubanov et al. 2012; Stritt, Nurden et al. 2016). Impaired channel function causes 
macrothrombocytopenia in mice and this is phenocopied in patients with two 
missense variants located outside of the α-kinase domain. The reduction in platelet 
count is caused by cytoskeletal alterations resulting in impaired proplatelet formation, 
this may be the result of perturbed NMMHC-IIA by deregulated Mg2+ homeostasis 
(Stritt, Nurden et al. 2016).  
1.5.2.6. ACTN1 – Bleeding disorder, platelet type-15 
α-actinin, encoded by the ACTN1 gene, is a member of the actin-crosslinking family 
that facilitates actin cytoskeleton rearrangement. Along with ACTN4, it is expressed 
in platelets and megakaryocytes, distinguishing itself from the muscle specific 
isoforms (Haudek, Slany et al. 2009). It exerts its effect through an actin binding 
domain (ABD), binding filamentous actin and allowing bundling which is believed to 
be important for cytoskeleton remodelling upon proplatelet formation. Variants, that 
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are mostly localised within this ABD or the C-terminally located calmodulin-like 
domain, have a gain of function effect, increasing actin bundling (Gueguen, Rouault 
et al. 2013; Kunishima, Okuno et al. 2013; Bottega, Marconi et al. 2015; Murphy, 
Lindsay et al. 2016). This increase in bundling is without regulation, leading to a 
disorganised actin-based cytoskeleton which is not circumferential and parallel to the 
cell periphery in foetal-liver derived mouse megakaryocytes (Kunishima, Okuno et al. 
2013). The platelets that are produced in patients with bleeding disorder, platelet 
type-15 are often increased in size and mildly decreased in quantity (Bottega, 
Marconi et al. 2015).  
1.5.2.7. DIAPH1 – Novel macrothrombocytopenia with hearing loss  
DIAPH1, which encodes the diaphanous related formin 1 protein, regulates 
microtubule stability and promotes actin assembly by forming a homodimer (Goode 
and Eck 2007; Chesarone, DuPage et al. 2010). DIAPH1 aids in the process of 
cytoskeleton remodelling upon competitive binding of Rho GTPases to a diaphanous 
auto-regulatory domain (DAD). The DAD domain, located near the carboxyl terminal, 
is usually bound to a diaphanous inhibitory domain (DID) inhibiting its activity. Two 
unrelated individuals were identified with a truncating nonsense c.3637C>T; 
p.Arg1213* transition that results in the loss of the RRKR motif in the DAD domain, 
rendering the protein in an inhibited state (Stritt, Nurden et al. 2016). A disruption in 
the process of DIAPH1 mediated cytoskeleton remodelling leads to a defect in 
proplatelet formation, similar to variants within ACTN1. Megakaryocytes also form 
heterogeneous clusters and patients show a mild thrombocytopenia with an increase 
in platelet volume characteristic with a defect in cytoskeleton remodelling.  
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1.5.2.8. FLNA – Isolated macrothrombocytopenia 
In platelets, filamin A acts as a cellular tether, connecting the underlying actin 
cytoskeleton, by a N-terminal ABD, to principal plasma membrane receptors such as 
GP1ba and the integrin αIIbβ3 (Falet 2013). This tether allows platelet-vessel wall 
interactions to mediate cytoskeleton remodelling upon activation and subsequent 
downstream signalling. Filamin A, encoded by FLNA, has previously been known to 
be the genetic cause of dominant X-linked bilateral periventricular nodular 
heterotopia (BPNH) (Sole, Coupry et al. 2009). Many FLNA related BPNH patients 
often present with haematological complications including haemorrhaging and 
thrombocytopenia. Due to FLNAs involvement in platelet function an unaffected 
related family member of two patients suffering from BPNH was sequenced due to 
presence of lifelong thrombocytopenia (80x109/L) and a history of menorrhagia 
(Nurden, Debili et al. 2011). A heterozygous point mutation, c.5407G>A, 
p.Glu1803Lys, was detected in a highly conserved region. X-inactivation was random 
but irregular megakaryocyte differentiation and a gradient FLNA expression pattern 
was noted in in vitro megakaryocyte cultures, supporting mutations in FLNA as the 
potential cause of a novel macrothrombocytopenia.  
1.5.2.9. PRKACG – Bleeding disorder, platelet type-19 
FLNAs role, although not fully understood carries importance as its proteolysis is 
tightly regulated through phosphorylation. To avoid targeted degradation FLNA is 
phosphorylated at p.Ser2152 by cAMP-dependant protein kinase A which is 
comprised of two catalytic subunits, the y-isoform of which is encoded by PRKACG 
(Jay, Garcia et al. 2000). To date, only one variant has only been found encoding 
PRKACG by whole exome sequencing of a single pedigree (Manchev, Hilpert et al. 
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2014). Paediatric patients displayed a severe thrombocytopenic count, requiring 
transfusion for life threating bleeding episodes. Platelets were also giant and 
megakaryocyte clusters were observed in bone marrow aspirations. Megakaryocytes 
derived from CD34+ patient progenitors also displayed rapid degradation of FLNA 
and a reduction in the percentage of proplatelet-bearing megakaryocytes.  
1.5.2.10. SRC – Novel thrombocytopenia with bone pathologies 
The SRC proto-oncogene, non-receptor tyrosine kinase, encoded by SRC, is a 
plausible pharmaceutical target due to the presence of activating mutations within 
several human cancers (Irby, Mao et al. 1999). SRC protein levels are high within 
platelets, and SRC-dependent phosphorylation plays an important role in platelet 
signalling pathways downstream from cell surface receptors (Golden, Nemeth et al. 
1986; Senis, Mazharian et al. 2014). So far a single heterozygous variation has been 
identified in a highly conserved residue within the C-terminal tail of the SRC kinase 
domain (Turro, Greene et al. 2016). The variant was identified using a unique 
approach comprising human phenotype ontology-term based filtering with whole 
genome sequencing (WGS). The mutated p.Glu527Lys allele predominates in patient 
platelets leading to elevated phosphorylation. Patients show a hyper-cellular bone 
marrow and patient-derived megakaryocytes show a reduced number of proplatelet 
extensions leading to a reduction in platelet number, a variable platelet size and 
alpha granule content.   
1.5.2.11. ANKRD26 – ANKRD26-related thrombocytopenia/THC2 
ANKRD26-related thrombocytopenia or Thrombocytopenia 2 (THC2) is a disorder 
unique due to its genetic cause. Unlike all other forms of IT, THC2 is not as a result 
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of disruptive mutations with the coding region of ANKRD26, instead mutations lie 
within a tight cluster within the 5’-UTR of the gene (Pippucci, Savoia et al. 2011). The 
majority of mutations lie within a 22 nucleotide stretch from c-113 to c-134 disrupting 
binding of RUNX1 and FLI1 which normally functions to silence expression during 
late megakaryopoiesis (Noris, Perrotta et al. 2011; Bluteau, Balduini et al. 2014). 
Prolonged expression of ANKRD26 causes increased circulating TPO and an 
increase in MPL-related TPO signalling via the MAPK pathway, leads to disrupted 
proplatelet formation (Bluteau, Balduini et al. 2014). The typical clinical presentation 
is a moderate reduction in platelet count, decreased platelet α-granules and a 
reduction in surface GP1a. Much like variants in RUNX1 and FLI1, there is also an 
increased propensity to developing myeloid malignancies (Noris, Favier et al. 2013). 
Recently the first missense mutation in ANRKD26, c.473A>G that segregates with 
disease and shares phenotypic similarities to THC2 patients was also reported (Al 
Daama, Housawi et al. 2013).   
1.5.2.12. GP1BA, GP1BB and GP9 – Bernard-Soulier Syndrome 
The products of four distinct genes (GP1BA, GP1BB, GPIX and GPV) assemble 
within the maturing megakaryocyte in a 2:2:2:1 stoichiometry to form the platelet 
membrane receptor GPIb/IX/V (Berndt, Shen et al. 2001). During haemostasis, the 
GP1b/IX/V receptor complex plays a critical role through binding of VWF to arrest 
platelets and form a thrombus. In BSS, surface expression is decreased or absent, or 
the function can be reduced (Lopez, Andrews et al. 1998). Although phenotypically 
characterised for over 60 years, genetic variations were first identified in the GP1BA 
gene just over 25 years ago (Bernard 1948; Ware, Russell et al. 1990). To date, 
genetic variations have been found to be the causative defect of BSS in three genes 
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of the GP1b/IX/V complex; GP1BA, GP1BB and GP9. Inheritance can be recessive 
or autosomal dominant causing two variably different forms of BSS, biallelic and 
monoallelic, respectively. Both diseases are characterised by a reduction in platelet 
count and the presence of giant platelets, often larger than red blood cells (Savoia, 
Kunishima et al. 2014). Monoallelic BSS is often limited to this phenotype whereas 
biallelic recessive BSS often causes a complete lack of response to sub-endothelial 
VWF which can be measured by in vitro aggregation response to ristocetin (RIPA) 
(Savoia, Kunishima et al. 2014). Outside of its role in haemostasis, the GP1b/IX/V 
complex also has an important role as a structural component of the cytoskeleton by 
binding FLNA, and the cytoskeleton signalling proteins calmodulin, 14-3-3ζ protein or 
the p85 subunit of phosphoinositide 3-kinase (Nurden, Debili et al. 2011; Andrews 
and Berndt 2013). This interaction aids in the relay of extracellular signals in 
proplatelet formation.  
1.5.2.13. ITGA2B and ITGB3 – Glanzmann Thrombasthenia 
Another platelet surface receptor with a major role in haemostasis that is affected by 
genetic variation is the integrin GPIIb-IIIa/αIIbβ3, the receptor for fibrinogen. Variants 
in the two encoding genes, ITGA2B and ITGB3, lead to qualitative deficiencies in the 
receptor causing the disorder known as Glanzmann thrombasthenia (GT) (Nurden, 
Fiore et al. 2011). Although still considered rare, GT is one of the more common 
bleeding diathesis (George, Caen et al. 1990). As with BSS, the main phenotypical 
attribute is mucocutaneous bleeding arising from a lack of platelet aggregation, 
however presentation is variable and often platelet count and size are unaffected. A 
number of patients have been reported however with heterozygous variants within 
either gene that leads to a reduction in platelet count and a marked increase in 
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platelet size (Peyruchaud, Nurden et al. 1998; Ghevaert, Salsmann et al. 2008). 
Platelet count is thought to be affected by aberrant proplatelet formation due to gain 
of function mutations leading to a partially activated receptor, however dominant-
negative variants have been reported in association with macrothrombocytopenia as 
well (Kunishima, Kashiwagi et al. 2011; Nurden, Fiore et al. 2011). 
1.5.2.14. CYCS – CYCS-related thrombocytopenia/THC4 
One gene whose involvement in platelet production currently, through the intrinsic 
apoptosis pathway, is controversial is Cytochrome C (CYCS). CYCS initiates 
apoptosis through the activation of caspase 9 and subsequently caspase 3, a 
dysregulation of which was originally suggested as a feature of platelet production 
(Jiang and Wang 2004; Morison, Cramer Borde et al. 2008). To date, two variants 
(p.Tyr49His [p.48 in original publication] and p.Gly42Ser [p.41 in original publication]) 
have been observed (Morison, Cramer Borde et al. 2008; De Rocco, Cerqua et al. 
2014). Intramedullary naked megakaryocyte nuclei, indicative of dysregulated 
megakaryopoiesis and premature platelet release, were identified in bone marrow 
aspirates. Furthermore, mouse lung fibroblasts transduced with Cycs variants show 
increased apoptotic activity in response to staurosporine. It was therefore first 
believed that apoptosis had a fundamental role in the timing of pro-platelet release, 
hypothesising that inhibition of actin polymerisation, a process required for 
appropriate proplatelet branching, activates the apoptotic pathway (Avanzi, Izak et al. 
2015). However, platelet production can proceed regardless of both the intrinsic and 
extrinsic apoptotic pathways (Josefsson, Burnett et al. 2014).  
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1.5.3. Disorders of platelet clearance/unknown functional 
disorders 
The fundamental processes governing the production of platelets are easily affected 
by deleterious mutations leading to thrombocytopenia. On the contrary, the main 
process regarding the intrinsic control of platelet lifespan and clearance is relatively 
untouched by genetic variation. There are two potential reasons that may explain 
this; that variants within the main pro-survival gene BCL2L1 are not viable or that 
they are considerably rare and even though the field of haemostatic genetics has 
progressed they have just not been identified yet. However, a number of genes with 
congenital mutations do exist that have a unique effect on platelet clearance by pre-
activating platelets. In addition, a number of genes have recently been identified 
where the functional effect of genetic variation has yet to be established. 
1.5.3.1. ADAMTS13 – Thrombotic thrombocytopenia purpura, 
Upshaw-Schulman Syndrome 
Variants in the metalloproteinase encoding gene ADAMTS13 are the genetic cause 
of a rare form of life-threatening systemic IT known as Upshaw-Schulman syndrome, 
or alternatively known as thrombotic thrombocytopenia purpura (TTP) (Levy, Nichols 
et al. 2001; Schiff, Roberts et al. 2004). Endogenous circulating ADAMTS13 cleaves 
VWF at the p.Tyr1605=Met1606 peptide allowing for the removal of circulating VWF 
from haemostatic vessels avoiding unwarranted platelet activation. In TTP, genetic 
variation renders the metalloproteinase function of ADAMTS13 inactive allowing for 
the accumulation of large hyperactive VWF multimers. These have the capacity to 
trigger platelet aggregation causing subsequent removal within the spleen. 
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Phenotypically this disorder presents with a reduction in platelet count due to this 
removal but also haemolytic anaemia, neurological symptoms and renal dysfunction 
which can threaten a patient’s life (Levy, Nichols et al. 2001). 
1.5.3.2. VWF – Von Willebrand disease type 2B 
The physical importance of VWF is known throughout haemostasis. Variants within 
the encoding VWF gene lead to functional deficiency causing von Willebrand disease 
(VWD). VWD encompasses a myriad of disorders, most of which do not affect the 
platelet count; however, type 2B does lead to thrombocytopenia. Causative variants 
of type 2B lead to a gain of function and an increased affinity of VWF for GP1b on the 
platelet surface (Othman 2011). Continuous interaction between the receptor and 
ligand disrupts megakaryopoiesis leading to the production of giant platelets (Nurden, 
Debili et al. 2006). In addition, large multimers of VWF that bind platelets are present 
in the circulation in a direct comparison to TTP (Nurden, Debili et al. 2006). In VWF 
knock-in mice these complexes are taken up efficiently by macrophages in the liver 
and spleen indicating an increased clearance as well as disruption to production 
(Casari, Du et al. 2013).  
1.5.3.3. STIM1 – Stormorken-York Syndrome 
Increased platelet clearance is also the proposed mechanism behind the 
thrombocytopenia observed in Stormorken-York syndrome. Caused by gain of 
function variants in STIM1, patients present with a reduction in platelet count due to 
pre-activation and subsequent removal within the spleen (Misceo, Holmgren et al. 
2014; Markello, Chen et al. 2015). The process of calcium uptake enables platelet 
activation. Upon sensing extracellular Ca(2+), STIM1 undergoes a conformational 
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change allowing it to interact and open ORAI1, a Ca(2+) release-activated Ca(2+) 
pore. Genetic variants within STIM1 lead to a gain of function, causing a 
constitutively active calcium channel and subsequent pre-activated platelet state.  
1.5.3.4. ABCG5 and ABCG8 – Thrombocytopenia with 
sitosterolemia 
Thrombocytopenia as a secondary symptom of sitosterolemia is a unique situation 
where a role in the normal balance of platelet production/platelet clearance is not 
affected. Sitosterolemia is a rare, autosomal recessive disorder caused by mutations 
in two adjacent ATP-binding cassette transport genes; ABCG5 and ABCG8. Both 
encoded proteins usually function to remove dietary sterols from the circulation by 
acting as a heterodimeric efflux pump. When mutated, there is a decrease in 
secretion of dietary sterols which leads to an accumulation in the circulation. 
Heterodimeric efflux pumps for sterols are not present on blood cells or platelets and 
therefore accumulated high levels are toxic, resulting in platelet death and 
subsequent thrombocytopenia. Interestingly, in ABCG5/ABCG8 KO mice, which are 
fed on high-plant-sterol diets, their platelets are also noted to be hyper-active and 
show impaired function.  
1.5.3.5. GNE – GNE-related myopathy with thrombocytopenia 
Like thrombocytopenia with sitosterolemia, variants in GNE have been noted to 
cause a disorder with a secondary symptom of thrombocytopenia. To date, two 
compound heterozygous variations have been reported in the gene encoding 
glucosamine (UDP-N-Acetyl)-2-epimerase (GNE) (Izumi, Niihori et al. 2014; Zhen, 
Guo et al. 2014). GNE functions as an enzyme in the sialic acid biosynthesis 
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pathway and is expressed within all cells of the haematopoietic lineage. Previous 
mutations have been associated with either sialuria or hereditary inclusion body 
myopathy, however a defining feature of severe platelet counts less than 45x109/L 
was identified in two unrelated pedigrees (Seppala, Lehto et al. 1999; Eisenberg, 
Avidan et al. 2001). All patients also presented with severe body myopathy as a 
primary symptom but patients did not display signs of myopathy until mid-
adolescence/early adulthood. The link between how variants in GNE can cause a 
reduction in platelet count is yet to be established. 
1.6. Genetic studies into inherited thrombocytopenia 
Due to the relative heterogeneity of ITs and the lack of definitive gold-standard 
platelet function test, DNA-based approaches have been vital in the improvement of 
clinical diagnosis. However, genetic studies have thus far been mainly focused 
around single disorders, utilising targeted sequencing mainly around an area of tight 
linkage to disease. DNA sequencing has revolutionised medical research since the 
invention of Sanger sequencing and the polymerase chain reaction (PCR) (Sanger, 
Nicklen et al. 1977; Mullis, Faloona et al. 1986). Traditional methods are now being 
replaced by massively parallel next generation sequencing of whole exomes and 
genomes, but their use in IT diagnosis is still limited and not without challenges. 
1.6.1. Pre-genomic era 
Many aforementioned disorders were often strongly phenotypically and clinically 
classified before the progression of genetic diagnostics became the clinical norm. 
This is indeed true for the three of the most prevalent disorders; Bernard-Soulier 
syndrome, Glanzmann Thrombasthenia and MYH9-related disorders. All disorders 
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were originally classified due to the presence of secondary symptoms in addition to a 
reduction in platelet count (George, Caen et al. 1990; Seri, Pecci et al. 2003; 
Andrews and Berndt 2013). Platelet function testing, mostly in the form of LTA, also 
played a strong role in the determination of disease. This allowed disorders to 
become characterised and distinguished, allowing for rapid genetic analysis later on 
in a number of individuals with a shared phenotype. A diagnostic approach like this 
follows a reverse genetics methodology, analysing the functional consequence and 
subsequently determining the genetic cause. It has allowed for a complete diagnosis 
of disorders and a move towards a situation where they are now routinely tested for 
in haematology labs throughout the UK. The tests utilise phenotypic assays; blood 
smears, aggregometry and flow cytometry, often in combination with single gene 
sequencing for efficient and accurate diagnosis. 
1.6.2. Post-genomic era 
As the field of molecular genetics has progressed, a number of studies have moved 
away from targeted sequencing of an area of disease linkage. More commonplace is 
utilising whole exome and whole genome sequencing when a patient’s genotype is 
not known. To date though this has largely been contained to small scale studies of 
single individuals or a small pedigree with a shared phenotype. While effective, and 
responsible for the discovery of a number of recent causative genes of IT, it is still 
often applied to patients with a strong phenotype. On the contrary, few studies have 
focused around the methodology of forward genetics; utilising genetic searching to 
find a variant and subsequently determining the effect of the variant and how it might 
be linked to the disease phenotype. 
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Panel sequencing refers to a strategy of designing singular baits or probes to a 
known region of interest allowing for parallel amplification and sequencing of multiple 
genes. It builds upon the fundamental methodology of Sanger sequencing but often 
now utilising next generation sequencing technology. This strategy has been adopted 
by a number of large scale studies that have begun into the genetic study of IT. Many 
are global and are pushing the boundaries of our knowledge but they are not without 
limitation. One of the largest studies into the genetics of IT utilised a combination of 
targeted panel sequencing with single gene Sanger sequencing to compile the 
results from 500 individuals (Balduini, Pecci et al. 2012). The study highlighted the 
correct prevalence of a number of forms of IT suggesting they are more common 
than previously thought. The most defining feature of the study though, was that 51% 
of index cases were without a genetic cause of disease. Over the past four years, 
since this study, a number of new forms of IT have been identified suggesting that 
this number would likely diminish. However, targeted sequencing is restrained by 
only being able to identify variants in genes that were previously known to cause 
disease. 
To combat this, a number of groups worldwide have started studies using the 
potential lack of restriction benefits of whole exome and whole genome sequencing 
to study IT. Each group has a unique approach to the problem and many form 
sections of larger consortiums looking at the molecular genetic effects of bleeding 
diathesis as a whole. Whole exome sequencing (WES) is becoming increasingly 
popular due to decreasing costs, improvements in efficiency and in ease of data 
handling (Warr, Robert et al. 2015). Since the first report of selectively sequencing all 
exomes successfully, WES has progressed into new capture methods, sample library 
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preparations and parallel sequencing techniques, but all retain the fundamental goal 
of sequencing all coding exons (Ng, Turner et al. 2009). 
The UK-GAPP study, which this thesis forms part of, takes a novel approach. The 
study aims to categorise completely a patient’s disease through a combination of 
extensive platelet phenotyping and broad whole exome sequencing to determine 
their genotype. 
The BRIDGE Consortium-Bleeding and Platelet Disorders (BPDs) study (B20) takes 
an alternative approach to genetic diagnosis in patients with a broad range of platelet 
and non-platelet based bleeding disorders. By combining whole genome and exome 
sequencing with annotation with Human Phenotype Ontology (HPO) terms they aim 
to characterise novel genetic variants in a large patient cohort (Robinson, Kohler et 
al. 2008; Maclachlan, Watson et al. 2016). Similarly, groups in Italy and the USA are 
progressing with projects incorporating next generation sequencing into the study of 
IT as well.   
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1.7. Thesis Hypothesis and Aims 
By combining extensive phenotyping with next generation sequencing in the form of 
WES I hypothesise that we will determine novel genetic variants in previously 
undiagnosed patients with IT; allowing for an expansion of our current knowledge of 
the fields surrounding platelet production, lifespan, function and death. 
The aims of this thesis are to build upon previous work within the UK-GAPP study 
specifically looking at the molecular genetics behind IT. As no large scale WES 
studies have been applied to this disease subtype before, the work will be novel in its 
approach. Through this work I aim to try to determine novel genetic causes of 
disease and try to determine how genetic variation can lead to a fundamental loss of 
function in platelet formation, function or lifespan. The overall aim of my thesis is 
therefore; 
 To elucidate novel causative mutations in patients with inherited 
thrombocytopenia. 
I will approach this in a number of ways, including: 
 Develop and use methodology to fully determine a patient’s phenotype and 
platelet function. 
 Utilise whole exome sequencing to determine novel candidate mutations in 
patients with unknown genetic aetiology of disease. 
 Validate the effect of genetic variation and how detrimental mutation can 
cause a patient’s bleeding diathesis.  
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2. Materials and Methods 
2.1. Materials 
All general lab consumables and plastic ware were purchased from StarLab 
(StarLab, UK). Unless otherwise stated all materials and reagents were available fro 
m Sigma Aldrich (Sigma Aldrich, UK). 
 
Table 2.1.1 Materials and software used throughout this project and their 
suppliers. 
 
Material/Software Supplier 
4% citrate concentrated solution Sigma Aldrich, UK 
AggroLink ChronoLog/LabMedics, UK 
Agilent SureCall v3.5 Agilent Technologies, UK 
Agilent SureDesign v3.5.4 Agilent Technologies, UK 
Chromas Technelysium Pty Ltd, Australia 
Citrate blood collection tubes BD, UK 
ExonPrimer Helmholtz Center Munich, 
Germany 
Human Protein Atlas Uppsala Universitet, Sweden 
Human Splicing Finder Aix Mareseille Universite, France 
IGV Broad Institute, USA 
MIT CRISPR database MIT, USA 
Mutation Surveyor SoftGenetics, USA 
Mutation Taster Charite, Berlin 
Novoalign Novocraft technologies, Malaysia 
Polymorphism Phenotyping v2 Harvard, USA 
Primer3 Open Source 
Protein Variation Effect Analyser J.Craig Venter Institute, USA 
Shandon™ColorFrost™ Plus microscope 
slides 
ThermoFisher, UK 
Siliconized glass cuvettes LabMedics, UK 
Sorting Intolerant From Tolerant J.Craig Venter Institute, USA 
Spray-coated KDEDTA blood collection tubes BD, UK 
Sysmex XN1000 reagents (all) Sysmex, UK 
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Database Website Last accessed 
1000G project www.internationalgenome.org/  Oct-16 
ClinVar www.ncbi.nlm.nih.gov/clinvar/  Oct-16 
dbSNP139 www.ncbi.nlm.nih.gov/projects/SNP/ Oct-16 
EVS evs.gs.washington.edu/EVS/ Oct-16 
ExAC exac.broadinstitute.org/ Oct-16 
HGMD www.hgmd.cf.ac.uk/ac/index.php  Oct-16 
 
Table 2.1.2 Databases used throughout this project. 
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2.2. Study approval 
The UK-GAPP study was approved by the National Research Ethics Service 
Committee of West Midlands–Edgbaston (REC reference: 06/MRE07/36) and 
participants gave written informed consent in accordance with the Declaration of 
Helsinki. This study was registered at www.isrctn.org as #ISRCTN 77951167. The 
UK-GAPP study is also included in the National Institute of Health Research Non-
Malignant Haematology study portfolio (ID9858). 
2.3. Patient recruitment 
All patients included in the UK-GAPP study were recruited either through regional 
Comprehensive Care Haemophilia centres across the UK or by referring 
haematologists specialising in bleeding disorders. Patients were recruited following a 
clinical history and subsequent diagnosis of a suspected platelet-based bleeding 
disorder. Patients were identified as suffering from inherited thrombocytopenia after 
whole blood platelet counts were found to be below 150x109/L in routine 
haematological analysis. Cases were included within the study that ranged between 
150-200x109/L if it was deemed that there was a strong family history of shared 
phenotypic disease between affected individuals or if previous platelet counts were 
below 150x109/L prior to enrolment. Genetic pedigrees were taken when available.  
Selection for recruitment to the UK GAPP study was dependent upon meeting 
specific criteria as set out by the study.  
Patients were invited to participate in the study if they satisfied all of the inclusion 
criteria:  
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a. Aged 0-85 years old 
b. Abnormal bleeding symptoms compatible with a platelet function disorder 
c. Results from coagulation factor tests all within local laboratory reference 
intervals 
d. Absence of demonstrable acquired platelet dysfunction. 
Patients were excluded from the study if they;  
a. Had recently undergone major surgery 
b. Had chronic renal failure requiring dialysis 
c. Had severe anaemia (Hb<8g/dl) 
d. Had recently had blood/platelet transfusion or taking medications known to 
affect platelet function. 
Patients were also excluded if they have a known form of inherited 
thrombocytopenia. Patients were routinely tested for the presence of BSS and 
MYH9-related disease upon suspicion of an inherited platelet based bleeding 
disorder as standard clinical practice. Clinical testing varied dependant on the 
referring haematological centre but comprised of initial analysis by blood film to 
determine the presence of giant platelets and leukocyte inclusion bodies in all cases. 
Results were then confirmed by genetic analysis if available. Patients were also 
excluded if bleeding was thought to be as a result of ITP (a highly variable platelet 
count was observed over a sustained period) or other non-platelet based bleeding 
disorders including von Willebrand disease (excluding type 2B) and inherited 
coagulation factor deficiencies.  
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2.4. Healthy controls 
Healthy donor volunteers were at least 18 years of age and considered healthy if 
they did not have a history of bleeding symptoms or did not require long-term medical 
therapy. They were also only included within the study if they had refrained from 
drugs known to influence platelet function in the previous two weeks and had not 
donated blood in at least that same time period.  
2.5. Sample collection 
Sample collection varies by age of consenting patient. In all cases, blood was 
collected simultaneously in both patient and control at the site of patient sample 
collection if possible. If not possible, the control sample was collected at the site of 
analysis in a similar time scale to the patient sample. One control sample was used 
for multiple patient samples collected on the same day at the same collection site. 
Blood was transported from all centres at ambient temperature (approximately 20°C) 
by courier to the laboratory in Birmingham. The UK-GAPP study has previously 
shown that the results in PRP in samples transported in this way are 
indistinguishable from those locally collected (Dawood, Wilde et al. 2007). 
For adults, fifty millilitres of blood in 3.2% trisodium citrate was collected by 
venepuncture. For paediatric patients (<18 years), up to 20ml, dependant on the age 
of the consenting patient, of blood in 3.2% trisodium citrate was collected by 
venepuncture. In most cases, blood was collected into BD Vacutainer® 2.7mL plastic 
citrate blood collection tubes (BD, UK, #363083), however, collection tubes did vary 
occasionally due to specific protocols at each referring haematological centre. 
Control samples that were collected in house at the site of analysis were collected by 
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venepuncture into a 1:9 ratio with 4% citrate concentrated solution (Sigma-Aldrich, 
UK, #S5770).  
For all patients, an additional 2-4mL of ethylenediaminetetraacetic acid disodium salt 
solution (EDTA) anti coagulated blood was collected for whole blood cell counts. 
Blood was collected by venepuncture into BD Vacutainer® plastic whole blood tubes 
with spray-coated KDEDTA (BD, UK, #367835) for a concentration of 1.8mg of EDTA 
per millilitre of blood. 
2.6. Preparation of whole citrated blood 
Platelet rich plasma (PRP) was utilised in both methods of platelet function analysis 
used in this thesis and was originally used to determine MPV up until October 2013. 
PRP was obtained by centrifugation of whole blood for 20 minutes at 200g in a 
Sorvall Legend XTR centrifuge (ThermoFisher, UK, #75004520). Platelet counts in 
PRP were measured with a Coulter Z2 analyser (Beckman Coulter Ltd, UK) to 
determine the method of platelet function analysis to use and to measure MPV. 5µL 
of prepared PRP was diluted in 10mL diluent, measured three times and an average 
value taken for both platelet count and MPV. After October 2013, only platelet count 
in PRP was measured. 
PRP from patients presumed to suffer from macrothrombocytopenia was prepared 
differently. Presence of macrothrombcytopenia was originally determined by clinical 
report, and since October 2013, macrothrombocytopenia was determined by an MPV 
>13fL in whole blood cell counts on the Sysmex XN-1000™blood analyser. In both 
instances, PRP was obtained by centrifugation for 30 minutes at 100g to try to 
eliminate loss of larger platelets in the final PRP layer.  
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2.7. Preparation of wash platelets 
Washed platelet were prepared for use within platelet spreading assays. 20mL of 
acid-citrate-dextrose (ACD) (Sigma Aldrich, UK, C3821) and 50mL of modified 
Tyrode’s buffer (134mM NaCl, 2.9mM KCl, 0.34mM Na2HPO412H2O, 12mM 
NaHCO3, 20mM HEPES, 1mM MgCl2 all reagents available from Sigma Aldrich) 
containing 0.045g glucose (pH 7.3) were pre-warmed to 30°C. 5mL of warmed ACD 
was added to 50mL fresh blood (containing 5mL sterile sodium citrate as 
anticoagulant) and centrifuged for 20 minutes at 200g in a Sorvall Legend XTR 
centrifuge. The supernatant PRP was removed and 10µg prostaglandin I2 (PGI2) 
(10µL of stock solution at 1mg/mL [Sigma Aldrich, UK. #P6188]) was added and 
mixed before centrifugation at 1000g for 10 minutes. The supernatant was discarded 
and the remaining pellet resuspended in 1mL of modified Tyrode’s buffer containing 
150µL of ACD before being made up to a final volume of 28mL containing 25mL 
modified Tyrode’s and 3mL ACD. Platelet count was determined using the Coulter Z2 
analyser. The platelets were re-pelleted by addition of 10µg PGI2 and centrifuged at 
1000g for 10 minutes. An appropriate volume of modified Tyrode’s buffer containing 
ACD was added to resuspend the pellet to a final platelet concentration in solution of 
2x107/mL. 
2.8. Platelet counts in whole EDTA-anticoagulated blood 
Whole blood cell counts were performed on EDTA-anti coagulated blood using the 
Sysmex XN-1000™ haematology analyser (Sysmex, UK) from January 2014. Prior to 
this date, platelet and white blood cell counts in whole blood were determined at the 
haematological centre of study consent. Repeat patients were measured by the 
Sysmex XN-1000™ if a repeat sample was received after January 2014. 
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Counts on the Sysmex XN-1000™ were taken in manual operating mode for both 
sealed and open tubes depending on the previous method of sample collection. The 
analyser utilises the properties of fluorescent flow cytometry to determine accurate 
whole blood cell counts. There are five standard channels of analysis, however for 
this study only two were used. The WNR channel evaluates white blood cell count 
(WBC), basophils and nucleated red blood cells. The PLT-F channel exclusively 
measures platelets. An accurate platelet count is determined using oxazine; an RNA 
binding dye. A measurement of platelet production (Immature Platelet Fraction - IPF) 
and the mean platelet volume (MPV) is also in this channel. Platelet counts were 
checked against both the impedance (PLT-I) and optical (PLT-O) channels that are 
generated. If the values differed significantly, samples were re-run. Quality control 
material (XN check [Sysmex, UK]) was tested on a daily basis to ensure instrument 
performance throughout the study. A normal range was determined by analysis of 40 
healthy volunteers in an alternate study; ranges are represented as the mean value 
+/-2 standard deviations as seen in section 3.6. 
2.9. Platelet function testing 
Platelet function testing was approached on an individual basis dependant on the 
platelet count in PRP. Patients with a platelet count in PRP exceeding 1.5x108/mL 
were analysed by light transmission aggregometry (LTA) with lumiaggregometry. 
Patients with a platelet count <1.0x108/mL were analysed by a custom designed flow 
cytometry assay as outlined in section 2.8.2. The reason for this was that previous 
work within the laboratory determined that LTA was insensitive for patients with 
thrombocytopenia and a platelet count lower than 1.0x108/mL (Dawood, Wilde et al. 
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2007). Patients with a borderline platelet count between 1.0x108/mL and 1.5x108/mL 
were measured by both assays in case of discrepancies.  
2.9.1. Light transmission aggregometry with lumiaggregometry 
LTA with lumiaggregometry was performed in adjacent studies originally by Dr Gillian 
Lowe and subsequently by Miss Sian Drake and Dr Rashid Al Ghaithi. All patients 
were analysed as mentioned in previous studies published by the UK-GAPP study 
group (Dawood, Wilde et al. 2007; Dawood, Lowe et al. 2012). 
Patient and control samples were run simultaneously in all cases and subjected to 
the same methodology and agonist conditions. All aggregations were performed 
using a dual Chrono-log 460VS lumiaggregometer (Chronolog, US) and measured 
for light transmittance from baseline in native undiluted PRP upon agonist 
stimulation. ATP secretion from dense granules was measured using the same 
lumiaggregometer utilising the luciferase assay (Holmsen, Holmsen et al. 1966; 
Dawood, Wilde et al. 2007). Undiluted autologous platelet poor plasma (PPP) was 
used as a reference, and to set the aggregation scale, and was obtained after further 
centrifugation of whole blood samples at 1000g for 10 minutes in the Sorvall Legend 
XTR centrifuge (mentioned in more detail in section 2.9). All aggregations were 
performed within 6 hours of preparation of the PRP; priority was given to time-
sensitive agonists which were used first e.g. ADP. PRP samples (400µl) were pre-
warmed in siliconized glass cuvettes (LabMedics, UK) at 37°C for 120s and stirred at 
1200rpm for 60s prior to agonist addition. Originally, a chart recorder was used, 
where percentage aggregation was calculated by the observed change in optical 
density compared to the full scale aggregation as set by the PPP control. In more 
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recent testing, responses were assessed using the AggroLink computer interface 
(ChronoLog/LabMedics, UK). 
Platelets from patients and healthy volunteers were exposed to the following agonists 
in Table 2.9.1. 
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Agonist Concentrations used Supplier 
ADP 3, 10, 30 and 100µM Sigma-Aldrich, UK, #A2754 
Adrenaline 10 and 30µM Sigma-Aldrich, UK, #E-4375 
Arachidonic acid 0.5, 1 and 1.5mM Cayman Chemical,USA,#10006607 
PAR-1 peptide 30 and 100µM Alta Biosciences, Birmingham, UK 
PAR-4 peptide 100, 250 and 500 µM Richard Farndale, Cambridge, UK 
Collagen 1, 3 and 10µg/mL Nycomed, Austria, #NYAR 1130630 
Collagen-related peptide 
(CRP) 
1 and 3µg/mL In-house synthesis 
Ristocetin 1.5 and 2mg/mL Helena Laboratories, USA, #5372 
 
Table 2.9.1 Agonists used for routine LTA assessment. PAR-1 peptide  [PAR-1 
specific thrombin receptor activating peptide with sequence SFLLRN]. PAR-4 
peptide [PAR-4 receptor-specific peptide with sequence AYPGKF]  
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A restricted panel of agonists was used initially and expanded or repeated if deemed 
necessary due to variable responses. If responses to ADP or arachidonic acid, two 
receptors involved in Gi signalling and the TxA2 pathway, were deemed abnormal 
PRP was also exposed to the thromboxane receptor agonist U46619 (1 and 3mM) 
(Cayman Chemicals, USA, #CAY16450).  
All agonists were diluted in phosphate buffer saline (PBS) with the exception of 
collagen and CRP which were diluted with their respective diluents. 
Secretion was measured by lumiaggregometry by adding 30µl of CHRONO-LUME™ 
(Chronolog, USA, #395) to the highest concentration of each agonist tested. 
CHRONO-LUME™ contains 0.2mg luciferin, 22,000 units d-luciferase plus 
magnesium sulphate, human serum albumin, stabilizers and buffer per vial. It was 
added during PRP pre-warming following manufacturer’s instructions. ATP secretion 
was quantified by adding a known amount (4nmol) of ATP standard (Chronolog, 
USA). As with aggregation most recently, secretion was assessed using the 
AggroLink computer interface. 
2.9.2. Flow cytometry 
An in-house flow cytometry assay was originally developed by Dr Gillian Lowe and 
was routinely used for the assessment of platelet function in patients with a platelet 
count in PRP of <1.5x108/L. Patient and control PRP was subjected to the same 
conditions, agonists and methodology simultaneously. 
Flow cytometry analysis focuses on three main areas; (i) the resting quantitative 
levels of cell surface receptors, (ii) alpha granule release upon activation by a panel 
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of agonists measured by quantitative P-selectin (CD62P) cell-surface expression and 
(iii) the binding of fibrinogen to activated platelets.  
(i) Resting cell surface levels of CD41 (integrin α-IIb, encoded by ITGA2B), CD42b 
(glycoprotein 1b α-chain, encoded by GP1BA) and GPVI were measured. 45µl of 
native PRP was added to individual reactions containing 5µL monoclonal mouse anti-
human CD41/FITC clone 5B12 (Dako, Denmark, #47088) or 5µL FITC mouse anti-
human CD42b (BD, UK, #555472), for a final concentration of antibody in PRP of 
1:10. The solutions were incubated for 40 minutes at room temperature (~20°C). 45µl 
was added to 5µl 1:1000 diluted in PBS unconjugated anti-GPVI antibody (Prepared 
in house by Dr Eelo Gitz) and incubated for 30 minutes at room temperature (~20°C), 
after 15 minutes 2.5µL of anti-mouse IgG (whole molecule) F(ab’)2 fragment-FITC 
(Sigma Aldrich, UK, #F2883) was added. All reactions are stopped after the allocated 
times with the addition of a five-fold volume (250µL) of ice-cold PBS. Reaction 
controls including a blank (void of any antibody) and an isotype control (5µL of 
Isotype reagent mouse IgG1/FITC [Dako, Denmark, #X0927]) were ran 
simultaneously on both patient and control samples. 
(ii) Alpha granule release upon agonist stimulation was measured as follows. 45µL of 
native PRP was added to 5µL of FITC mouse anti-human CD62P (BD, UK, #555523) 
and incubated at room temperature (~20°C) for 40 minutes. Individual solutions of 
antibody and PRP were then exposed to the following agonists separately; ADP (3 
and 30µM), CRP (0.3 and 3µg/mL) and PAR-1 peptide (10 and 100µM) and the 
solutions incubated for 2 minutes at 37°C. The reaction was subsequently terminated 
with the addition of a fivefold excess of ice cold PBS. Blank and IgG isotype controls 
were run simultaneously in tandem without the addition of any agonists. 
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(iii) Fibrinogen binding was measured by determining the relative levels of polyclonal 
rabbit anti-human Fibrinogen/FITC (Dako, Denmark, #F0111) to the cell surface 
receptor GpIIb/IIIa acting as a marker of integrin activation. 45µL of PRP, diluted 1:10 
in PBS, was added to 5µL of FITC-conjugated fibrinogen. The same panel of 
agonists were used to determine fluorescent fibrinogen binding as P-selectin 
expression. All reactions were incubated at 37°C for 2 minutes before the reaction 
was terminated by the addition of a fivefold excess of ice cold PBS. In addition to all 
individual agonist reactions, a blank control was run in tandem. 
All agonists used were the same as those used in LTA with lumiaggregometry so 
were sourced from the same suppliers. 
All reactions including stimulated and resting cell surface reactions from both 
patient(s) and control were then analysed using an Accuri™ C6 flow cytometer (BD, 
UK). Samples were run ungated, at slow flow rate, 14µL/min, 10µm core, and 10,000 
events were recorded per sample.  
Mean fluorescent intensity (MFI) was calculated from the 10,000 recorded events 
and compared for each reaction against the parallel travel control. All reactions were 
also compared to responses from a panel of 20 healthy volunteers for each reaction. 
2.10. Sample storage – Protein and buffy coat 
Remaining PRP, after use for platelet function testing, was processed for storage of 
platelet based protein. An appropriate volume of PRP containing 3x108 platelets, as 
determined from the mean platelet count in PRP, was added to labelled 
polypropylene Falcon™ 15mL conical centrifuge tubes. 1µL of PGI2 (1mg/mL stock 
solution) was added to each sample and mixed, and the samples immediately 
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centrifuged at 2000g for 10 minutes creating a cell pellet. The supernatant was 
removed and discarded by pipetting and the cell pellet resuspended in 1mL PBS 
before being transferred to a labelled 1.5mL Eppendorf tube. 1µL of PGI2 was then 
added, the sample mixed, and immediately centrifuged in a ThermoFisher Heraeus 
Pico 21 microcentrifuge (ThermoFisher, UK) at 13,000rpm for 2 minutes. Following 
centrifugation, the supernatant was removed and the remaining cell pellet 
resuspended in 600µL 1x sample buffer (SB). Samples were stored at -80°C until 
needed. 
1x sample buffer; 60mM Tris-HCl pH 6.8 (Sigma Aldrich, UK, T6455), 2% SDS (20% 
solution) (Sigma Aldrich, UK, #L3771), 10% glycerol (Sigma Aldrich, UK, #G5516), 
and made up to 10mL with dH20. Brilliant Blue R (Sigma Aldrich, UK, #B7920) was 
added to visualise loaded protein in electrophoresis gels.  
Following removal of PRP from patient and control whole blood samples after 
centrifugation, samples were subsequently centrifuged at 1000g for 10 minutes in a 
Sorvall Legend XTR centrifuge. Further centrifugation separated the remaining whole 
blood into PPP and a red cell mass separated by a thin layer of white blood cells 
known as the buffy coat. The buffy coat was removed by pipetting and added to 
labelled 1.5ml Eppendorf tubes. Buffy coat was stored at -80°C until needed. Control 
buffy coat was not stored. 
2.11. Preparation of platelet lysates from washed platelets 
Prior to preparation of platelet lysates 2x lysis buffer was prepared. 2x lysis buffer 
contained; 300mM NaCl, 20mM Tris, 2mM EGTA, 2mM EDTA, and 4mL NP-40 
detergent (IGEPAL® CA-630) (Sigma Aldrich, UK, #I8896). 2x lysis buffer was made 
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up to 200mL with dH2O and adjusted to a pH of 7.5. On the day of preparation, 10mL 
of extraction buffer was prepared containing; 9.536mL of 2x lysis buffer and the 
addition of the following protease inhibitors (250µL sodium vanadate, 100µL 
leupeptin, 100µL AEBSF, 10µL aprotinin, and 4µL pepstatin). An equal volume of 
extraction buffer was added to prepared washed platelets and incubated on ice for 40 
minutes with mixing by vortex every 10 minutes. Following incubation cells and lysis 
buffer were spun at 4°C at 12000g for 20 minutes. Following centrifugation, the 
supernatant was collected and used for subsequent experimentation. 
2.12. Preparation of lysates for protein analysis from cell lines 
Three cell lines were utilised within Western blot (WB) analysis as positive and 
negative controls of expression.  
DAMI (Megakaryoblast, human) (ATCC, US, #CRL-9792) 
OAT1 HEK 293T/17 (referred to as HEK293T herein) (ATCC, US, #CRL-11268G-1) 
HEL (human erythroleukaemic cell line) (Mike Tomlinson, Birmingham, UK) 
Cell line lysates were prepared in the same fashion as washed platelet lysates. 
2.13. DNA extraction from buffy coat and whole blood 
DNA extraction from both buffy coat and whole blood was completed using the 
Gentra Puregene Blood DNA extraction kit (Qiagen, UK, #158389).  
For buffy coat, 750µL of thawed, mixed buffy coat was dispensed into a 15mL 
polypropylene Falcon™ tube. Three volumes of RBC lysis solution (2.25mL) was 
added and inverted to mix. The mix was left to incubate for 10 minutes at room 
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temperature (~20°C) and inverted once during incubation. The non-lysed cells were 
pelleted by centrifugation at 2000g for 5 minutes. The supernatant was discarded by 
pouring leaving approximately 100-200µL residual liquid left. The cell pellet was 
resuspended in this residual supernatant by vortexing the tube vigorously for 30 
seconds. 3mL of cell lysis solution was then added to the resuspended pellet and the 
mixture vortexed for 30 seconds to lyse the cells. If cell clumps were visible, the 
mixture was incubated at 37°C for up to 24 hours, the mixture was periodically 
vortexed throughout the period to aid in lysis. Once the solution was homogenous, 
15µL of RNase A solution was added and the solution mixed by inverting 25 times. 
The solution was re-incubated at 37°C for another 30 minutes before being cooled to 
room temperature. 3mL of protein precipitation solution was then added and the 
solution was vortexed for 20 seconds at high speed. The precipitated protein was 
pelleted by centrifugation at 2000g for 5 minutes. The DNA containing supernatant 
was transferred into a clean labelled 15mL polypropylene Falcon™ tube before 3mL 
of 100% isopropanol was added. The solution was mixed by inverting gently 50 times 
before the DNA was pelleted by centrifugation at 2000g for three minutes. The 
supernatant was discarded and the tube drained on a paper towel. 3mL of freshly 
made 70% ethanol was added and the tube inverted to wash the DNA pellet. The 
DNA was re-pelleted by centrifugation at 2000g for one minute. Again, the 
supernatant was discarded and the pellet left to air dry inverted on a paper towel. 
Once dry, 100-500µL of DNA hydration solution was added depending on the size of 
the DNA pellet as judged by eye and the mixture was vortexed for 10 seconds. The 
solution was incubated at 55°C overnight to allow the DNA to go into solution. 
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DNA extraction of whole blood followed the same process with the exception of an 
original starting volume of 2mL of fresh whole EDTA-anticoagulated blood added to a 
three times volume of RBC lysis solution. 
Stored buffy coat was freeze thawed a maximum of twice before being discarded to 
avoid degradation of the stored DNA. 
All DNA was stored at -80°C, DNA to be used frequently was aliquoted to avoid 
excess free-thawing.  
2.14. DNA quantification 
DNA was quantified depending on the following uses. DNA extracted for whole 
exome sequencing was quantified using Qubit® 3.0 fluorometric quantification 
(ThermoFisher, UK). 3µL of DNA sample was quantified each time according to the 
manufacturer’s Qubit® dsDNA Broad Range (BR) assay kit instructions, and quantity 
and quality was determined on a Qubit 3.0 Fluorimeter (ThermoFisher, UK, #Q32850 
for BR kit). Standards were re-run each day samples were analysed.  
DNA for any other use other than whole exome sequencing was quantified using a 
NanoPhotometer® P360 Spectrophotometer (Implen, UK). Samples were vortexed to 
mix and 1µl of sample was tested and repeated two additional times. The average 
concentration and 260/280 values were recorded. Readings were blanked with 1µL 
of DNA hydration solution. 
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2.15. Next generation sequencing 
2.15.1. Whole exome sequencing 
Whole exome sequencing was performed externally by collaborators in King’s 
College London headed by Prof Michael Simpson. <1µg of quantified genomic DNA 
was transported at ambient room temperature in sealed 1.5mL Eppendorf tubes. 
DNA was subsequently enriched for coding regions and intron/exon boundaries using 
the SureSelect Human All Exon 50Mb Kit (Agilent Technologies, UK) following the 
manufacturer’s instructions. Sequencing was performed on an Illumina HiSeq 2500 
(Illumina, UK) with 100bp paired-end reads. Sequences were aligned using 
Novoalign (Novocraft technologies, Malaysia) that aligns based upon a Needleman-
Wunsch algorithm with affine gap penalties to the reference genome (hg19). 
Duplicate reads and reads mapping to multiple locations were excluded from 
downstream analysis. Single nucleotide variations and small insertions/deletions 
were identified and filtered for quality using the SAMtools software package and in-
house software tools (Li, Handsaker et al. 2009). All calls with a read coverage of <4 
were excluded from further analysis. Novelty of filtered variants was determined by 
comparison to known variants present within dbSNP139, the 1000 Genomes Project, 
EVS (evs.gs.washington.edu/EVS/) and the results from over 1200 in house control 
exomes analysed using the same protocol.  
Copy number variants (CNVs) were detected using ExomeDepth (Plagnol, Curtis et 
al. 2012). CNVs were analysed using bioinformatics tailored to IT and will be 
discussed in section 4.3.4. 
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Variant called and post aligned sequencing bioinformatics was approached in a 
unique way and will be discussed in results section 4.3.1 as it forms part of this 
thesis. 
2.15.1.1. Analysis of 5’UTR ANKRD26 variants 
Raw aligned reads of all exomes were analysed separately using the Integrative 
Genomics Viewer software (Robinson, Thorvaldsdottir et al. 2011) to determine the 
presence of variants within the 5’ untranslated region (UTR) of ANKRD26. 
2.15.1.2. Conservation and pathogenicity prediction 
Conservation at the site of variation was determined using phyloP and phastCons 
scores. Scores were precomputed and offered by UCSC and coupled with the 
pathogenicity prediction software MutationTaster. PhlyoP values range between -14 
and 6 and measure conservation at individual columns, ignoring the effects of 
neighbouring bases. Sites predicted to be conserved are assigned positive scores, 
those that are considered fast-evolving are assigned negative scores. phastCons 
values vary between 0 and 1 and reflect the probability that each nucleotide belongs 
to a conserved region, based upon the multiple alignment of genome sequences 
from 46 different species. The closer the value is to 1, the more probable the 
nucleotide is conserved. Only the value for the site of variation will be noted, the 
values for flanking bases are computed but not considered.   
Pathogenicity was predicted using three separate in silico based pathogenicity 
prediction software. These were; MutationTaster (Schwarz, Cooper et al. 2014), 
Sorting Intolerant from Tolerant (SIFT) with Protein Variation Effect Analyzer 
(PROVEAN) (Kumar, Henikoff et al. 2009; Choi, Sims et al. 2012), and Polymorphism 
Phenotyping v2 (PolyPhen-2) (Adzhubei, Schmidt et al. 2010). 
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MutationTaster uses a Bayes classification to predict the disease potential of an 
alteration. Individual models are used dependant on the nature of the variant in 
question and the predictions questioned with outputted probability value of certainty. 
Variants are predicted as either disease causing or polymorphisms, if the variants are 
known they are described automatically. 
SIFT deciphers tolerated from deleterious sequences dependant on the sequence 
homology in multiple aligned sequences. It works on the premise that protein 
evolution is correlated with protein function. Positions with a normalised probability of 
less than 0.05 are predicted to be deleterious, those greater than or equal to 0.05 are 
tolerated. 
PROVEAN introduces a delta alignment score based on the reference and variant 
versions in comparison to sequence homologs. The threshold is set at -2.5 for binary 
classification, scores below the threshold are deleterious, those above, neutral.  
PolyPhen-2 determines pathogenicity dependant on the sequence, phylogenetic and 
structural information characterising the substitution. Two pairs of datasets predict 
the pathogenicity score independently, for this study HumVar scores were used 
which uses all human disease-causing mutations from UniProtKB as a positive 
control together with common human nsSNPs (minor allele frequency (MAF)>1%) 
with no involvement in disease, which are treated as non-damaging.  
Splice site predicted was performed using Human Splicing Finder 
(www.umd.be/HSF3 Last accessed February 2017) which combines algorithms 
based on either PWM matricies or maximum entropy principle to predict donor or 
acceptor splice site changes (Desmet, Hamroun et al. 2009).  
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2.15.1.3. Variant classification 
Candidate variants were classified following the guidelines for the interpretation of 
sequence variants as recommended by a joint consensus of the American College of 
Medical Genetics and Genomics and the Association for Molecular Pathology 
(Richards, Aziz et al. 2015). Dominant inheritance was assumed for all patients 
unless exception was noted from patient provided family histories. All criteria for the 
determination of predicted pathogenicity were maintained as stated with the 
exception of segregation within multiple affected family members. As the majority of 
variants observed in this study are novel, classification of segregation was 
determined as follows:  
When the variant was present in either; two affected related individuals and 
not present in at least one unaffected related family member or one affected 
individual and at least two unaffected related individuals, it was classed as supporting 
evidence of pathogenicity.  
When the variant was present in either; three affected related individuals and 
not present in at least one unaffected related individual or at least three affected 
individuals across at least two families it was classified as moderate evidence of 
pathogenicity.  
When the variant was present in more than three affected related individuals 
across at least three generations and not present in at least two controls it was 
classified as strong evidence of pathogenicity.  
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2.15.2. Thrombocytopenia specific panel sequencing 
A thrombocytopenia panel was designed and performed as an initial NGS 
sequencing/pre-screen before whole exome sequencing in collaboration with the 
Regional Genetics laboratory at Birmingham Women’s Hospital.   
The panel was designed using the Agilent SureDesign v3.5.4 (Agilent Technologies, 
UK) design software. The original design included the 30 genes present in Table 
2.15.1. 
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Gene 
ABCG5 
ABCG8 
ADAMTS13 
ANKRD18A 
ANKRD26 
CYCS 
FLI1 
FLNA 
FYB 
GATA1 
GFI1B 
GP1BA 
GP1BB 
GP5 
GP9 
HOXA11 
ITGA2B 
ITGB3 
MKL1 
MPL 
MYH10 
MYH9 
NBEAL2 
ORAI1 
RBM8A 
RUNX1 
SLFN14 
STIM1 
TUBB1 
WAS 
 
 
Table 2.15.1 Genes including within the first version of the Agilent 
SureSelectQXT IT specific sequencing panel 
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The 30 genes encompassed; genes previously identified to cause IT as well as some 
of their related genes and novel genes identified within this study. Sequencing 
probes/baits were designed to cover the following regions; all coding exons, the 
5’UTR and 3’UTR regions and ±10 bp flanking from the intron-exon boundary. 
Sequencing baits were designed with 2x density so that each desired region was 
covered by at least two overlapping probes. Baits were also designed with the 
strictest masking stringency settings possible. SureDesign masks repetitive 
sequences dependant on three masking tools; RepeatMasker, WindowMasker and 
Uniqueness 35 track. The design software uses combinations of all three tools to 
create three masking stringencies which vary in their inclusiveness of repeat regions. 
If baits could not be found in the highest stringency possible, stringency was 
decreased until they could be found. 18 genes were covered entirely by the most 
stringent of settings, eight genes were covered by most and moderate stringency 
settings and the remaining four genes were covered in sections by a combination of 
all three stringency settings. Balanced boosting of GC-rich probes was used which 
replicated the amount of probes within a GC-rich region by a defined factor to 
improve capture of difficult genomic fragments. The final design incorporated 3,309 
probes with an overall size of 212.189kbp.  
For subsequent sequencing beyond the first group of 16 patients, an improved 
design was utilised to include new genes implicated in inherited thrombocytopenia. 
The second version of the design included all probes from the first design with the 
addition of baits designed to sequence the following genes; ACTN1, ETV6, PF4 and 
PRKACG. All genes, with exception of PRKACG, were covered by probes with the 
most stringent masking settings. Probes designed for amplification and sequencing 
 80 
 
of PRKACG included 4 probes with the least stringent masking settings applied. 
Overall the new design incorporated 3447 probes covering 221.305kbp.  
Target enrichment was performed for all designs using Agilent SureSelectQXT NGS 
target enrichment kit for Illumina multiplexed sequencing (Agilent Technologies, UK). 
Sample preparation followed the workflow outline in the accompanying 
manufacturer’s instructions (Figure 2.15.1). Methodology followed the supplied user 
manual throughout. Due to the relatively small size of the capture library, all size 
related steps followed the methodology for capture libraries <3 Mb. In the preparation 
for hybridization, 750ng of gDNA, prepared to a volume of 12µL was used. 
A maximum of 16 samples were prepared per run. DNA samples were quantified 
using BR and High Sensitivity (HS) Qubit® dsDNA fluorometric quantification kits and 
were analysed using a Qubit® 2.0 Fluorimeter (ThermoFisher, UK, #Q32854 for HS 
kit) in initial sample preparation. Purification steps utilised Agencourt AMPure XP 
magnetic capture beads (BeckmanCoulter, UK, #A63880). DNA quantity and quality 
was assessed at two separate points throughout the protocol using an Agilent 2200 
Tapestation system and associated D1000 and high sensitivity D1000 screen tape 
(#5067-5582 for D1000, #5067-5584 for HS D1000), and reagents (including ladder 
and sample buffers) (#5067-5583 for D1000 reagents, #5067-5585 for HS D1000 
reagents) (Agilent Technologies, UK). Dynabeads MyOne Streptavidin T1 magnetic 
beads were used for hybrid capture (ThermoFisher, UK, #65601). Index tags were 
added using the SureSelectQXT P7 and P5 dual indexing primers. All thermocycling 
steps were performed using a Bio-Rad DNA Engine Tetrad® 2 Thermal Cycler (Bio-
Rad, UK). Magnetic separation was achieved using DynaMag™-96 Side magnet 
(ThermoFisher, UK). 
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Figure 2.15.1 Sample preparation workflow for the IT specific next generation 
sequencing panel using Agilent SureSelectQXT capture methodology 
Genomic locations  
gDNA samples 1,2…n 
Adaptor-tagged DNA library 
Prepared DNA-library 
amplicons 
Capture Library/prepared DNA library hybrids 
Captured, target-enriched DNA library 
Dual-indexed, target-enriched DNA library 
SureSelect-enriched dual-indexed NGS samples 
SureSelect Capture Library 
Design target 
sequences in 
SureDesign 
Fragment DNA and 
adaptor tag DNA ends in 
single enzymatic step 
PCR amplify 
Hybridize using SureSelect Capture Library 
Capture hybrids on streptavidin-coated 
magnetic beads 
PCR amplify using Dual 
Indexing primers 
Pool libraries for multiplex sequencing 
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Samples were pooled for multiplexed sequencing so that each index-tagged sample 
was in equimolar amounts in the pool. For each sample the following formula was 
used to determine the amount of index sample to use. 
 
 
V (f) = Final desired volume of pool 
C (f) = Desired final concentration of all DNA in pool 
# = is the number of the indexes 
C (i) = Initial concentration of each sample 
A final desired volume of pool of 20µL was used and a final concentration of 4nM. In 
all cases, 16 indexes were pooled. 
To achieve an optimal cluster density, a final concentration of 10pM of DNA was 
used. DNA was firstly denatured by the addition of 5µL of 0.2M NaOH to 5µL of 4nM 
pooled library and allowed to incubate at room temperature (~20°C) for five minutes. 
990µL of pre-chilled HT1 hybridisation buffer was added to achieve a 20pM solution. 
300µL of the 20pM solution was added to 300µL HT1 to achieve a final concentration 
of 10pM in 600µL.  
Sequencing was performed using an Illumina MiSeq (Illumina, UK) and MiSeq v2 300 
Cycle Reagent Kits (Illumina, UK, #15033626). Sample sheets were designed to 
allow for the use of custom primers and no adaptor trimming. Sequencing followed a 
Nextera XT sample preparation kit and amplicon chemistry.  
Sequence alignment, annotation, categorisation and variant calling was performed 
using the SureCall v3.5 software (Agilent Technologies, UK) and the GenAligners 3.0 
alignment tool (Agilent Technologies, UK). Post aligned, annotated and categorised 
Volume of Index = 
# x C (i) 
V (f) x C (f) 
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sequence data was analysed using a personalised bioinformatics pipeline that will be 
discussed in section 5.3. 
2.16. Polymerase chain reaction 
Polymerase chain reaction (PCR) was used throughout the project for the 
amplification of genomic DNA for subsequent Sanger sequencing. All PCRs were 
performed following a standardised in house protocol. All reactions formed a total 
volume of 25µL, consisting of: 100ng DNA, 5µmol of both forward and reverse 
primers, 12.5µL of Sigma RedTaq PCR ready mix (Sigma Aldrich, UK, #R2523) and 
UltraPure™ DNase/RNase-free distilled water (ThermoFisher, UK, #10977035). 
MyTaq™ Red Mix (Bioline, UK, #BIO-25043) was also used at the same volume as 
an alternative DNA polymerase ready mix if amplification was unsuccessful with 
Sigma RedTaq. Genomic DNA was used at a concentration of 20ng/L in all reactions 
and was prepared from extracted DNA stocks and diluted with UltraPure™ water. 
Where 20ng/µl was not available, DNA was used neat and the volumes of water and 
DNA adjusted to achieve 20ng/µl. All reactions were performed in parallel with a 
negative UltraPure™ water control. 
Oligonucleotide primers were designed using Primer3 software (http://primer3.ut.ee/ 
Last accessed October 2016) (http://ihg.helmholtz-muenchen.de/ihg/ExonPrimer.html 
Last accessed October 2016) and validated using In-Silico PCR software 
(http://genome.ucsc.edu/cgi-bin/hgPcr Last accessed October 2016). 
Oligonucleotides were designed for an optimum annealing temperature of 60°C, 
length of 20bp and presence of a GC clamp. All oligonucleotides are available from 
Sigma Aldrich and sequences are available upon request. 
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PCR was conducted with the universal cycling conditions of denaturation, annealing 
and hybridisation as follows; 
 94°C for 3 minutes 
o 94°C for 1 minute 
o 60°C for 1 minute 
o 72°C for 1 minute 
 72°C for 5 minutes 
All reactions were performed using the DNA Engine Tetrad® Peltier Thermal Cycler 
(BioRad, UK). PCR products were visualised after running using electrophoresis in a 
1% ethidium bromide stained 1% agarose tris base, acetic acid, EDTA (TAE) buffer 
gel and viewed on an ultraviolet transilluminator system (Syngene Genegenius 
Bioimaging, UK). Sizes of bands were determined by loading all gels with 5µl of 1kb 
DNA ladder (NEB, UK, #N3232).  
2.17. Sanger sequencing 
Amplified DNA from PCR reactions was purified and concentrated using 
microCLEAN solution (Microzone, UK, #2MCL). PCR products and microCLEAN 
solution were applied in equal volumes (2.4µL) to individual wells of a 96 well plate 
and the DNA pelleted by centrifugation at 2218g for 40 minutes. The plate was 
inverted and centrifuged for 30 seconds at 34.6g to remove any residual liquid. All 
centrifugation steps were performed using a Hettich Universal 320 plate centrifuge 
(Hettich, Germany). 
4pmol of the appropriate forward and reverse primers specific to the gene of interest 
were used in conjunction with the Big Dye® Terminator v3.1 Cycle Sequencing Kit 
(ThermoFisher, UK, #4337454) for sequencing reactions. The sequencing was 
x 30 cycles 
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performed under the following PCR cycling conditions for optimal elongation and 
random termination of fragments: 
 96°C for 30 seconds 
 50°C for 15 seconds 
 60°C for 4 minutes 
DNA was precipitated by the addition of 2µL 0.125M EDTA (Sigma Aldrich, UK, 
#E7889) and washed twice, firstly in 30µL 100% EtOH and secondly in 90µl 70% 
EtOH in water. DNA was denatured with 10µL of Hi Di Formamide (ThermoFisher, 
UK, #4311320) at 94°C for two minutes before snap chilling on ice. Subsequent 
sequencing analysis was performed using an ABI 3730 automated sequencer 
(Applied Biosystems®, UK).  
Sequencing results were analysed using MutationSurveyor® software available from 
Soft Genetics® or alternatively viewed using the Chromas sequence chromatogram 
viewer. Variants occurring in regions not covered by >20 fold read coverage were 
discarded from further analysis. Areas with excessive background signals were 
repeated for clarity. If amplification and subsequent sequencing was unsuccessful, 
primers were redesigned flanking the region of interest and the process repeated.  
2.18. PCR based X-inactivation assay 
A PCR based X-inactivation assay was completed by collaborators at the Regional 
Genetics Laboratory, Birmingham Women’s Hospital. Skewed X-inactivation was 
assessed using a PCR based assay that amplifies the first exon, containing a CAG 
repeat, of the androgen receptor gene on chromosome Xq11-12. 500ng of DNA was 
either digested overnight at 37°C using a methylation-sensitive restriction enzyme 
(H), HpaII (NEB, UK, #R0171), or left undigested (U). PCR was performed using 
x 30 cycles 
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forward and reverse primers flanking the androgen receptor CAG repeat and the 
following cycling conditions; 
 95°C for 5 minutes 
o 95°C for 1 minute 
o 59°C for 1 minute 
o 72°C for 1 minute 
 72°C for 10 minutes 
 60°C for 30 minutes 
Samples were run on the ABI3130XL genetic analyser (Applied Biosystems, UK) with 
a 12 second injection and standard formamide mix to determine length of fragments, 
indicating number of CAG repeats, and quantity of that fragment present in the 
sample. Skewing was determined by the use of a formula that calculates the ratio of 
the allele peak areas from the H samples (HpaII digested) to those of the U samples 
(undigested genomic DNA). Samples were run in parallel with a female control (50:50 
random skewing) and a positive female control (100:0 completely skewed). 
2.19. Western blot analysis 
Western blots were utilised to determine protein expression of the encoded candidate 
genes of interest. Western blots were performed on stored platelet protein or patient 
platelet lysates if available, details regarding specific assays are outlined in the 
appropriate results sections. 
All samples were denatured for five minutes at 105°C. 5µL of Colour Prestained 
Protein Standard, Broad Range (NEB, UK, #P7712S) ladder, made up to 20µl with 
SB, and 20µl of denatured samples were loaded into wells of a precast 
polyacrylamide 10 well Bolt™ 4-12% Bis-Tris Plus Gels (Invitrogen, UK, #NW04120). 
x 26 cycles 
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Bolt® Mini Gel Tanks (Invitrogen, UK, discontinued) were used with 20x Bolt® MES 
SDS Running Buffer (ThermoFisher, UK, #B0002) diluted to 1x in dH2O. Running 
buffer also contained 500µL Bolt® Antioxidant applied to the front chamber of gel 
tanks. Gels were run at 70V for 10 minutes and the voltage increased to 120V for 
>30 minutes depending on the size of the band of interest. 
Protein bands were transferred from polyacrylamide gels to polyvinylidene difluoride 
(PVDF) membranes using the BioRad Trans-Blot® Turbo™ RTA mini transfer kit 
(BioRad, UK, #1704272) and the Trans-Blot® Turbo™ Transfer System (BioRad, 
UK). PVDF membranes were activated in 100% methanol for 2 minutes prior to 
transfer.  
Membranes were blocked for 1 hour at room temperature (~20°C) in 5% skimmed 
milk powder in TBS-T (Sigma Aldrich, UK, #70166). 
All primary antibodies were diluted in 5% skimmed milk powder in TBS-T and 
incubated overnight at 4°C on a rolling incubator. Primary antibodies and 
concentrations used are detailed in the appropriate results sections. In all cases 
Western blots were probed with an anti-GAPDH antibody loading control (Abcam, 
UK, #ab9485). Following primary antibody incubation, membranes were washed 3x 
in TBS-T.  
Membranes were incubated at room temperature for one hour in secondary 
antibodies. The following secondary antibodies were used for WB analysis, 
dependant on the species of host the primary antibody was generated within; 
Amersham ECL Mouse IgG, HRP-linked whole Ab (from sheep) (GE healthcare, UK, 
#NA931) 
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Amersham ECL Rabbit IgG, HRP-linked whole Ab (from donkey) (GE healthcare, UK, 
#NA934) 
Rabbit anti-Goat IgG (H+L) Secondary Antibody, HRP (ThermoFisher, UK, #81-
1620). 
Following incubation with secondary antibodies, WBs were washed 3x in TBS-T 
before staining with Pierce™ ECL Western Blotting Substrate (ThermoFisher, UK, 
#32106) following the manufacturer’s instructions. WBs were visualised using 
Amersham Hyperfilm ECL (GE healthcare, UK, #28906836). 
 
2.20. Platelet spreading and immunohistochemistry 
Platelet spreading was performed on washed platelets prepared from whole blood. 
Shandon™ColorFrost™ Plus microscope slides (ThermoFisher, UK, #6776214) were 
prepared the day before experimentation. Slides were firstly washed in 100% EtOH 
and rinsed with PBS before being coated with 400µL 100µg/mL human fibrinogen 
(Enzyme Research Laboratories, UK) diluted in PBS. Slides were incubated 
overnight at 4°C and blocked the following day by the removal of fibrinogen and 
addition of 300µl of 5mg/ml denatured Bovine Serum Albumin (BSA) in PBS for 1 
hour at room temperature. Slides were washed 3 times with PBS to remove any BSA.  
PBS was removed by aspiration and 300µL of washed platelets at a concentration of 
2x107/mL was added and subsequently incubated at 37°C, 5% CO2. After 45 
minutes, the slides were rinsed in 1x sterile PBS. Cells were then fixed by the 
addition of 300µL 10% formalin (Sigma Aldrich, UK, #HT501128) for 10 minutes. 
Slides were washed 3x with PBS. 
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Cells were permeabilised using PBS + 0.1% Triton X-100 (Sigma Aldrich, UK, 
#X100) for five minutes at room temperature and subsequently washed 3x in PBS. 
Slides were then stained with either Alexa Fluor® 488 Phalloidin (ThermoFisher, UK, 
#A12379) for one hour stain was removed by washing in 3x PBS. Slides stained with 
phalloidin were incubated in the dark. Slides requiring secondary antibodies were 
stained with secondary antibody in PBS + 0.5% BSA for one hour in the dark. All 
slides were washed 3x in PBS and once in dH2O before mounting with 4µL 
hydromount (National Diagnostics, UK, #HS-106). Slides were stored at 4°C until 
imaging. 
2.21. TTF2 guide RNA in silico guide design and cloning 
Guide sequences were generated using the MIT CRISPR database (crispr.mit.edu 
Last accessed July 2016) and targeted towards the C-terminus of TTF2 spanning the 
stop codon. Guide sequences were selected as 20bp fragments which immediately 
preceded at the 3’ with the universal 5’-NGG protospace adjacent motif (PAM) site for 
Cas9 recognition. An additional G-C base pair was added at the 5’ end of the guide 
sequence to allow guanine as the first base of the U6 transcript. This does not 
adversely affect targeting efficiency. Guide sequences were also designed to include 
4 bp overhangs complementary to the overhangs created by digestion with BsmBI. 
Four guide sequence complementary pairs were selected on the basis of inverse 
likelihood of off-target binding and are shown below in Table 2.21.1.
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Guide Orientation Sequence 
TTF2 guide A Top 5’ CACCGCATCTAACCTCCTGTGGATA 
TTF2 guide A bottom 3’ CGTAGATTGGAGGACACCTATCAAA 
TTF2 guide B Top 5’ CACCGCAGGAGGTTAGATGCCAAAAAGG 
TTF2 guide B bottom 3’ CGTCCTCCAATCTACGGTTTTTCCCAAA 
TTF2 guide C Top 5’ CACCGTTTTGGCATCTAACCTCCTGTGG 
TTF2 guide C bottom 3’ CAAAACCGTAGATTGGAGGACACCCAAA 
TTF2 guide D Top 5’ CACCGAGATGCCAAAAAAGGACTCTGAGG 
TTF2 guide D bottom 3’ CTCTACGGTTTTTTCCTGAGACTCCCAAA 
 
 
Table 2.21.1 TTF2 CRISPR RNA guide sequences
 91 
 
The highest off target sites occurred within guide D and included 395 off target sites 
43 of which occur within the gene. All guides were of above a quality score of 50. 
Guide sequences were suspended at 10µM and annealed to form a phosphorylated 
oligo duplex by incubation at 37°C with the addition of 2µL 10x T4 DNA ligase buffer 
(NEB, UK, #B0202S), 0.5µL T4 Polynucleotide kinase (NEB, UK, #M0201S), and 
15.5µL H20.  
BPK1520 guide vectors were used to express the U6 promotor and small guide 
RNAs (Figure 2.21.1) (Addgene, UK, #65777). We thank the depositing K Joung lab 
for use of the BPK1520 vector. The vector backbone was digested by incubation with 
BsmBI (NEB, UK, #R0580S) and NEB 10x 3.1 Buffer (NEB, UK, #B7203S) overnight 
at 37°C. Vectors were also dephosphorylated by treatment with 0.5µl Alkaline Calf 
Intestinal Phosphatase (NEB, UK, #M0290S).  
2µg of digested vector per guide was ligated with 0.5µM oligo duplexes at room 
temperature for 30 minutes with 1µL 10x T4 DNA ligase buffer and 0.5µL DNA ligase 
(NEB, UK, #M0202S). 
2µL of ligated vector were transformed into 50µL Alpha-Select Silver Efficiency cells 
(Bioline, UK, #BIO-85206). Cells were first incubated with the DNA on ice for 30 min 
before heat shock at 40°C for 40 seconds, followed by a further two minutes on ice. 
Cells were suspended in 950µL S.O.C medium (ThermoFisher, UK, #15544034) and 
incubated on a rotary shaker for one hour at 37°C. Following incubation, 50µL of cell 
containing medium was plated on agar plates containing 100µg/mL ampicillin (Sigma 
Aldrich, UK, #A9393) and incubated at 37°C overnight. The following day, colonies 
were picked and grown overnight on a rotary shaker at 37°C in 10mL liquid ampicillin 
containing Lysogeny broth (LB).
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Figure 2.21.1 BPK1520 vector map indicating restriction sites, open reading 
frames and site of AmpR promoter. 
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3. Patient phenotypical presentations and platelet function testing 
3.1. Summary of background to this research 
Understanding a patient’s phenotype is critical to the correct diagnosis of IT. The 
presence of secondary qualitative platelet function defects commonly associated with 
IT disorders has allowed many forms to be extensively phenotypically categorised. 
Disorders such as Bernard Soulier Syndrome and Glanzmann Thrombasthenia can 
often be distinguished based upon platelet function testing alone, due to the absence 
of CD42b (GP1b) and CD41 (GPIIb/IIIa) cell surface expression, respectively. 
Additionally, determining an accurate morphology of patient platelets can also help 
determine the aetiology, where disorders such as WAS are commonly associated 
with small platelets and MYH9-related disease and BSS are often associated with 
giant platelets. As a result, platelet function testing now forms a part of routine 
diagnosis when many forms of IT are suspected from a patients bleeding history. To 
date though, there is still a lack of a gold standard platelet function test with the 
capability to efficiently diagnose all forms of IT. The reason for this is that certain 
disorders present without a qualitative secondary defect or that the defects are 
heterogeneous dependant on a patient’s individual genotype. It is even thought that 
phenotypic presentation can vary in individuals with the same genetic aetiology of 
disease, suggesting that secondary factors may have an impact on platelet function. 
Variable phenotypic presentation of disease suggests that instead of focusing on one 
method of diagnosis, patients should be considered individually and categorised 
dependant on a number of factors that may influence their clinical symptoms.  
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The UK-GAPP study works on this ethos and aims to completely categorise a 
patient’s individual disease by a combination of extensive phenotyping and platelet 
function testing with next generation sequencing-based genotyping. The UK-GAPP 
study is a multinational study into rare inherited bleeding disorders which 
incorporates three research groups at the Universities of Birmingham, Bristol and 
Sheffield. Patients are recruited from 28 haematology referral centres in the UK 
which accounts for more than 2/3rds of the overall number of Haemophilia 
Comprehensive care centres (Figure 3.3.1). The study also recently started recruiting 
patients from Our Lady’s Children’s Hospital Crumlin, Dublin.  
3.2. Aims 
This section aims to build upon previous work by the UK-GAPP study group to 
completely categorise individual patient’s phenotypes. Patients were tested following 
a unique workflow designed for patients with IT. I aim to combine whole blood cell 
counts with platelet function testing to help understand the pathophysiology of an 
individual’s disease and aid in the subsequent genetic analysis.  
3.3. Patients with inherited thrombocytopenia recruited to the 
UK-GAPP study 
The UK-GAPP study has been recruiting patients with suspected inherited bleeding 
disorders for 10 years. Overall in excess of over 900 patients and healthy volunteers 
have been recruited to the study. Of those 900 patients, 153 patients have been 
recruited with suspected or sustained IT that meets the inclusion criteria as detailed 
in the methods section (Chapter 2). The 153 patients included 112 index 
cases/probands and 41 related affected family members. The work in this thesis is 
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based on 95 patients who have undergone platelet phenotyping in addition to 
genotyping by either WES or a next generation thrombocytopenia specific gene 
panel. These 95 patients represent those that have undergone the full workflow of 
the UK-GAPP study to analyse a patient’s aetiology of disease. The UK-GAPP study 
incorporates all steps from patient recruitment, patient phenotyping, patient 
genotyping and further functional work. The workflow is outlined in Figure 3.3.2. 
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Figure 3.3.1 Map of the UK-GAPP study network 
Red pins indicate all referring Haemophilia Comprehensive Care Centres and shown 
in blue are the research centres part of the study.  
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Figure 3.3.2 UK-GAPP patient workflow 
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3.4. Patient characteristics – Age, gender and ethnicity 
All 95 patients that were fully analysed were recruited from participating UK 
haematology centres. Referral centres included both paediatric and adult clinics and 
as such patient age varies considerably across the cohort of tested individuals. 
Patient age was provided for 74 individuals. An average age of 30 was observed 
across the whole study of 74 individuals (range 2-79 years) (Figure 3.4.1). 
Patient gender was known in 87 individuals. The cohort was 63% female (n=55) and 
37% male (n=32) (Figure 3.4.1). 
All patients recruited to the study were of European (non-Finnish) ethnicity. This is 
with the exception of patients 35.I and 35.II who were two related cousins of South 
Asian ethnicity. Downstream post-sequencing analysis was adjusted to factor in the 
difference in known inheritance in these patients. 
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Figure 3.4.1 Age and gender distribution, including mean and standard 
deviation of 73 patients in which the data was available.  
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3.5. Patient bleeding symptoms and treatment 
A patient bleeding history was taken at the point of examination and inclusion into the 
study. Most patients suffered from mild bleeding symptoms including cutaneous 
bruising, bleeding and epistaxis in addition to more severe bleeding symptoms in 
some cases. Detailed patient clinical symptoms related to bleeding were available for 
all patients and are displayed in Table 3.5.1. 
Most common clinical symptoms were related to easy cutaneous bleeding/bruising; 
overall 86% of patients (79/91) said they had previously suffered from such 
symptoms. Epistaxis and prolonged oral cavity bleeding, especially after dental 
extractions and treatment, was the next most common symptom, present in 33% 
(30/91) and 12% (11/91) of patients, respectively. Of the 46 known female patients 
who had undergone menarche, menorrhagia was present in 41% (19/46). Several 
female patients also suffered from post-partum haemorrhage following vaginal child 
birth that was resolved using uterovaginal packing in most cases, but some cases 
required the use of antifibrinolytics and in rare cases a blood transfusion.  
Two patients suffered from clinical symptoms not directly related to a bleeding 
diathesis which could be associated as a secondary symptom to a platelet function 
related disorder as follows.  
Patient 14.I, a 29-year-old female at enrolment, presented with frequent epistaxis 
requiring cauterisation, menorrhagia, easy bruising and prolonged healing following 
minor cuts. She had also suffered previously with occasional haematochezia and oral 
cavity bleeding requiring dental extraction that required packing. In addition, the 
patient had undergone surgery for congenital cataracts aged eight months and 
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surgery to correct strabismus and detached retina aged 24. The patient is registered 
as partially sighted and suffers from tinnitus and hearing loss. Blood films were 
prepared following routine assessment and were negative for any neutrophil 
inclusions or the presence of giant platelets that may be attributed to MYH9-RD or 
Paris-Trousseau/Jacobsen syndrome, disorders often associated with secondary 
symptoms of hearing loss and cataracts.  
Patient 71.I, a 15 year old female at the time of study inclusion, presented with 
menorrhagia, lethargy, joint aches and swelling, and gum bleeding and ulceration. 
She was initially investigated under the rheumatology team at Leeds General 
Infirmary for a possible diagnosis of systemic lupus erythematosus (SLE). Antinuclear 
antibody (ANA) results were negative in clinical testing and the patient was 
subsequently managed by the Regional Centre for Paediatric Haematology at Leeds 
Children’s Hospital where she was enrolled within the study.  
Patient 63.1 has also previously been tested clinically for antinuclear antibodies 
(ANA). Initial results dated 2011 were observed to be “weakly positive” for the 
presence of ANA but have since been negative when re-tested.  
Developmental delay and skull abnormalities secondary to related hydrocephalus 
were noted in patient 41.II. Patient 37.II, a 3 year old boy, also presented with 
developmental delay. 
The majority of patients were treated with methods to stem symptomatic episodes; 
cauterization for repeat epistaxis, packing for oral cavity bleeding and uterovaginal 
packing following post-partum haemorrhage. Rarely patients required more intensive 
therapy to treat bleeding episodes including; antifibrinolytics (including tranexamic 
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acid), DDAVP and platelet, RBC, plasma and whole blood transfusions. All 
treatments were used to stem bleeding episodes and treatment was stopped after 
recovery. In a few cases with severe menorrhagia, treatments such as tranexamic 
acid and other antifibrinolytics were utilised on a regular basis to improve symptoms. 
Four patients received HLA matched blood product transfusions on a regular basis. 
RBC transfusions were used to treat recurrent bleeding episodes in patient 22.II. 
Whole blood transfusions were used in patient 25.I following an initial diagnosis of 
ITP but the patient did not respond to the treatment. Regular transfusions are still 
used to date in patients 35.I and 35.II, with patient 35.I receiving weekly HLA 
matched transfusions and patient 35.II receiving transfusions up to twice a month. 
Ten patients were initially diagnosed with ITP before being reclassified as suffering 
from IT. All patients subsequently received treatment for the presence of ITP before 
correct diagnosis. 
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Family Patient 
Age Gender 
Platelet count 
(x109/l) MPV (fL) IPF (%) Secondary defect Bleeding Phenotype 
1 I 35 F 73 9.6   Yes (Fibrinogen) 
Cutaneous bruising/bleeding, 
menorrhagia 
2 I 5 F 50 8.6 
 
No Cutaneous bruising 
3 I 
  F 101 10.7   
Yes (Secretion and 
cyclooxygenase) 
Haematuria 
4 I 35 F 80 10.3 
 
Yes 
(Cyclooxygenase) 
Cutaneous bruising, 
menorrhagia 
 
II 33 F 50 12 
 
Yes 
(Cyclooxygenase) 
Cutaneous bruising, epistaxis, 
purpura 
 
III 8 M 98 10.5 3.2 
 
Cutaneous bruising, epistaxis, 
purpura 
5 I     88  11.7      
   II     76  9.3        
6 I 19 F 142 11.8+ 
 
Yes (Secretion and 
Gi) 
Oral cavity bleeding, epistaxis, 
menorrhagia 
 
II 48 F 157 11.4+ 
 
Yes (Secretion) 
Cutaneous bruising, oral cavity 
bleeding 
7 I 
    
92 8.8   Yes (Secretion) 
Cutaneous bruising, epistaxis, 
bleeding into joints 
  
II     100 8.6   Yes (Secretion) 
Cutaneous bruising, life 
threatening bleeding following 
surgery 
8 I 39 F 200 13.9+ 24.5+ Yes (Secretion) Cutaneous bruising/bleeding 
 
II 54 F 107 N/A 53.5+ Yes (Secretion) Cutaneous bruising/bleeding 
 
III 28 F 85 N/A 55.1+ Yes (Secretion) Cutaneous bruising/bleeding 
9 I   M 123 13 11.3+ Yes (Secretion) Cutaneous bruising 
10 I 57 M 110 
  
Yes (Secretion) Cutaneous bruising, excessive 
bleeding following surgery 
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II 36 M 100 8.9 
 
Yes (Secretion) Cutaneous bruising, epistaxis 
11 I 22 F 70 10.7+   No 
Cutaneous bruising, 
menorrhagia, post-partum 
haemorrhage 
  
II 29 F 70 10.1   No 
Cutaneous bruising, epistaxis, 
haematuria, menorrhagia, post-
partum haemorrhage 
12 I 
30 F 
50 10.4 
 
Yes (Secretion) 
Cutaneous bruising, 
menorrhagia 
13 I 29 F 147 12.7+ 10.7 Yes (CD41) 
Cutaneous bruising, 
hematomas, oral cavity 
bleeding, menorrhagia 
14 I 29 F 35 11.4+ 
 
No 
Cutaneous bruising, epistaxis, 
menorrhagia, haematochezia 
and oral cavity bleeding 
15 I     55       Cutaneous bruising, epistaxis 
16 I 9 F 62 
  
Yes (Secretion) Cutaneous bruising 
 
II 
38 F 
   
Yes (Secretion) 
Cutaneous bruising, epistaxis, 
menorrhagia 
 
III 17 M 146 
  
Yes (Secretion) Cutaneous bruising, epistaxis 
17 I 19 M 100 8   Yes (Secretion) Excessive cutaneous bleeding 
18 I 46 F 163 9.1 
 
No 
Cutaneous bruising, epistaxis, 
haematoma 
 
II 17 M 45 11.9+ 
 
Yes (GPVI) Cutaneous bruising, epistaxis 
19 I 16 F 139 8   Yes (Secretion) Epistaxis, haematoma 
20 I 3 M 90 7.6- 
 
Yes (Secretion) Cutaneous bruising, petechiae 
21 I 33 M 130 7.1-   
Yes (Secretion and 
Gi) 
Cutaneous bruising, epistaxis, 
oral cavity bleeding 
  II 6 M 70 7.5-   Yes (Complex) 
Cutaneous bruising, epistaxis, 
oral cavity bleeding 
22 I   
    
Excessive bruising/bleeding 
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23 I 15 M 110 8.1   Yes (Secretion) 
Cutaneous bruising/bleeding, 
petechiae, haematoma 
24 I 16 M 100 9 
 
No Cutaneous bruising/bleeding 
 
II 37 F 100 9.2 
 
No Cutaneous bruising/bleeding 
25 I 
  F 145 9.4 
  
Yes (Secretion) Cutaneous bruising, epistaxis, 
hematomas, menorrhagia 
26 I 
2 M 
89 13+ 17.5+ 
Yes (Secretion and 
Gi) Cutaneous bruising 
27 I   F 63 11.9 19.1+ Yes (Secretion) 
Cutaneous bruising, epistaxis, 
haematoma 
  
II   F 83 11.9 24.3+ Yes (Secretion) 
Cutaneous bruising, epistaxis, 
haematoma 
28 I 30 M 74 11.2 
 
Yes (Secretion and 
Gi) 
Cutaneous bruising/bleeding, 
haematuria 
 
II 31 F 62 12.7+ 20.8+ 
Yes (Secretion and 
Gi) 
Cutaneous bruising/bleeding, 
menorrhagia, postpartum 
haemorrhage, haematoma 
 
III 
 
F 109 11 
 
Yes (Secretion) 
Cutaneous bruising, 
haematoma, menorrhagia 
29 I 16 F 119 11.1   Yes (Secretion) Cutaneous bruising/bleeding 
30 I 
51 F 
104 9.6 26.8+ No 
Menorrhagia, post-partum 
haemorrhage 
 
II 79 M 133 8.6 
 
No Epistaxis 
31 I 
70 M 
11 13.4+   
Yes (Secretion and 
Fibrinogen) Cutaneous bruising 
32 I 43 F 43 14+ 
 
No 
Cutaneous bruising, 
menorrhagia, oral cavity 
bleeding 
33 I 29 F 100 10.3   Yes (Secretion) Cutaneous bruising/bleeding, 
epistaxis, oral cavity bleeding 
34 I 16 M 25 8.5 
 
Yes (Secretion) Cutaneous bruising 
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35 I 16 F 15 9.4   Yes (Secretion) Haematomas 
36 I 
38 F 
137 7.9 
 
Yes (Secretion) 
Cutaneous bruising, epistaxis, 
menorrhagia 
 
II 
35 F 
186 8.6 
 
No 
Cutaneous bruising, 
menorrhagia, haematuria 
 
III 63 M 80 8.2 
 
Yes (Secretion) Cutaneous bruising 
37 I 
30 F 
20 9.7   Yes (Secretion) 
Cutaneous bruising, epistaxis, 
oral cavity bleeding             
  II 
3 M 
17 N/A 56.4+ Yes (Secretion) 
Easy bruising, bleeding after 
surgery. 
38 I 51 F 15 9.5 20.2+ No Cutaneous bruising 
39 I 16 M 66 9.9 1.8 Yes (Secretion) Cutaneous bleeding 
40 I 67 M 93 14.4+ 20.5+ Yes (Secretion) Cutaneous bleeding, epistaxis 
41 I 
7 F 
15 10.4 87+ 
Yes (Secretion and 
other) 
Cutaneous bruising, epistaxis, 
haematomas 
  II 
3 M 
14 15+ 83+ 
Yes (Secretion and 
other) Cutaneous bleeding 
42 I 32 F 104 13.3+ 17+ No Menorrhagia 
43 I 
66 F 
130 9.7   No 
Cutaneous bruising, epistaxis, 
menorrhagia 
44 I 
73 M 
70 12 12+ N/A 
Haematuria, bleeding following 
surgery 
45 I 
63 F 
100 9.9 2.8 
Yes 
(Cyclooxygenase) 
Haematomas, ovulation 
bleeding 
46 I 6 M 147 12.4 
 
Yes (Secretion) Cutaneous bruising 
47 I 
29 F 
53 11.7 9.1 No 
Cutaneous bruising, haematuria, 
oral cavity bleeding 
48 I 5 M 125 9.1 
 
Yes (Secretion) Cutaneous bruising, petechiae 
49 I 41 M 30 N/A 9.4 Yes (CD42b) Cutaneous bruising 
50 I 41 M 30 N/A 59.4+ Yes (CD42b) Cutaneous bleeding 
51 I   162 9.2 
 
Yes (Secretion and Cutaneous bleeding, oral cavity 
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GPVI) bleeding 
52 I 43 F 131 8.7 14.7+ 
Yes (Secretion and 
Gi) 
Cutaneous bleeding, epistaxis, 
menorrhagia, Gi bleeding, oral 
cavity bleeding 
53 I 27 F 104 9.1 
 
No Cutaneous bleeding 
54 I 12 M 101 10 39.8+ Yes (Secretion) Cutaneous bleeding 
55 
I 
 
F 30 8.6 2.3 No 
Cutaneous bruising, oral cavity 
bleeding, menorrhagia 
56 I 15 F 48 10.2 45.2+ No Cutaneous bleeding, epistaxis 
57 I 11 F 153 12.1 9.2 Yes (Secretion) Cutaneous bruising/bleeding 
58 I 
9 F 
82 8.6 6.4 
Yes (Secretion and 
Fibrinogen) Cutaneous bruising/bleeding 
59 I  
M 94 12.3 7.1 No Cutaneous bruising/bleeding 
60 I  
F 
146 13.4+ 15.8+ No 
Cutaneous bruising, oral cavity 
bleeding, menorrhagia 
61 I  
F 
76 9.7 3.4 
Yes (CD41 and 
other) 
 62 I 34 F 138 13.8+ 17.5+ No Cutaneous bleeding 
63 I 
13 F 
37 14.6+ 16+ Yes (Secretion) 
Cutaneous bruising, petechiae, 
epistaxis 
64 I  
F 105 14.5+ 23.1+ Yes (Secretion) Cutaneous bruising, epistaxis 
65 I 35 F 52 14.9+ 19.4+ Yes (other) Cutaneous bruising/bleeding 
66 I 18 F 87 10 1.8 Yes (Secretion) Cutaneous bruising/bleeding 
67 I 
22 M 
40 13.1+ 15.7+ No 
Cutaneous bruising/bleeding, 
epistaxis 
68 I 72 M 50 8.4 
 
Yes (Secretion) Cutaneous bruising, epistaxis 
69 I 
48 F 
92 
   
Cutaneous bruising, 
haematomas 
70 I  
F 92 10.2 
 
No 
 
71 I 
15 F 
76 9.4 13.5+ No 
Oral cavity bleeding, 
menorrhagia 
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72 I  
M 101 13.9+ 14.4+ No Cutaneous bleeding 
 
Table 3.5.1 Phenotypic symptoms of all patients recruited to the UK-GAPP study with IT of unknown aetiology. Family 
members 41.I and 41.II are cousins born from consanguineous relationships. MPV – Mean platelet volume. IPF- Immature 
platelet fraction. M – male, F – Female. + denotes an elevated MPV/IPF, - denotes a reduction in MPV when compared to 
controls.  
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3.6. Platelet counts and morphology 
Platelet counts were measured by different haematology cell counters dependant on 
the date of inclusion into the study, the differing methods are outlined in methods 
section 2.7. 
Platelet counts were determined at the haematological referral centre in 62 patients 
and 33 patients were analysed using the Sysmex XN-1000. All platelet counts are 
shown in Table 3.5.1. Platelet counts are also displayed in comparison to travel 
controls and a panel of 40 healthy volunteers who have been analysed by the 
Sysmex XN-1000 in Figure 3.6.1.  
Platelet counts were available for all patients with the exception of patients 16.II and 
22.II as follows. 
A platelet count was unavailable for patient 16.II at the time of enrolment; the patient 
shared a bleeding phenotype similar to affected family members and was included in 
further study due to clinical history of thrombocytopenia.  
Platelet counts, morphology and platelet function testing were unavailable in patient 
22.I due to the enrolment of the patient posthumously. This patient will be discussed 
in further detail in section 4.4. 
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Figure 3.6.1 Circulating platelet counts in whole blood in all patients recruited 
to the UK-GAPP study compared to a panel of 40 healthy controls analysed by 
the Sysmex XN-1000.  
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Overall platelet counts ranged from 15-200x109/L across all patients analysed. An 
average platelet count across all individuals of 88x109/L was observed (n=91) 
(normal range to 2SD 147-327x109/L as measured on the Sysmex XN-1000, n=40). 
Six patients (patients 6.I, 8.I, 18.I, 36.II, 51.I and 57.I) were included within the study 
with a platelet count exceeding 150x109/L at the time of enrolment. All six patients 
had previous platelet counts <150x109/L prior to enrolment (n=2) or showed a shared 
phenotype to related affected family members (n=4).  
Mean platelet volumes were assessed by two different methods. 88 patients were 
assessed for mean platelet volume in total, this is comprised of 48 patients analysed 
by the Beckman Coulter counter and 40 patients analysed by the Sysmex XN-1000. 
All MPV values are shown in Table 3.5.1. An average MPV of 10.64fL was observed 
across all patients (range 7.1-14.9fL) (normal range to 2SD 7.8-12.69fL, n=40). 
Values are denoted with + and – depending on the presence of macro or 
microthrombocytopenia, respectively, when compared to a range of healthy 
volunteers specific to the method of measurement used. In total 18 patients 
presented with a macrothrombocytopenia and three; two related individuals 16.I and 
16.II, and 15.I presented with a microthrombocytopenia. Mean platelet volume was 
unable to be established in five patients due to abnormal platelet distribution when 
analysed by the Sysmex XN-1000. This is denoted with N/A in Table 3.5.1 and is 
often due to large/clumped platelets exceeding the predefined threshold size and 
appearing within the RBC range.  
Immature platelet fraction (IPF) measurements were available for 38 patients. 
Immature platelet fractions ranged from 1.8-87% of the total platelet count (normal 
range 1.3-10.8%). An average IPF of 23% was observed across all 28 patients. 
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Twenty-eight patients presented with an IPF that exceeded the normal range. In 13 
individuals, both an increased MPV and IPF were observed simultaneously.  
3.7. Whole blood white cell counts 
White cell counts were measured in whole EDTA anti-coagulated blood as outlined in 
methods section 2.7. In a two-stage reaction, cells were initially lysed and then 
labelled with a fluorescent marker specific to white blood cells, basophils and 
nucleated red blood cells.  
White blood cells were measured in 25 patients and were present within a normal 
range in all patients (normal range ± 2SD 3.78-10.11x109/L, n=40). 
3.8. Platelet function testing 
Platelet function testing was performed on 86 of the 95 recruited patients. Nine 
patients were unavailable for testing either due to the lack of enough material to 
perform testing or recruitment of the patient specifically for genetic testing only and 
sent as a DNA sample. As mentioned in the methods section, platelet function testing 
was split dependant on the platelet count in PRP. 21 patients were tested by light 
transmission aggregometry with lumiaggregometry only. 46 patients were tested by a 
flow cytometry assay developed in house. 19 patients had a borderline count in PRP 
of >1 and <1.5x108/mL and were thus tested by both assays. 
3.8.1. Light transmission aggregometry 
In total, platelet function was analysed in 40 patients by LTA with lumiaggregometry 
(Table 3.5.1). Overall, a qualitative defect secondary to the reduction in platelet count 
was observed in 82.5% of patients (31/40). Nine patients therefore showed no 
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alteration in platelet function as analysed by light transmission aggregometry. Two 
patients, who were analysed by both methodologies, revealed normal responses to 
all doses of agonists when measured by LTA but presented with defects in cell 
surface receptors when analysed by flow cytometry.  
One patient, 44.I, showed a lack of response to all agonists when tested by LTA. The 
patient had a platelet count in PRP of 1.02x108/mL which is within the cut off for 
testing by LTA. However, upon analysis a lack of response was observed to all 
agonists and the results were difficult to interpret, potentially due to the low platelet 
count. Analysis by flow cytometry was unavailable on the day of testing. 
Defects in dense granule secretion, as determined by lumiaggregometry measuring 
ATP secretion in response to 100µM PAR1 stimulation, were most common, 
occurring in 27 patients (60%) (representative trace shown in Figure 3.8.1). When 
available, secretion was measured as a concentration of ATP (nmol)/1x108 platelets. 
These values are displayed in Figure 3.8.2 simultaneously with travel controls tested 
on the same day and a panel of healthy volunteers. Average secretion values of 
those available were 0.69 nmol ATP/1x108 platelets for patients and 1.24 nmol 
ATP/1x108 platelets for travel controls. The 5th percentile for secretion in response to 
PAR1 peptide 100µM lies at 0.65 nmol ATP/1x108 platelets in previously studied 
healthy volunteers (n=40). When comparing secretion values in the patient 
population to those in the control a significant difference (p 0.0008) was observed. 
Seven patients showed a transient aggregation in response to all doses of ADP 
tested, indicative of a defect in Gi signalling or potentially defective alpha granule 
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secretion (representative trace shown in Figure 3.8.3). All patients, with the exception 
of 21.I also showed a subsequent lack of response to all doses of adrenaline. 
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Figure 3.8.1 Representative trace of a patient dispalying a defect in secretion in 
response to PAR-1 peptide 100µM (Patient 27.I). Red – Patient aggregation, 
blue – control aggregation, green – patient secretion, black – control secretion. 
Patient secretion (green) shows no response to stimulation by PAR-1 peptide 
when compared to control secretion (black).
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Figure 3.8.2 Secretion values in response to PAR1 100µM in 24 patients 
compared to 17 travel healthy controls. Secretion values calculated from 
aggregation traces as a concentration of ATP (nmol)/1x108 platelets. Using an 
unpaired t-test the two-tailed P value was statistically significant at 0.008. 
 
p = 0.0008 
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Figure 3.8.3 Representative traces displaying a defect in Gi signalling correlating as a lack of response to all doses of 
ADP (3, 10 and 30µM) (Patient 52.I). Black/red – patient aggregation, blue – control aggregation, green – patient 
secretion, black (in 30µM only) – control secretion. Patient aggregation traces (black in resonse to 3 and 10µM and 
red in response to 30µM ADP stimulation) show a lack of full or transient aggregation in response to agonist 
stimulation.
ADP 30µM     
 
 ADP 10µM 
 
ADP 3µM 
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An absence of response to all doses of arachidonic acid was noted in three patients, 
4.I, 4.II and 45.I. The suggestion of a defect in the cyclooxygenase pathway in all 
three patients showed a complete lack of response at low dose 0.5mM AA and partial 
responses at high dose 1mM AA.  
Aggregation in response to U46619, a thromboxane A2 mimetic, was measured in 
two patients. Aggregation was normal when compared to the travel control in patient 
22.I, however a lack of aggregation was noted in patient 45.I indicating a potential 
receptor defect.  
Patient 18.II showed inhibition of aggregation to all concentrations of collagen and 
CRP tested. This observation was not shared within the affected mother, 18.I, and 
indicates a potential defect in the collagen signalling pathway through the GPVI 
receptor. 
Patient 22.II presented with a complex platelet function phenotype when tested by 
LTA. The patient shared the observation of a defect in dense granule secretion with 
the patient’s maternal uncle, 22.I. However, in addition, the patient displayed an 
impairment in response to ADP which resulted in reversible aggregation, primary 
wave only when stimulated with adrenaline and reduced aggregation to AA, PAR-1 
and collagen. The patient was further tested with a combination of ADP (30µM) and 
PAR-1 peptide (100µM) and full aggregation was observed indicating that the 
complex defect is not a result of insensitivity of LTA when measuring patients with a 
low platelet count.  
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3.8.2. Flow cytometry 
46 patients were analysed by an in house developed flow cytometry protocol, either 
solely or in combination with LTA. A secondary qualitative defect was observed in 
50% of patients (23/46). 23 patients showed no observable defect when analysed by 
flow cytometry and when compared to travel controls and a range of healthy 
volunteers.   
As with patients analysed by LTA, defects in secretion were the most common 
secondary qualitative defect in platelet function. 33 patients showed a reduction in 
the secretion overall, 23 of which showed a reduction in secretion when only tested 
by flow cytometry. Unlike LTA, secretion defects presenting in flow cytometry results 
indicate a predicted defect in alpha granule secretion due to a reduction in P-selectin 
expression upon stimulation. An example of this is shown in Figure 3.8.4. The 10 
patients with a defect in secretion who were analysed by both methodologies point to 
a pan-secretion defect due to a reduction in both alpha and dense granule secretion. 
Three patients, 1.I, 31.I and 58.I, showed a reduction in response to all agonists of 
fluorescent fibrinogen binding (Figure 3.8.5). A reduction in response to all agonists 
may be indicative of a defect in the integrin αIIbβ3 complex, however CD41 (encoded 
by ITGA2B, which makes up the αIIb section of the complex) surface receptor levels 
were normal when compared to a travel control in all three patients. Two of the three 
patients, 31.I and 58.I, also displayed a reduction in P-selectin expression as well as 
a reduction in fluorescent fibrinogen binding. 
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Figure 3.8.4 Representative example of a defect in alpha-granule secretion as analysed by a reduction in P-selectin 
expression in flow cytometry analysis (Patient 64.I). In response to all doses of agonist, median fluorescent 
intensities for patient agonist stimulations (red) are reduced when compared to the travel control (blue). 
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Figure 3.8.5 Representative example of defect in fluorescent fibrinogen binding in flow cytometry analysis (Patient 
58.I). In response to all doses of agonist, median fluorescent intensities for patient agonist stimulations (red) are 
reduced when compared to the travel control (blue).
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Surface receptor levels were disrupted in a total of five patients. Two patients, 13.I 
and 61.I, showed marked reductions in surface receptor levels of CD41, encoded by 
ITGA2B (Figure 3.8.6). Two patients showed a marked reduction to around 50% of 
the travel control in median fluorescent cell surface levels of CD42b, encoded by 
GP1BA (Figure 3.8.6). One patient, 51.I, showed a mild reduction in cell surface 
receptor levels of GPVI in addition to a phenotype with a suggested alpha granule 
secretion defect (Figure 3.8.6). 
Two patients showed agonist-specific defective responses when analysed. Patient 
61.I showed a reduction in P-selectin expression and fluorescent fibrinogen binding, 
specifically when stimulated with both low and high dose CRP (0.3µg/mL and 
3.0µg/mL, respectively). This phenotype was observed in addition to a reduction in 
cell surface CD41 receptor levels. Patient 65.I also presented with a unique reduction 
in response to PAR-1 peptide at both low and high doses (10 and 100µM). Like 
patient 61.I, the defect was observed, upon stimulation, in both P-selectin expression 
and fluorescent fibrinogen binding. 
Patient 4.II was tested by flow cytometry only due to a low platelet count in PRP that 
did not exceed the cut off for LTA. As a potential defect in the cyclooxygenase 
pathway was observed in the affected sibling, patient 4.I, the patient was also 
analysed by Optimul® 96 well platelet aggregometry assay that was being tested in 
the laboratory at the time of patient recruitment. Indeed the patient shared the same 
reduced aggregation in response to doses of arachidonic acid as her affected sibling. 
The patients flow cytometry results were normal. 
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Figure 3.8.6 Examples of a reduction in cell surface levels of: (A) CD41 (Patient 
61.I), (B) CD42b (Patient 50.I), and (C) GPVI (Patient 51.I). In response to all 
doses of agonist, median fluorescent intensities for patient agonist 
stimulations (red) are reduced when compared to the travel control (blue).
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3.9. Discussion 
This section covers the patients’ characteristics, phenotypes and the presence or 
absence of secondary qualitative defects in addition to a reduction in platelet count. 
Patient characteristics were in line with a multicentre UK based study. Patient age 
varied considerably among all consenting patients due to enrolment of consenting 
patients from both paediatric and adult haematological centres and inclusion criteria 
of <85 years of age. Due to the relatively silent nature of many cases of IT that only 
present upon haemostatic challenge, the average age of patients included within the 
study is significantly into adulthood at 30 years. As such the 25th percentile lies at 16 
years and the 75th percentile at 39 years. This is in line with previous studies into IT 
with clinical detailing (Perez Botero, Pruthi et al. 2016). It therefore could be 
predicted that the paediatric cases that present with IT before the age of 10 would be 
of a severe life-threatening composition. However, only two of the 12 patients aged 
under the 10 were regularly receiving intensive therapy to combat bleeding episodes. 
In addition, only four patients were recruited with related affected adult family 
members. 
A slight skewing towards a higher percentage of female patients (63%) to male 
patients (37%) was observed and this is in line with previous large scale studies into 
the patient characteristics of IT (Noris, Biino et al. 2014). Due to the increased 
prevalence of regular haemostatic challenge in women of menstrual age, this is of no 
surprise. 
Most patients suffered from mild bleeding symptoms relating to their IT. As 
mentioned, cutaneous bleeding often leading to bruising was the most commonly 
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described symptom in patient provided questionnaires (example in appendix). In rare 
cases bleeding episodes were potentially life threatening; however, these were often 
in response to extensive haemostatic pressure such as in childbirth and surgery. 
Many of the patients who suffered from these events fall below the 30x109/L platelet 
cut off, above which blood loss as a result of haemostatic challenge rarely requires 
treatment (Burrows and Kelton 1990). The prevalence of mild-bleeding related 
symptoms is therefore considerably higher within our cohort of patients potentially 
due to the lack of significant haemostatic challenge. However, unlike previous studies 
into IT, all patients within our cohort displayed a defined bleeding phenotype (Latger-
Cannard, Philippe et al. 2016). 
Four patients in total presented with non-bleeding symptoms. All patients were 
recruited under the belief that known causes of IT that are routinely tested for within 
UK haematological centres have been excluded. As such the presence of congenital 
cataracts and hearing loss in patient 9.I but a lack of a definitive MYH9-RD or Paris-
Trousseau diagnosis is an interesting case to pursue with next generation 
sequencing. 
Treatment for the clinical complications of bleeding episodes followed UKHCDO 
guidelines and therapy mostly consisted of minimally-invasive methods to stem 
bleeding and allow clotting to occur naturally, albeit at a slower rate (Bolton-Maggs, 
Chalmers et al. 2006). In rare cases, pharmacotherapy and blood product 
transfusions were required to return platelet counts to normal circulating levels and 
minimise the clinical impact of bleeding episodes. All followed previous management 
guidelines (Bolton-Maggs, Chalmers et al. 2006). Only two patients required regular 
transfusions to maintain a healthy circulating platelet count and avoid severe 
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bleeding episodes. These patients, 41.I and 41.II, were noted for a particular low 
platelet count and extensive bleeding history despite their young age.  
Interestingly, a subset of 10 patients were initially diagnosed with ITP upon discovery 
of a low platelet count. As mentioned, ITP treatment is often severe, aiming to 
increase the circulating platelet count through often the first-line use of 
corticosteroids such as prednisolone (Force. 2003). Prednisolone improves platelet 
count by suppressing systemic reticulo-endothelial phagocytic function and reducing 
antibody production but it is often associated with severe adverse effects relating to 
patient wellbeing and health (Mizutani, Furubayashi et al. 1992; Provan, Stasi et al. 
2010). Accurate molecular diagnosis of patients upon presentation of a low platelet 
count is crucial therefore to avoid unnecessary treatment. Several studies have 
worked on trying to improve separation of the two disorders dependant on clinical 
presentation, however as many of the symptoms overlap it remains difficult and may 
benefit from progressing molecular genetic diagnostic techniques (Drachman 2004). 
None of the patients recruited to the study initially diagnosed with ITP underwent a 
splenectomy.  
Platelet counts varied from mild to severe forms of thrombocytopenia. Platelet count 
is often thought to be correlated to the genetic aetiology of disease and this will be 
determined in the following section (Chapter 4). The range in platelet counts matched 
previous studies into the platelet diameters of patients with known forms of IT (Noris, 
Biino et al. 2014). Platelet counts are often misinterpreted in cases of 
macrothrombocytopenia. Indeed, in our cohort, cases of increased platelet size are 
often associated with a severely low platelet count. Platelet counts determined by 
impedance or optical analysis are often clouded by the inclusion of reticulocytes in 
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cases of giant platelets. However, analysis using the Sysmex XN-1000 PLT-F 
channel should circumvent any underestimation by determining the platelet count 
specifically by the binding of a fluorescent RNA specific dye.  
Unlike previously published studies, patients with a platelet count between 150-
200x109/L in whole blood were retained for analysis with our study if they met specific 
criteria. Platelet counts are unique to an individual and vary considerably among 
family members and also due to ethnicity, age and gender. It is therefore possible 
that a reduction in platelet count due to genetic mutation can occur in an individual in 
whom a normal circulating platelet count would be within the upper region of normal if 
unaffected. If such an individual is affected by a defect within platelet production, 
function or consumption, then their platelet count would be reduced but may not lie 
below the traditional cut-off value of 150x109/L. Patients with a borderline count 
between 150-200x109/L, therefore, may still provide us with insight into the genetic 
aetiologies of IT and are an interesting subset of patients yet to be studied. 
Mean platelet volumes of patient platelets were also within normal ranges previously 
reported in patients with known forms of IT (Noris, Biino et al. 2014). MPV is often  an 
indicator of the genetic cause of disease, with macrothrombocytopenias often related 
to mutations in cytoskeletal regulatory genes and microthrombocytopenias usually 
confined to disorders such as WAS and CYCS-related thrombocytopenia. Our cohort 
consists of 19 patients with an increase in MPV and three with a decrease below a 
range of normal healthy volunteers.  
Immature platelet fractions are a non-invasive indication of platelet lifespan. An 
increase in IPF is often associated with a decreased platelet survival which can be 
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directly related to an increased consumption or defect in platelet maturation. 17 
patients presented with an increased IPF above a reference range established in 40 
healthy volunteers. IPF was consistent across affected family members when 
available and was often correlated with an increase in MPV and a severely reduced 
platelet count. 
Although many patients within our cohort suffered from a moderate to severe 
reduction in platelet count, platelet counts were often disproportionate to the bleeding 
phenotype observed. Secondary qualitative defects in platelet function are often 
additive to a patients bleeding phenotype; increasing their risk of bleeding episodes 
and the severity and duration of haemostatic events.  
A secondary qualitative defect in platelet function was observed in a total of 71% of 
patients (61/86) that were tested by LTA, flow cytometry or a combination of both 
assays. As mentioned previously, the most common platelet function defect was 
within either alpha or dense granule secretion. Secretion plays a crucial role in the 
amplification of activation within platelets. Without a functioning secretion 
mechanism, platelets have the ability to bind to exposed subendothelial matrix 
proteins and tether, but lack a positive feedback loop to aid in the formation of a 
stable platelet-fibrin plug/clot. This defect in the positive feedback mechanism of 
platelets may explain the increased bleeding risk and duration of haemostatic events 
observed in our cohort of patients when compared to their platelet counts.  
A defect in dense granule secretion is often a secondary qualitative defect observed 
in patients with genetic variants in genes such as RUNX1 and FLI1. Conversely, 
defects in alpha granule secretion measured by flow cytometry, may be an indicator 
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of a reduced platelet alpha granule content associated with Grey platelet syndrome 
and variants in GFI1B and NBEAL2. Due to the similar presentation in LTA of 
patients with secretion defects as those who have ingested aspirin prior to analysis, it 
is difficult to confirm or deny the defect without performing genetic sequencing. 
Variants in ITGA2B and GP1BA are associated with GT and BSS, respectively. 
Variants in both genes can cause a reduction in platelet count and a disruption to 
platelet function through the production of non-functional, or the lack of functional 
presentation of, cell surface receptors. Both disorders are often highly syndromic and 
easily identified either through routine analysis or a detailed patient clinical history 
and therefore are unlikely to present within our study. However, four patients have 
been noted with reductions in the presentation of the associated cell surface 
receptors as indicated by flow cytometry. This is a strong marker of both diseases but 
requires genetic confirmation to be able to claim causality. 
3.10. Further work 
As platelet counts vary within an individual, multiple counts over a pre-defined period 
would be the optimum way of determining a patient’s platelet count. The same can 
be said for measurements of platelet diameters and morphology. For patient samples 
this is often a difficult feat both logistically and temporally. Different methods of 
platelet diameter measurement can also introduce unwanted variance within a 
sample set. However, by extending the parameters of a study to be more inclusive to 
those with borderline counts and morphology one can mitigate the risk of excluding 
patients that are not within a pre-defined cut-off on the day of analysis. 
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Without a gold standard platelet function test it is often difficult to determine the 
presence or absence of secondary qualitative defects in each individual. Further 
testing such as including broad function assays such as microchip flow chamber 
systems or the PFA-100 to analyse thrombus formation under shear could provide a 
unique tactic to furthering platelet phenotyping (Harrison 2005; Hosokawa, Ohnishi et 
al. 2011). In addition, further conformational tests could be utilised after initial testing 
such as transmission electron microscopy for patients with suspected alpha and 
dense granule deficiencies.  
Although furthering our knowledge of platelet function can often help to describe a 
patient’s phenotype and explain the clinical bleeding diathesis observed, it lacks an 
ability to clinically diagnose a patient. This is especially apparent in a cohort of 
patients with a presumed disorder of unknown genetic aetiology. To fully understand 
a patient’s inherited disease a combination of phenotyping and genotyping is 
required. 
3.11. Key findings 
 Average patient age and patient gender distributions are in line with previously 
published studies surrounding haematological bleeding disorders 
 Patients present with broad ranging platelet counts and variance in platelet 
diameters and morphology consistent with the heterogeneity of IT. 
 70% of patients display with a secondary qualitative defect in platelet function 
which may explain the disproportionate bleeding observed in patients when 
compared to platelet counts. 
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4. Patient genotyping by whole exome sequencing 
4.1. Summary of background to this research 
Due to limitations of platelet function testing discussed in chapter 3, patient 
genotyping is an ideal way to clinically diagnose patients with IT of unknown 
aetiology. 
Molecular genetic sequencing has progressed rapidly since the invention of Sanger 
sequencing and the subsequent completion of sequencing of the human genome 
(Sanger, Nicklen et al. 1977; Venter, Adams et al. 2001; Consortium 2004). Sanger 
sequencing has evolved away from radiography and gel electrophoresis into utilising 
fluorescence and capillary array electrophoresis, thereby improving efficiency and 
efficacy, however it still suffers from limitations in sensitivity. The emergence of next 
generation sequencing techniques with improved sensitivity has aided in a shift in 
usage from small scale applications of sequencing areas of disease linkage into large 
scale studies in whole exome and genome sequencing. This progression has been 
adopted clinically, allowing for rapid diagnosis dependant on patient genotype in a 
number of disease areas.  
Part of this increase in clinical usage is due to decrease in cost, especially of next 
generation sequencing techniques such as whole exome and whole genome 
sequencing. The completion of the reference genome sequence cost nearly $3 billion 
to complete, and during the past decade the price of genome sequencing has 
plummeted to an estimated $1000 dollars for a genome at 30x coverage (Warr, 
Robert et al. 2015). Not only that, but the time taken to sequence and analyse the 
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subsequent data has also diminished allowing for allocation within a clinical time-
frame. 
Improvements and the emergence of multiple next generation sequencing techniques 
has helped research into IT progress from a pre-to a post-genomic era, incorporating 
sequencing into fundamental research. As mentioned previously, this has aided in 
the discovery of novel causes of disease and has allowed for clarity in the molecular 
aetiology behind a number of previously well-classified disorders. However, the 
application of next generation sequencing remains solely in the confirmation of 
disorders that are already well characterised. The exceptions to this rule occur in 
single pedigrees with a strong, shared phenotype and often clinical symptoms in 
addition to bleeding complications. The question arises then whether a disease 
subset such as IT would benefit from direct next generation sequencing in the form of 
whole exome sequencing and whether this will aid in the discovery of novel causative 
genes not previously implicated in disease. 
4.2. Aims of this chapter 
This results chapter will aim to genotype 95 patients with suspected IT of unknown 
aetiology that have been entered into the UK-GAPP study. All patients were analysed 
using WES to try and determine a variant in a gene likely causative of disease. The 
results will grant insight into a patient’s disease, aiding in their overall diagnosis and 
potentially offering us novel candidate genes with which to pursue functional 
characterisation. 
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4.3. Whole exome sequencing overview 
Whole exome sequencing was performed on 69 patients following patient 
phenotyping and platelet function testing as detailed in Chapter 3 and outlined in 
Figure 3.3.2. One patient, 47.I, was analysed by WES following analysis by the 
inherited thrombocytopenia specific next generation sequencing panel. This patient 
will be discussed in further detail in both chapters and the rationale for analysing the 
patient using both methodologies will be explained in section 5.7. 
4.3.1. Development of a thrombocytopenia gene specific 
bioinformatics pipeline 
A bioinformatic pipeline was created to determine candidate variants from WES data 
(Figure 4.3.1). Alignment, annotation and variant calling as well as novelty 
determination were performed as described in section 2.13.1 by collaborators in 
King’s College London. Bioinformatics proceeded on variant called files from each 
individual patient. 
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Whole Exome Sequencing 
Filtered against database of 358 genes known 
or predicted to be associated with platelet 
count / function 
  
  
Alignment to hg19 
Novelty determined by comparison of variants against 
EVS 
1000 genomes 
GAPP database of over 800 whole exomes 
dbSNP135 
Exome aggregation consortium dataset of 61,486 unrelated individuals 
Exclude Variants with: 
MAF≥ 0.01, 
≥1% frequency in GAPP database  
Synonymous changes 
Splice site variants occurring > 4 bp away from the exon 
Not shared in additional affected family members 
  
Remove all non-novel variants 
  
  
Predict Pathogenicity using: 
PolyPhen2, Provean, SIFT, Mutation Taster, mRNA expression levels 
Candidate Gene Defects 
Removal of variants with non-significant changes; 
Synonymous changes 
Splicing > 4 base pairs away from the exon 
  
Compare to whole exomes from other 
affected family members. 
Exclude all non-shared variants 
Variant classification 
  
Figure 4.3.1 Bioinformatics pipeline for the analysis of WES data.   
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Analysis consisted of two methods; comparison to a database of genes known to be 
implicated in platelet formation, function, lifespan or death (which includes all genes 
previously known to cause IT) and analysis of novel only variants.  
Comparison to a database of 358 known platelet related genes was performed 
initially (genes outlined in Table A within the appendix). Prior to comparison to a 
database of platelet related genes, variants were selected to be filtered dependant on 
frequency. A traditional rare variant cut off value of 0.01 or 1% of the population was 
used to filter out variants, variants with a MAF of >0.01 are not excluded but “rare” 
frequency variants are preferentially analysed first by pathogenicity prediction and 
classification. Also, synonymous variants not known to change the amino acid were 
excluded. 
The database of genes was developed by members of the UK-GAPP study and is an 
extended version of the one first used by Stockley et al, (Stockley, Morgan et al. 
2013). The initial list of genes was formulated based upon genes known to be 
involved with platelet disorders, those implicated in platelet formation and lifespan, 
and candidate genes from animal models and in vitro studies. The list has been 
updated following the literature and also encompasses genes from an N-ethyl-N-
nitrosourea (ENU) based mutagenic screen into platelets as performed by our 
collaborator Professor Ben Kile.  
Average coverage of all genes within the database in all exomes analysed is 
displayed in Table A within the appendix. Average percentage at 20x coverage was 
0% for five cases as the gene IDs were not found within the targeted regions of WES. 
Eight genes were noted with 20x coverage <50%, this included one gene, GP1BB, 
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that has previously been identified as causing IT. Therefore, this gene was checked 
manually due to the overall low coverage. Overall, average coverage across all 358 
genes was 89.2%.  
Following comparison to the panel of platelet related genes, variants were excluded 
dependant on location and frequency. Variants predicted to affect the splice site 
occurring >5bp from the intron-exon boundary were excluded. Variants with a 
frequency of >0.01 or 1% in the in house UK-GAPP exome database were also 
excluded. 
Candidate variants that met the inclusion criteria were then scrutinised for presence 
in affected family members, if available. Variants not present in all affected family 
members were also excluded. 
Following comparative analysis to a panel of platelet related genes, exomes were 
analysed by selecting candidates from novel variants only. 
Exomes were initially filtered to display only novel variants and subsequently filtered 
to remove splice site variants occurring >4bp from the intron-exon boundary and 
synonymous variants. 
Like with the variants that were present within the panel of platelet related genes, 
novel variants that met the inclusion criteria were scrutinised for presence in affected 
family members who had also undergone WES. Variants that were present in all 
affected family members were pooled as candidates with those from the comparative 
analysis to a panel of platelet-related genes. 
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All candidate variants subsequently underwent in silico pathogenicity predictions to 
rank variants as the most likely to be disease causing. Variants occurring in genes 
known to previously cause IT were preferentially selected. 
All candidate variants were subsequently classified as stated in section 2.14.1.3. 
4.3.2. Average number of sequence variants, sensitivity and false 
discovery rate 
WES revealed, on average, between 24,000 and 26,000 variants (single nucleotide 
variants (SNVs), small scale insertions/deletions, and splice site variations) in the 
DNA from each patient. Of these variants, an average of 201 per exome analysed 
were novel in the databases scrutinised (n=69). Per individual, an average of 2531 
variants with a MAF of ≤0.01 were observed excluding synonymous variants. 
Over 99% sensitivity and an approximate 3% false discovery rate was found by 
evaluating the specificity of the pipeline in calling small variations (SNVs, small scale 
insertions/deletions, splice site changes). 
4.3.3. Coverage of exome sequencing data 
Fold coverage across the entire targeted region was available for 67 patients. 
Patients 7.I and 7.II were unavailable for coverage analysis due to the date in which 
the patients were analysed by WES. On average, 70.6% of all reads were mapped to 
target regions, 76.6% were mapped to target reads plus 150bp. An average of 91.8% 
of accessible target bases were covered with at least 20 overlapping reads. The 
overall mean coverage of targets across all 67 patients was 119.0. 
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4.3.4. Copy number variants using exome data 
CNVs were analysed using a bioinformatics pipeline similar to the analysis of small 
scale variants such as SNV, small insertions/deletions and splice site variants. CNV 
were initially compared to determine presence of variants within genes of the same 
panel of 358 platelet related genes that small variants are analysed with. Variants 
occurring within one of the genes within the panel of platelet related genes were then 
scrutinised for their novelty.  
Copy number data was available for 44 exomes and unavailable for 25. On average 
185.7 variants were observed across all exomes where CNV data was available. 
Fifteen patients were observed to have no CNVs in the genes within the panel of 358 
platelet related genes. 
Only two patients, 22.I and 45.I, displayed variants in genes previously known to 
cause IT. Patient 22.I was observed with a previously identified 18,455bp deletion 
(Accession number – nsv829233) in MKL1 in addition to a 21,001bp duplication in 
ANKRD18A (nsv1020605) and a 19,898bp duplication in PDPK1 (esv2422427). All 
three variants have been previously identified and the variant in PDPK1 forms part of 
a segmental duplication.  
Patient 45.I, was observed to have two CNVs in genes previously implicated in IT. A 
previously unidentified duplication in ANRKD26 was noted that spans 7,893bp. Also 
a 4,388bp known duplication in FLNA (nsv519042) was also observed. 
4.3.5. Variants in known thrombocytopenia causing genes 
Following bioinformatic analysis as outlined in section 4.3.1, 71% of patients (49/69) 
were observed to harbour a variant within a gene previously implicated in IT. This 
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corresponds to a potentially determined genetic aetiology of disease in 66% of index 
cases (31/47). All variants exceeded 30x coverage at the point of variation and 
passed all quality control (QC) that was performed externally by collaborators at 
King’s College London. 
All variants were present within genes of the panel of 358 platelet related genes. On 
average, 36 variants excluding synonymous variants, with a frequency of ≤0.01 in the 
EVS database were noted in the panel of 358 platelet related genes (n=69). On 
average, four variants were deemed significant (frequency of ≤0.01 in the in house 
UK-GAPP exome database and <4bp from the intron-exon boundary for splice site 
variants) per exome analysed (n=69). Of these, variants in genes previously known 
to cause IT were deemed the most likely candidates and are displayed in Table 
4.3.1.
 140 
 
Family Patient Gene(s) Genomic variation Protein effect Variation type Prevalence 
1 I ACTN1 c.2647G>C p.Gly883Arg Missense Novel 
2 I ANKRD26 c.-126T>G 
 
5'-UTR variation Known 
3 I CYCS c.104G>T p.Gly35Val Missense Novel 
4 I CYCS c.155C>T p.Ala52Val Missense Novel 
 
II CYCS c.155C>T p.Ala52Val Missense Novel 
 
III CYCS c.155C>T p.Ala52Val Missense Novel 
5 I DIAPH1 c.3637C>T p.Arg1213* Nonsense Known 
  II DIAPH1 c.3637C>T p.Arg1213* Nonsense Known 
6 I FLI1 c.992_995del p.Asn331Thr fs*4 Frameshift deletion Novel 
 
II FLI1 c.992_995del p.Asn331Thr fs*4 Frameshift deletion Novel 
7 I FLI1 c.1028A>G p.Tyr343Cys Missense Novel 
  II FLI1 c.1028A>G p.Tyr343Cys Missense Novel 
8 I GFI1B c.503G>T p.Cys168Phe Missense 0.0006011 (ExAC)(rs527297896) 
 
II GFI1B c.503G>T p.Cys168Phe Missense 0.0006011 (ExAC)(rs527297896) 
 
III GFI1B c.503G>T p.Cys168Phe Missense 0.0006011 (ExAC)(rs527297896) 
9 I GFI1B c.814+1G>A   Splicing Novel 
10 I 
GFI1B c.814+1G>A 
 
Splicing Novel 
STIM1 c.1828G>A p.Ala610Thr Missense 0.00019 (1k) 
 
II 
GFI1B c.814+1G>A 
 
Splicing Novel 
STIM1 c.1828G>A p.Ala610Thr Missense 0.00019 (1k) 
11 I GP1BA c.413G>T p.Gly138Val Missense Novel 
  II GP1BA c.413G>T p.Gly138Val Missense Novel 
12 I GP1BA c.1761A>C p.Gln587His Missense 0.00043 (EXaC) (rs570515282) 
13 I 
ITGA2B c.2033C>T p.Ala678Val Missense 0.0001848 (ExAC)(rs200481952) 
ITGA2B c.2176A>T p.Lys726* Nonsense Novel 
THPO c.609insG p.Glu204Gly fs*123 Frameshift insertion Novel 
14 I MYH9 c.3493C>T p.Arg1165Cys Missense Known (rs80338829) 
15 I 
NBEAL2 c.1376delT p.Leu459Arg fs*13 Frameshift deletion Novel 
NBEAL2 c.6893A>G p.Asn2298Ser Missense Novel 
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16 I RUNX1 c.16G>A p.Asp6Asn Missense Novel 
 
II RUNX1 c.16G>A p.Asp6Asn Missense Novel 
 
III RUNX1 c.16G>A p.Asp6Asn Missense Novel 
17 I 
RUNX1 c.236G>A p.Trp79* Nonsense Novel 
ITGB3 c.349C>T p.Arg117Trp Missense Novel 
18 I RUNX1 c.270+1G>T 
 
Splicing Novel 
 
II RUNX1 c.270+1G>T 
 
Splicing Novel 
19 I RUNX1 c.270+1G>T   Splicing Novel 
20 I RUNX1 c.322G>A p.Gly108Ser Missense Novel 
21 I RUNX1 c.427+1G>T   Splicing Novel 
  II RUNX1 c.427+1G>T   Splicing Novel 
22 I RUNX1 c.505A>G p.Thr169Ala Missense Novel 
23 I RUNX1 c.512A>T p.Asp171Val Missense Novel 
24 I RUNX1 c.530G>A p.Arg177Gln Missense Known 
 
II RUNX1 c.530G>A p.Arg177Gln Missense Known 
25 I 
RUNX1 c.568G>A p.Gly190Arg Missense 0.00002475 (ExAC) 
DIAPH1 c.1820insCTCCTC p.Thr607delinsTTP Nonframeshift insertion Novel 
26 I SLFN14 c.652A>G p.Lys218Glu Missense Novel 
27 I SLFN14 c.657A>T p.Lys219Asn Missense Novel 
  II SLFN14 c.657A>T p.Lys219Asn Missense Novel 
28 I SLFN14 c.659T>A p.Val220Asp Missense Novel 
 
II SLFN14 c.659T>A p.Val220Asp Missense Novel 
 
III SLFN14 c.659T>A p.Val220Asp Missense Novel 
29 I 
TPM4 c.548C>T p.Ala183Val Missense Novel 
TUBB1 c.726C>G p.Phe242Leu Missense Novel 
30 I TUBB1 c.721C>T p.Arg241Trp Missense 0.0001071 (ExAC)(rs368923302) 
 
II TUBB1 c.721C>T p.Arg241Trp Missense 0.0001071 (ExAC)(rs368923302) 
31 I TUBB1 c.1080_1081insG p.Leu361Ala fs*19 Frameshift insertion Novel 
32 I Unknown 
    
33 I Unknown         
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34 I Unknown 
    
35 I Unknown         
36 I Unknown 
    
 
II Unknown 
    
 
III Unknown 
    
37 I Unknown         
  II Unknown         
38 I Unknown 
    
39 I Unknown         
40 I Unknown 
    
41 I Unknown         
 
II Unknown 
    
42 I Unknown         
43 I Unknown 
    
44 I Unknown         
45 I Unknown 
    
46 I Unknown         
47 I Unknown 
    
 
Table 4.3.1 Results of variants in known IT causing genes following WES analysis in 47 index cases covering 69 
patients. Displayed on the patient identifiers as well as candidate genetic variants in genes known previously to 
cause IT if available. Shown are the genomic and protein effect of variation, type of variation and the prevelance in 
the previously listed databases. 
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In total, 36 variants were observed in 17 genes known previously to cause IT. 
Twenty-five index cases presented with variants in one single gene previously known 
to cause IT. Five index cases had two variants in genes known to previously to cause 
IT and one patient, 13.I, had three variants. Candidate variations were present within; 
ACTN, the 5’-UTR of ANKRD26, CYCS, DIAPH1, FLI1, GFI1B, GP1BA, ITGA2B, 
ITGB3, MYH9, NBEAL2, RUNX1, SLFN14, STIM1, THPO, TPM4 and TUBB1.  
Of the 47 index cases, five index cases presented with two variants in known 
thrombocytopenia causing genes. Four of these index cases displayed variants in 
two alternate genes. These were as follows: patient 10.I (and also the related family 
member 10.II) - GFI1B; c.814+1G>A and STIM1; c.1828G>A, p.Ala610Thr. Patient 
17.I - RUNX1; c.236G>A, p.Trp79* and ITGB3; c.349C>T, p.Arg117Trp, patient 25.I 
– RUNX1; c.586G>A, p.Gly190Arg and DIAPH1; c.1820insCTCCTC, 
p.Thr607delinsTTP and patient 29.I – TUBB1; c.726C>G, p.Phe242Leu and TPM4; 
c.548C>T, p.Ala138Val. One patient displayed two variants in one gene, this was 
patient 15.I and the variants were both located within NBEAL2. The variants were 
compromised of a frameshift causing deletion; c.1376delT, p.Leu459Arg fs*13 and a 
missense variant; c.6893A>G, p.Asn2298Ser indicating the recessive inheritance of 
GPS.  
One patient was observed with three variants in two genes previously implicated 
within IT. Patient 13.I presented with two variants within ITGA2B, consisting of a 
missense variant, c.2033C>T, p.Ala678Val, and a nonsense causing SNV, 
c.2176A>T, which is predicted to truncate the coded protein sequence; p.Lys726*. In 
addition, patient 13.I was also identified with a frameshift causing insertion within 
THPO; c.609insG, p.Glu204Glyfs*123. The predicted effect of the variant is a 
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frameshift which allows for the subsequent translation of an altered stretch of 123 
amino acids and a formation of a new stop codon, truncating the wild type protein 
sequence by 26 amino acids (p.Glu204Glyfs*123).  
4.3.5.1. Protein effects of genetic variants 
Of the 36 variants observed within all cases, four variants were identified in non-
coding regions of the genes. The most commonly observed variation type was a SNV 
leading to a missense change in amino acid sequence; this was noted in 64% of all 
variants observed (23/36). Three SNVs altered the amino acid sequence to introduce 
a premature stop codon at the point of variation. These nonsense variants occurred 
in index patients 5.I, 13.I and 17.I with variants in DIAPH1, ITGA2B and RUNX1, 
respectively.  
The four variants occurring outside of the coding region consisted of three splice site 
variants all located within 1bp of the intron-exon boundary, and one variant upstream 
of the coding sequence within the 5’ UTR of ANKRD26. This variant was noted 
initially by a separate project to determine the presence of variants within the 5’ UTR 
of ANKRD26 and was later confirmed by exome and Sanger sequencing. The variant 
was not present within the variant called and annotated exome data and was 
determined by analysing the raw aligned sequence data manually as mentioned in 
the methods section 2.14.1.1. This variant was the only variant to occur within the 5’ 
UTR of ANKRD26 in all of our patients analysed where coverage was possible.  
Three splice site variants were noted in all patients. These included; a splice site 
variant in GFI1B; c.814+1G>A, which was noted in two unrelated index cases, 9.I 
and 10.I, as was RUNX1; c.270+1G>T which was noted in index cases 18.I and 19.I 
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and RUNX1; c.427+1G>T in index case 22.I. GFI1B; c.814+1G>A and 
RUNX1;c.427+1G>T are both predicted to alter the WT donor site affecting normal 
splicing. RUNX1;c.270+1G>T is predicted to activate an intronic cryptic donor site 
potentially altering splicing.  
Five small scale insertions/deletions were observed in the patient dataset. Only one 
variant, a 6bp in frame insertion within DIAPH1 in patient 25.I, did not cause a 
change in reading frame. All other variants are predicted to cause a frameshift 
truncating the coded protein sequence due to the introduction of a premature 
downstream codon. These variants are outlined in Table 4.3.1. 
4.3.5.2. Novelty of variants found in patients 
All variants in index cases were found to be novel in all databases scrutinised with 
the exception of 10 variants in total. Four of the 10 variants have been previously 
implicated in disease and have been determined causative of IT. These variants 
occurred within; patient 2.I: ANKRD26;c.-126T>G, patients 5.I and 5.II: 
DIAPH1;c.3637C>T, patient 14.I: MYH9;c.3493C>T and patients 24.I and 24.II: 
RUNX1;c.530G>A. All variants were initially analysed for novelty in the EVS, the 
1000G project and our in-house UK-GAPP database of over 1200 exomes as 
depicted in Figure 4.3.1. Candidate variants that were not excluded during 
bioinformatics post sequencing analysis were also scrutinised against the ExAC 
database for prevalence. The ExAC database may include data from individuals with 
low platelet counts who were either undiagnosed or recruited through an unrelated 
study. Six variants were observed in patients that were not novel and were present in 
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the databases outlined in Table 4.3.1. All variants were present at a frequency of 
<0.0005 in their relative databases. 
On average, less than one novel variant was expected to be observed in the 
causative genes in which variants were observed. This was calculated by 
determining the percentage of the overall target exome that a targeted gene occupies 
and applying the average number of novel variants. The number of variants occurring 
in genes known to cause IT also exceeds the expected number when extending the 
analysis to cover variants with a MAF of ≤0.01. 
4.3.5.3. In silico pathogenicity prediction and conservation 
Pathogenicity was predicted for all variants using the in silico prediction software as 
outlined within the bioinformatics pipeline in section 4.3.1. Results of pathogenicity 
predictions are shown in Table 4.3.2. 
Variants predicted to alter the length of the encoded transcript (insertions, deletions 
and nonsense variants) as well as variants predicted to effect splice sites were not 
analysed by SIFT, PROVEAN and PolyPhen-2 software. Results were unavailable 
from using these software due to limitations in the software in predicting only SNV 
that lead to missense changes. Splice site variant pathogenicity was predicted as 
mentioned previously. 
Conservation was determined by two methods and are displayed in Table 4.3.2. 
Conservation was in agreement between both methods used in 83% of variants 
(30/36)
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Family Patient PhyloP Phastcons Mutation taster PolyPhen-2 SIFT Provean ACMG criteria Classification 
1 I 5.969 1 Disease causing Damaging Damaging Deleterious 
PM2, PP2, PP3, PP1, 
PP4 
Likely Pathogenic 
2 I -0.433 0 Polymorphism 
   
PS1, PS3, PP1, PP5, 
PP4 
Pathogenic 
3 I 5.962 1 Disease causing   Damaging Deleterious PM2, PP3 Uncertain significance 
4 I 
5.962 1 Disease causing Benign Damaging Deleterious 
PM2, PP3, PP2, PS 
(segregation), PP4 
Likely Pathogenic 
 
II 
 
III 
5 I 
1.798 1 Disease causing       
PM4, PS1, PVS1, PP 
(segregation) 
Pathogenic 
  II 
6 I 
4.943 
1 
Disease causing 
   
PM2, PVS1, PP 
(segregation), PP4 
Pathogenic 
 
II 
 
7 I 
3.302 0.995 Disease causing Damaging     
PM2, PP3, PP2, PP 
(segregation), PP4 
Likely Pathogenic 
  II 
8 I 
5.229 1 Disease causing Damaging Damaging Deleterious PP3, PM (segregation) Uncertain significance 
 
II 
 
III 
9 I 3.444 1 Disease causing       PM2, PP3, PP2, PP4 Uncertain significance 
10 I 
3.444 1 Disease causing 
   
PM2, PP3, PP2, PP 
(segregation), PP4 
Likely Pathogenic 
-0.084 0.493 Disease causing 
   
PP3, PP2, PP 
(segregation), PP4 
Uncertain significance 
 
II 
3.444 1 Disease causing 
   
PM2, PP3, PP2, PP 
(segregation), PP4 
Likely Pathogenic 
-0.084 0.493 Disease causing 
   
PP3, PP2, PP 
(segregation), PP4 
Uncertain significance 
11 I 
0.812 0.208 Polymorphism Damaging Damaging Deleterious 
PM2, PP3, PP2, PP 
(segregation),  PP4. 
Likely Pathogenic 
  II 
12 I -0.015 0.812 Polymorphism 
 
Damaging Neutral PP2,  PP4 Uncertain significance 
13 I 4.959 0.999 Disease causing Damaging Damaging Deleterious PP3, PP2, PP4 Uncertain significance 
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1.419 0.957 Disease causing       PM2, PM4, PVS1, PP4 Pathogenic 
    Disease causing       PM2, PVS1 Pathogenic 
14 I 4.131 1 Disease causing Damaging Damaging Deleterious 
PS1, PS3, PP2, PP5, 
PP4 
Pathogenic 
15 I 
2.687 0.997 Disease causing       
PM2,  PM4, PM6, BP2, 
PP4 
Likely Pathogenic 
4.508 1 Disease causing Damaging Damaging Deleterious 
PM2, PP3, PP2, PM6, 
BP2, PP4 
Likely Pathogenic 
16 I 
5.86 1 Disease causing Damaging Damaging Deleterious 
PM2, PP3, PM 
(segregation), PP4 
Likely Pathogenic 
 
II 
 
III 
17 I 
4.077 1 Disease causing       
PM2, PVS1, PM4,  PP4, 
PP3 
Pathogenic 
1.362 0.454 Polymorphism Damaging Damaging Deleterious PM2, PP3, PP4 Uncertain significance 
18 I 
6.077 1 Disease causing 
   
PM2, PM4, PM 
(segregation), PP4 
Likely Pathogenic 
 
II 
19 I 6.077 1 Disease causing       
20 I 6.077 1 Disease causing Damaging Damaging Neutral PM2, PP3,  PP4 Uncertain significance 
21 I 
5.36 1 Disease causing       
PM2, PM4, PP 
(segregation),  PP4 
Likely Pathogenic 
  II 
22 I 4.429 1 Disease causing Damaging 
  
PM2, PP3, PP4 Uncertain significance 
23 I 4.429 1 Disease causing Damaging Damaging Deleterious PM2, PP3, PP4 Uncertain significance 
24 I 
5.36 1 Disease causing Damaging Damaging Deleterious 
PS1, PM2, PP3, PP 
(segregation), PP4 
Pathogenic 
 
II 
25 I 
2.485 1 Disease causing Damaging Damaging Deleterious PP3, PM1 Uncertain significance 
    Polymorphism       PM2, BP4, PM4 Uncertain significance 
26 I 2.338 1 Polymorphism Damaging Benign Neutral PM2, PP (segregation) Uncertain significance 
27 I 
0.852 0.952 Polymorphism Damaging Benign Neutral PM2, PP (segregation) Uncertain significance 
  II 
28 I 
2.366 0.167 Polymorphism Damaging Damaging Deleterious PM2, PS (segregation) Likely Pathogenic 
 
II 
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III 
29 I 
5.582 1 Disease causing Damaging Damaging Deleterious PM2, PP3, PP4 Uncertain significance 
1.414 1 Disease causing Damaging Damaging Deleterious PM2, PP3, PP2, PP4 Uncertain significance 
30 I 
5.701 1 Disease causing Damaging Damaging Deleterious 
PP3, PP2, PP 
(segregation), PP4 
Uncertain significance 
 
II 
31 I 2.413 1 Disease causing       PM2,  PM4,  PP4, PP3 Likely Pathogenic 
 
Table 4.3.2 Pathogenicity prediction and variant classification of the variants displayed in Table 4.3.1. PhyloP scores 
vary between -14 and +6 and measure conservation at each individual base, sites predicted to be conserved are 
assigned a positive score, fast evolving sites are assigned a negative score. PhastCons values vary between 0 and 1 
and reflect the probability that each nucleotide belongs to a conserved element. MutationTaster uses a Bayes 
classifier to predict the effect of a mutation from a feed of classifiers. SIFT damaging prediction score= <0.05. 
Provean deleterious score = <-2.5. PolyPhen-2 predictions are appraised qualitatively as benign or damaging.  The 
ACMG consensus guidelines, including supporting evidence, are also shown.  
 
 
 150 
 
4.3.5.4. Variant classification 
Variant classification was performed as detailed in the methods section 2.14.1.3 and 
the results are shown in Table 4.3.2. Each criteria that each variant met is also 
shown which are then combined allowing for determination of the classification. In 
total, of the 36 variants occurring within the known IT-related genes; 8 variants were 
deemed “pathogenic” (22%), 12 were deemed “likely pathogenic” (33%) and 16 were 
of “unknown significance” (45%). 
Of the eight variants deemed pathogenic; four variants in index cases 2.I, 5.I, 14.I, 
and 24.I were classified as pathogenic as they are previously identified variants 
known to be detrimental to the function of the protein and causative of disease. The 
remaining four variants deemed to be pathogenic residing in index cases; 6.I, 13.I 
(includes two variants, one in ITGA2B and one in THPO), and 17.I were classified 
due to the protein size altering effect of the nonsense and frameshift variants.  
No variants were classified as benign or likely benign, however one variant, an in-
frame insertion within DIAPH1 (c.1820insCTCCTC), did show supporting evidence of 
benign classification in addition to supporting pathogenic evidence. 
4.3.5.5. A high percentage of variants within RUNT1-related 
transcription factor 
Of the 36 variants identified, nine variants were identified in 10 index cases within the 
RUNT-related transcription factor (RUNX1). The variants consisted of six missense 
variants, two splice site changes and one nonsense premature stop codon-
generating variants. The variants represent the plausible candidate variants 
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causative of disease in 32% of all index cases (10/31), identified with variants in 
known IT causing genes. With the exception of a missense variant, c.16G>A, 
p.Asp6Asn, occurring in patients 16.I, 16.II and 16.III, all variants occur within the 
highly conserved genetic region encoding the runt homology domain of RUNX1 
(Figure 4.3.2). 
4.3.5.6. Sanger sequencing confirmation 
All variants were confirmed by Sanger sequencing to remove potentially false-
positive derived results. Additional family members, both affected and unaffected, 
that were also recruited to the study were available for families; 4, 26, 27, and 28. In 
all cases the candidate variants in known IT causing genes segregated with disease 
status and were not present within any unaffected family members. Example 
sequencing traces of variants are shown in  
Figure 4.3.3. 
4.3.6. Potentially damaging variants in novel candidate genes 
After scrutinising individuals for variants within the panel of 358 platelet associated 
genes, focus was turned towards the novel variants especially in individuals without a 
variant in a gene within the gene panel. In three families, WES analysis revealed 
potentially damaging candidate variants in genes not known to cause IT at the time of 
analysis. Six variants were identified in the three families that may be causative of 
disease (Table 4.3.3). All variants were novel when scrutinised within the EVS, 
1000G and our in house GAPP database of over 1200 exomes. Upon further 
analysis within the ExAC database, only the variants within ANKRD18A and GNE 
within family 37 were not previously identified. 
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Figure 4.3.2 Schematic showing the protein location of all previously published variants within RUNX1 (Top) 
compared to all variants identified by WES analysis (Bottom). Numbers refer to amino acid locations and the Runt-
homology domain spanning from amino acid 49-182 is also displayed. A high number of variants are located within 
the Runt-homology domain potentially implying a genotype-phenotype correlation. 
Runt domain 
p.D6N p.W79* 
c.270+1G>T 
c.427+1G>T 
p.G108S p.T169A 
p.D171V 
p.R177Q 
182 49 
RUNX1 
0 453 
Missense variants 
Splice site variants 
Small in-dels 
p.G190R 
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Figure 4.3.3 Representative sanger sequencing traces confirming three variants identified by WES analysis. 
Patient 13.I 
ITGA2B 
c.2176A>T 
p.Lys726* 
Patient 9.I 
GFI1B 
c.814+1G>A 
Patient 4.I 
CYCS 
C,155C>T 
p.Ala52Val 
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Table 4.3.3 Potentially damaging variants in novel candidate genes. When a variant has been previously observed it 
was annotated in the prevalence column with the database it was observed in. PhyloP and Phastcons scores are 
shown following the cut offs displayed in Table 4.3.2. Variants are noted as D – Disease causing and P – 
Polymorphism in MutationTaster, D – Damaging and T – Tolerated in SIFT, D – Deleterious and N – Neutral in 
Provean, D – Damaging and B – Benign in PolyPhen-2 in silico pathogenicity prediction software. 
Fam
ily Gene Variant 
Protein 
effect 
Preval
ence 
Phy
loP 
Phast
Cons 
Mutation 
Taster 
SI
FT 
Prov
ean 
PolyP
hen-2 ACMG criteria Classification 
36 
PADI2 c.1496A>G 
p.Lys499
Arg 
0.0000
08681 
1.64
7 1 D T N B PM (segregation)  
Uncertain 
Significance 
TTF2 
c.3265C>
G 
p.His108
9Asp 
1.65E-
05 
5.13
1 1 D D D D 
PM (segregation) 
, PP3  
Uncertain 
Significance 
41 
ANKR
D18A 
c.2395_23
97delhom 
p.Glu799
delhom 
Novel 0.77
2 0.965 P 
 
D 
 
PM2, PP 
(segregation), 
PM6 
Uncertain 
Significance 
GNE 
c.1339G>A
hom 
p.Gly447
Arghom 
Novel 5.34
3 1 D D N D 
PM2, PP 
(segregation), 
PM6 
Uncertain 
Significance 
FRMP
D1 
c.1526C>T
hom 
p.Ala509
Valhom 
0.0003
708 
-
1.45
9 0 P T N B 
PP 
(segregation), 
PM6 
Uncertain 
Significance 
43 MKL1 c.1723G>A 
p.Val575
Met 
0.0007
718 
3.35
8 1 D D N D 
 
Uncertain 
Significance 
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4.3.6.1. Novel missense candidate variants in PADI2 and TTF2 
Two variants in genes not known previously to cause IT were identified in three 
individuals from family 36. The three patients were part of a larger kindred including 
four unaffected family members that were also recruited to the study. The two 
variants were part of 14 novel variants shared between the three family members as 
derived from WES analysis. Sanger sequencing of all 14 variants within the four 
unaffected family members narrowed down the candidate variants to only two 
missense changes; PADI2;c.1496A>G and TTF2;c.3265C>G. Both variants 
segregate with disease status, not being present within any of the unaffected related 
individuals. Further analysis showed that both variants were present within the ExAC 
database at frequencies of 0.000008681 and 0.00001648, respectively. Both variants 
are highly conserved at the point of variation, however only the variant within TTF2 
was predicted to be unanimously deleterious by all pathogenicity prediction software 
tools used. Both variants are classified as of “unknown significance”. 
4.3.6.2. Variants within ANKRD18A, GNE and FRMPD1 in two 
related individuals from consanguineous relationships 
WES analysis of two related patients (41.I and 41.II) was adapted due to the specific 
inheritance patterns of the patients. Both patients were born from consanguineous 
relationships within a single large consanguineous kindred, therefore, analysis was 
focused on the identification of shared homozygous variants due to recessive 
segregation of disease. Two missense variants; GNE; c.1339G>A, p.Gly447Arg and 
FRMPD1; c.1526C>T, p.Ala509Val were identified in addition to an in-frame deletion 
of three base pairs; ANKRD18A; c.2395_2397del, p.Glu799del. At the time of 
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analysis, the link between GNE and thrombocytopenia was not yet published. Both 
patients show no signs of the accompanying muscular dystrophy that is attributed to 
variants within GNE, they are therefore considered in this section and not section 
4.3.5 regarding variants in genes known to cause IT. Both patients were of South 
Asian ethnicity so prevalence analysis was adapted to analyse the variants within the 
database of the same ethnicity. Variants in ANKRD18A and GNE were absent from 
South Asian and all ethnic databases, the variant within FRMPD1 was noted at a 
frequency of 0.0003708 in the South Asian population present within the ExAC 
database. The variant within GNE was highly conserved, however all variants 
showed variation in results among the pathogenicity prediction software used and as 
such all three variants are classified as of “unknown significance” using the ACMG 
consensus guidelines.  
4.3.6.3. Missense variant in the recently proposed IT linked gene; MKL1 
One individual, patient 43.I, was observed with a rare frequency variant (≤0.01) within 
MKL1. The variant was initially identified as novel and was the only gene of 
haemostatic relevance of 109 novel variants identified within the patient following 
WES analysis. The variant; MKL1; c.1723G>A, p.Val575Met, has been noted 
previously at a frequency of 0.0007718 (allele count of 6/7774 in the EXAC 
database). As MKL1 is present within the panel of 358 platelet related genes the 
variant was also identified during the comparison to the panel. However, the variant 
was observed in a heterozygous state where only one homozygous variant has 
previously been identified as leading to IT secondary to immunodeficiency. The 
variant is highly conserved, but pathogenicity prediction is not in agreement and 
subsequent classification was of “unknown significance”.  
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4.3.6.4. Sanger sequencing confirmation 
All novel sequence variants have been confirmed by Sanger sequencing. This 
includes sequencing within unaffected related individuals for family 36 to help 
determine segregation of variants with disease status that will be discussed further in 
chapter 6.  
4.4. Discussion 
Presented within this chapter is the first large scale application of WES analysis to 
patients with inherited bleeding diathesis. 
A novel pipeline for the analysis of variants called, annotated and aligned sequence 
data was developed to determine candidate variants. The pipeline was designed to 
be all-encompassing; allowing analysis of variants that may affect platelet formation, 
function and lifespan as well as assessing novel variants in patients where there are 
not likely to be candidate genes. The average incidence of IT has most recently been 
estimated to be approximately 270 cases per 1 million live births (Balduini 2014). The 
bioinformatics pipeline uses a traditional rare “cut off” value of 100 cases per 1 million 
live births or a prevalence of 1% (0.01) within the population databases tested. 
Although the incidence is believed to be increasing, potentially due to the rise of 
genetic diagnosis, the pipeline retained this value for two reasons: 
1) That on average, the population databases used within post-annotated 
bioinformatics often understates the prevalence of rare variants. This is 
most evident in the number of variants that are deemed novel within 
dbSNP135, EVS, 1000G and our in-house database of over 1200 exomes 
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but have been previously identified in larger scale studies such as the 
ExAC database. 
2) That variants with a MAF exceeding 0.01 that are in genes of the panel of 
358 platelet related genes are not excluded but are considered less likely 
and analysed further if a potential candidate with a low frequency is not 
identified.  
Splice site variants were excluded if they exceeded 4bp from the intron-exon 
boundary. The vast majority of splice site variants are believed to occur at positions 
±1 and 2 from the intron-exon boundary (Krawczak, Reiss et al. 1992). At these 
positions, splice site variants are likely to be detrimental to the length of the protein 
sequence by exon skipping or intron inclusion (Richards, Aziz et al. 2015). By 
expanding our analysis to include splice site variants up to and including those that 
occur 5bp from the intron-exon boundary, we aim to include the vast majority that 
may impact protein function and filter out the variants more likely to not have a 
functional effect. 
The panel of 358 platelet-related genes has been developed within the UK-GAPP 
study drawing on data from published literature, animal models of disease and expert 
knowledge. This panel of genes has grown throughout the lifespan of the UK-GAPP 
study in line with recent advances in the knowledge of IT. Although limiting the broad 
scope of WES, it creates a strong starting point for the determination of candidate 
variants. Overall average 20x coverage was relatively high for the genes in question 
but was impacted by a failure of the software to recognise five gene IDs effectively 
scoring each gene with coverage of 0%. 20x coverage in genes known to previously 
cause IT exceeded 75% with the exception of GP1BB. As variants in areas of low 
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coverage are often removed following QC, GP1BB was checked manually using 
integrated genomics viewer (http://software.broadinstitute.org/software/igv/ Last 
accessed October 2016) for all exomes and no variants were identified. One caveat 
of using a cut off of 20x coverage is the possibility that variants may be missed, 
particularly in those in difficult to amplify regions such as the first exon and 
intron/exon boundaries. When lowering the coverage to less than 20x a much higher 
percentage of each gene previously known to cause IT was identified reducing the 
possibility of missed variants. 
Copy number variants occurring in genes previously known to cause IT were only 
found in two patients after analysis of CNV data using the ExomeDepth tool. The 
18,455bp variant identified in MKL1 (nsv829233), found in patient 22.I, was 
previously identified as part of a large scale study to determine Asian-specific CNVs 
(Park, Kim et al. 2010). Located on chromosome 22, the variant spans the last 11 
coding exons of MKL1, which are predicted to be lost by deletion. This variant was 
first identified by oligo aCGH and is considered a common CNV among the 
population it was first identified in.  No immunodeficiency has been noted within the 
patient, suggesting the presence of a MKL1 CNV may not impact protein function 
causing disease. 
Two CNVs were identified in patient 45.I. No observable SNVs, small scale 
insertions/deletions or splice site variants in genes from the panel of 358 platelet 
related genes were observed within this patient. WES analysis revealed a previously 
identified duplication within FLNA and an unidentified duplication within ANKRD26. 
The variant within FLNA has been previously identified in a large scale SNP array to 
determine human CNV variants (Shaikh, Gai et al. 2009). It occurs in a region with 
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complex rearrangements in addition to a previously identified CNV duplication. The 
variant in ANKRD26 occurs within a region spanned by previously identified copy 
number deletions but a duplication has yet to be observed. The duplication is 
predicted to effect internal exons of ANKRD26, to date only variants within a small 
stretch of the upstream activating sequence of ANKRD26 have been reported to 
cause IT. These variants elicit an effect by disrupting the normal silencing of 
ANKRD26 expression during late megakaryopoiesis. Theoretically, to elicit an effect 
similar to variants within the 5’UTR, coding sequence variants would need to extend 
the relative lifespan of ANKRD26 so that a persistent effect on the TPO/MPL 
signalling pathway can lead to impaired proplatelet formation. Predicted duplications 
to internal segments of the gene would most likely lead to an alternately transcribed 
protein. This may or may not have an impact on ANKRD26 based signalling but 
further work would be needed to determine this.   
Overall, genetic variants within previously known IT causing genes were identified in 
69% of index cases by WES analysis. The majority of variants were missense and 
most variants were novel and not previously identified in the databases scrutinised. 
Missense variants were expected to be most common due to relative impact on the 
expressed protein; missense variants are generally tolerated by retaining expression 
and partial function of the affected allele.   
When considering pathogenicity, WES analysis revealed a positive prediction of 
pathogenicity (classified “pathogenic” or “likely pathogenic” in a gene consistent with 
the patients phenotype and zygosity consistent with expected inheritance) in 43% of 
index cases (20/47). Twenty-five percent of the index cases (12/47) were of 
uncertain/possible pathogenicity (results classified of “uncertain significance” in 
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known IT causing genes). The remaining 32% of index cases (15/47) had a negative 
prediction of pathogenicity (no convincing variants identified in known causative 
genes).  
Positive variant discovery rates are comparable to or exceed previous large scale 
WES clinical multicentre studies of Mendelian disorders (Yang, Muzny et al. 2013; 
Chong, Buckingham et al. 2015). The number of patients with a proposed genetic 
aetiology of disease is reduced when compared to previous studies into IT however. 
This may be a result of using a strict classification system to predict the in silico 
capability of the variants to cause disease. If the analysis is allowed to encompass all 
patients with a variant in a gene previously linked to IT, our detection rate of 69% far 
exceeds that of any previous large scale study into IT.    
In addition, by only recruiting patients with an unknown aetiology of disease we 
potentially exclude patients that may have been clinically diagnosed with a form of IT. 
In particular, this may correspond to patients with known BSS and MYH9-related 
disorders as these two forms of IT are routinely tested for in many haematological 
centres within the UK. Because of this, the spectrum of variants generated by WES 
analysis differs from previous large scale genetic studies into IT. If patients with 
predicted BSS or MYH9-related disorders by clinical test were included in our 
analysis, our positive detection rate would most likely be higher as well. 
Even though patients with BSS and MYH9-related disorders should not be present 
within our cohort, three index cases, corresponding to four patients, were identified 
with variants within genes causative of the two disorders.  
 162 
 
Three patients, 11.I, 11.II and 12.I, were identified with variants within GP1BA 
encoding the glycoprotein 1b platelet alpha subunit. The two variants observed were 
missense changes, one of which was novel. All three patients were analysed by flow 
cytometry and no reduction in the cell surface expression of CD42b was noted in any 
patient. Patient 12.I, was phenotypically analysed by both methodologies, however 
aggregation to ristocetin (RIPA) was not measured. Patient 11.I was the only patient 
to present with a macrothrombocytopenia, although this was not within the normal 
range of giant platelets observed in patients with BSS. The patients with variants in 
GP1BA therefore are most likely representative of an atypical presentation of BSS, 
consistent with the variance in clinical presentation of previously identified variants 
(Savoia, Kunishima et al. 2014). 
One patient, 14.I, was identified with a variant within MYH9; c.3493C>T, 
p.Arg1165Cys. The variant was predicted to cause a missense change in the amino 
acid sequence and has been previously reported to cause Sebastian syndrome (Seri, 
Cusano et al. 2000). The patient was tested initially by microscopic assessment of a 
peripheral blood smear after conventional staining but no leukocyte inclusions were 
noted. The clinical symptoms of the patient do however correlate with disease with 
secondary associated congenital cataracts and hearing loss present from an early 
age. In addition, a marked increase in platelet volume was noted, indicating the 
presence of macrothrombocytopenia. Döhle-like bodies are only present within 42-
84% of individuals with MYH9-related disease, therefore the variant within MYH9 is 
likely a positive diagnosis of the genetic aetiology of disease in this patient but the 
patient presents with an atypical phenotype (Seri, Cusano et al. 2000; Kunishima, 
Matsushita et al. 2003). 
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Excluding patients with BSS and MYH9-related disease, two of the more prevalent 
disorders, has given rise to a relatively large percentage of individuals identified with 
variants within RUNX1. Variants were present in 10 index cases, corresponding to 15 
patients. Two thirds of patients with a variant in RUNX1 presented with a defect in 
granule secretion, a common attribute of patients with categorised mutations in 
RUNX1 (Stockley, Morgan et al. 2013). All variants, with the exception of a missense 
variant in patients 16.I, 16.II and 16.III, occur within the runt homology domain. The 
runt homology domain mediates DNA binding and heterodimerization with CBFβ. 
Previous variants span the entire gene (Figure 4.3.2) but the majority of variants 
within the runt homology domain have a dominant-negative effect on protein function 
and are predicted to be associated with a higher propensity to develop leukaemia 
(Michaud, Wu et al. 2002). To date, haematological malignancies have not been 
reported in any patients; however, the brother of patient 21.I has a history of AML but 
was unavailable for testing. Apart from a nonsense causing SNV in patient 17.I, 
c.236G>A, and a known missense variant in patient 23.I and 23.II, c.530G>A, the 
remaining variants are classified as “likely pathogenic” or of “uncertain significance”. 
An increasing number of patients with IT are being reported with variants in RUNX1 
(Latger-Cannard, Philippe et al. 2016). Without functional confirmation to determine 
the effect of variation it is difficult to confirm causality; however this raises the 
question of whether it should be considered as clinically significant as BSS and 
MYH9-related disorders and be primarily screened by genetics upon initial diagnosis 
with IT.  
Patient 22.I, is a unique case of a patient identified with a variant in RUNX1. The 
patient was observed following WES analysis with a missense variant c.505A>G 
 164 
 
which leads to a threonine to alanine change at position 169 within the amino acid 
sequence. The patient was recruited to the study posthumously and as such platelet 
counts, morphology and platelet function testing were unavailable, however a 
reduced platelet count was noted in neonatal examination. Upon post-mortem 
examination excessive bruising and subcutaneous haemorrhaging was observed. 
The variant observed in RUNX1 is therefore likely to be the causative variant of the 
haemostatic disorder observed, although uncertain significance of pathogenicity was 
predicted, however, it is unlikely to explain the cause of death.  
WES analysis revealed two missense variants within patient 29.I. The variants 
resided within TUBB1 and TPM4. TPM4 is a novel gene not previously implicated 
within IT within the literature. Unpublished data from a murine ENU-based mutagenic 
screen as performed by Professor Ben Kile, elucidated the role of TPM4 in 
megakaryopoiesis. Mice containing a prematurely truncated protein Tpm4 display an 
increase in mean platelet volume and decrease in platelet number because of 
aberrant proplatelet formation characterised by impaired branching. An increased 
active dephosphorylated cofilin level is observed, suggesting enhanced actin 
turnover and altered Myh9 localisation is also observed. Functional confirmation is 
required to distinguish whether the two variants are additive to the reduction or 
platelet count or one is a tolerated variation.  
A benefit of WES analysis is the lack of limitation to a subset of genes. This allows 
the possibility to find candidate variants in novel genes not previously known to 
cause IT. A combination of WES analysis with segregation analysis by Sanger 
sequencing has previously been adopted by the UK-GAPP study in the discovery of 
variants within SLFN14 (Fletcher, Johnson et al. 2015). Three adjacent variants were 
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identified within three index cases, 26.I, 27.I and 28.I, who shared a similar 
phenotype of a secondary qualitative secretion defect due a reduction in the number 
of dense granules; in addition to a reduction in platelet count, and increase in MPV 
and IPF. Since the initial publication, additional patients sharing a similar phenotype 
have been identified with variants in SLFN14 (Marconi, Di Buduo et al. 2016).  
WES analysis combined with segregation analysis by Sanger sequencing has 
narrowed down 14 novel variants within patients 36.I, 36.II and 36.III to two candidate 
variants of disease. Variants were identified in PADI2 and TTF2. Neither gene has 
previously been implicated in haematological abnormalities. Mutations in PADI2 are 
associated with schizophrenia, breast cancer and rheumatoid arthritis (Watanabe, 
Nunokawa et al. 2009; McElwee, Mohanan et al. 2012; Chang, Xia et al. 2013), 
whereas mutations in TTF2 are causative of Thyroid dysgenesis (Castanet and Polak 
2010). Although both variants require further work to confirm the functional effect of 
the variation, WES has provided us with the first steps in determining the impact of 
these two genes within IT. 
Family 41 was consciously approached in a different way and led to the identification 
of three novel recessive variants within ANKRD18A, FRMPD1 and GNE, in affected 
cousins of a single consanguineous kindred. The molecular function of ANKRD18A is 
currently unknown and FRMPD1 functions to regulate the subcellular localisation of 
activation of G-protein signalling 3 (AGS3) (An, Blumer et al. 2008). GNE, an enzyme 
in the sialic acid biosynthesis pathway, is highly expressed in cells of the 
haematopoietic lineage when compared to ANKRD18A and FRMPD1. Currently 
mutations within GNE are known to be the genetic cause of sialuria (OMIM269921) 
and hereditary inclusion body myopathy (HIBM; OMIM600737) (Seppala, Lehto et al. 
 166 
 
1999; Eisenberg, Avidan et al. 2001). Recently however, two separate groups have 
reported patients with compound heterozygous variations in GNE, causing GNE 
related myopathy with congenital thrombocytopenia (Izumi, Niihori et al. 2014; Zhen, 
Guo et al. 2014). Platelet counts in the individuals within the reported literature do not 
exceed 45x109/L, a severe count which is shared in patients 41.I and 41.II. 
Thrombocytopenia though is observed secondary to degenerative muscle myopathy 
presenting from adolescence onwards. Patients 41.I and 41.II are currently aged 7 
and 3, respectively and show no signs of myopathy. It is feasible though that the 
variants within GNE are causative of disease in addition to myopathy that has yet to 
clinically present due to the patients age. For this to be confirmed, patients would 
need to undergo regular observation and potentially platelet associated IgG 
examination as elevation is characteristic of the disorder. Without this confirmation, it 
is difficult to draw a conclusion regarding the genetic aetiology of these patients as 
currently, the patient’s phenotype lacks consistency with the genetic defects 
observed.  
Currently the link between MKL1 and IT is a secondary intermittent symptom to a 
severe immunodeficiency. WES analysis revealed one patient, 43.I, with a novel 
missense variant, c.1723G>A, p.Val575Met, occurring within a highly conserved 
region. This variant represents the only variant to occur in a gene with previous 
haematological implications. The zygosity observed does not match that of published 
literature but the crucial role of MKL1 in megakaryocyte maturation through its 
binding partner SRF makes it an interesting candidate of disease. One further variant 
in MKL1 was observed in addition to a “likely pathogenic” frameshift causing insertion 
within TUBB1 in patient 31.I. Due to the predicted loss of function of the frameshift 
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causing TUBB1 variant it is unlikely that the variant within MKL1 is additive to the 
patient’s phenotype. However the presence of two variants within two individual 
patients is interesting for further study.  
4.5. Further work 
The effectiveness of molecular next generation sequencing relies on subsequent 
functional confirmation of the effect of genetic variation. Further work would follow 
this mantra in trying to functionally confirm all genetic variants observed as disease 
causing. Variants can be classified dependant on a number of in silico prediction 
software tools but without in vitro or in vivo studies into the mechanism of mutation 
they are often ambiguous and uncertain.  
Due to the high frequency of variants within RUNX1, with phenotypic similarities in a 
reduction in platelet secretion, further work will first initially aim to categorise these 
variants. Variants within RUNX1 and FLI1 additionally, are often associated with an 
elevated MYH10 expression in platelet lysates as a biomarker of genetic variance. 
Determining the expression of MYH10 will allow for initial categorisation of the effect 
of each variant. Due to associated predisposition to myeloid malignancy with variants 
in RUNX1, it is critical to establish diagnosis as early as possible to aid in patient 
management and guidance. 
A number of other genes are often associated with biomarkers of variance. These 
include: A lack of an intact β-tubulin ring in resting fixed platelets when stained by 
immunohistochemistry in patients with variants in TUBB1. Disorganised actin 
bundling in megakaryocytes derived from patients harbouring ACTN1 variants, as 
well as an increase in apoptotic activity in patients with variants within CYCS. All of 
 168 
 
these can be tested with further work to be able to confirm or deny the genetic 
diagnosis.  
Determining causality as a result of genetic variance in genes not previously known 
to cause IT is a more difficult task. As many of the genes mentioned have no 
previous haemostatic relevance, linking the genetic defect to a reduction in platelet 
count requires first establishing the role of the encoded protein within normal healthy 
haemostasis. Often the best method to achieve this is through the use of animal 
models of disease, but with interspecies differences this is often time consuming and 
costly. If effective though, it has the potential to expand our current knowledge of 
haemostasis and aid in further study and clinical categorisation. 
4.6. Key findings 
 WES analysis revealed 69% of patients with a genetic variant within a gene 
previously associated with IT. 
 Of these variants 43% were deemed to have a positive prediction of 
pathogenicity and are likely the causative variant of disease within the 
individual patient.   
 A high percentage of variants were observed in RUNX1 suggesting the 
importance of the gene within the genetic landscape of IT. 
 In addition to variants identified in known genes, variants in novel genes or 
genes in which variants were associated with a phenotype inconsistent with 
previously viewed phenotypes were identified in three families. 
 Likely causative CNVs of disease were not found within in any of the patients 
analysed.  
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5. Thrombocytopenia gene specific panel sequencing 
5.1. Summary of background to this research 
Targeted panel gene sequencing using next generation sequencing techniques have 
recently been applied to investigate the genetic basis of IT. As new genes emerge 
following the continuing use of WES and WGS in small individual kindreds, a static 
panel of genes becomes a non-sustainable long-term option for clinical diagnosis. 
WES, without limitations is therefore the best methodology for the future. However, 
as a technically more challenging method it is not without caveats.  
One of the main difficulties is the sheer volume of data that is created. As sequencing 
technology progresses, the rate-limiting step within the method becomes not the time 
taken to sequence the sample, but the time taken to carry out the bioinformatic 
analysis and confirm any plausible genetic variations of disease. Whole exome 
sequencing is a temporally condensed version of WGS. It also retains a novel 
capability to identify variants in genes not known previously to cause disease, which 
although powerful is also a first step to continued work to confirm or deny causality of 
identified genetic variants.  
WES, when applied to a large cohort of patients with IT, is effective in determining 
the potential genetic aetiology of disease. However, in this thesis, the study of 69 
individuals with IT of unknown aetiology at the time of diagnosis, 71% patients were 
identified with variants in genes previously known to cause IT. If we exclude a subset 
of patients with variants in SLFN14, which was identified as a novel candidate gene, 
the percentage hit rate is still 62%. Although providing insight into novel genes with a 
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potential role in haemostasis, the main finding was a higher percentage of patients 
with variants in known IT genes when compared to previous studies. 
As new sequencing library capture methods are developed, the speed of sample 
preparation time is vastly reduced. This is mostly noted through the recently released 
capture methods; Illumina Nextera Rapid Custom Capture Enrichment and Agilent 
SureSelectQXT. Both methods propose an improvement in sample preparation without 
limitations in sequence depth, coverage and accuracy (Garcia-Garcia, Baux et al. 
2016). When applied to small-scale custom gene panels, the preparation time can be 
reduced to a day. In addition, DNA input is also reduced allowing for amplification 
from <50ng of DNA. 
Due to the high percentage of variants within known IT genes as identified by WES in 
this study, and the increasing advances in custom panel next generation sequencing, 
an IT specific next generation sequencing panel was designed and included within 
the UK-GAPP patient workflow. Incorporating a small custom panel prior to WES has 
the potential to filter out patients with a genetic aetiology of disease within known IT 
causing genes. Coupled with the Agilent SureSelectQXT transposon based system of 
sample preparation, an increase in the efficiency of genetic diagnosis, as well as a 
reduction in the overall cost, can potentially be achieved. 
5.2. Aims of this chapter 
This section aims to implement a next generation sequencing panel in the UK-GAPP 
patient workflow on patients recruited under the same UK-GAPP inclusion criteria. 
The panel will be designed to incorporate all genes known to be previously 
associated with IT, which effectively pre-screens patients before WES. The panel will 
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also take advantage of a rapid sample preparation technique allowing for quick 
genetic diagnosis following patient phenotyping and hypothetically improving the 
overall efficiency of the workflow. 
5.3. Bioinformatics pipeline to determine candidate variants 
In total 34 patients, eight of which used for validation, analysed by the IT specific next 
generation sequencing panel were analysed post sequencing using an adapted 
pipeline of that used for the analysis of WES data. Variants were initially filtered on 
frequency, excluding variants with a MAF ≤0.01 in the 1000G database. Synonymous 
variants not predicted to change the amino acid sequence in the protein coding 
transcripts were then excluded. As the panel was designed to include the 5’ and 3’ 
UTR, variants were additionally filtered dependant on their genomic location within 
the coding region ±10bp into the intron-exon boundary. The UTRs were including in 
bait design to try and identify variants within the 5’ UTR of ANKRD26 so that all 
variants occurring within the 5’UTR of genes were analysed individually. Candidate 
variants identified were scrutinised using the same in silico pathogenicity prediction 
software and variant classification system as candidates from WES analysis as 
mentioned in chapter 4.  
5.4. Quality of sequencing data, average number of variants 
and coverage of sequencing data 
All individual DNA samples were processed and passed QC at two points throughout 
sample preparation. Prior to sample pooling, an average calibrated DNA 
concentration of 2.957ng/µL and a molarity of 13.3nmol/L was observed across all 
samples. All sequencing runs passed internal QC that is used within the West 
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Midlands Regional Genetics Service at the Birmingham Women’s Hospital and 
internal QC from the SureCall analysis software. All candidate variants identified 
were classified as high quality mapped variants with a quality score of 255.  
On average, 326 variants were noted in each individual analysed by the IT-specific 
next generation sequencing panel. This ranged from 265 to 400 variants across all 
samples analysed. An average of 73 variants, excluding synonymous variants, were 
noted with a MAF ≤0.01 in the 1000G database per individual. When each of the 
variants occurring in non-UTR regions were analysed for presence in the ExAC 
database, only the variants displayed in Table 5.6.1 were of a rare frequency. 
Average coverage across the targeted regions was in excess of 95% in all patients 
analysed. An average read depth of 380 was noted at the site of each variation. This 
read depth was not observed below 121 at each point of all candidate variants and 
reached a filtered read depth of 823.  
5.5. Validation of IT specific next generation sequencing panel 
Validation of the IT specific next generation sequencing panel was performed by 
analysing the panel’s sensitivity in detecting 8 previously identified variants. Variants 
were identified previously in WES analysis and confirmed by Sanger sequencing. 
Variants, at the time of validation, were likely candidate variants and include variants 
in genes not known previously to cause IT, they are shown in Table 5.5.1. All 
variants, excluding a previously identified frameshift causing insertion in TUBB1; 
c.1080_1081insG, p.Leu361Alafs*19 previously identified in patient 31.I, were 
successfully identified. All known candidate variants tested were the only candidate 
variants following bioinformatics analysis of panel sequencing results in each patient.  
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Patient Gene Variation Type 
2.I ANKRD26 c.-126T>G 5'-UTR 
17.I RUNX1 c.G236A, pTrp79* Nonsense 
20.I RUNX1 c.G332A, p.Gly108Ser 
Partial heterozygous 
missense 
21.I RUNX1 c.427+1G>T Splice site variant 
26.I SLFN14 c.A652G, p.Lys218Glu Missense 
31.I TUBB1 
c.1080_1081insG, 
p.Leu361Alafs*19 
Frameshift causing insertion 
36.I WAS c.G1456A, p.Glu486Lys X-linked Missense 
41.I ANKRD18A c.2395_2397del, p.Glu799del 
Non-frameshift causing 
deletion 
 
Table 5.5.1 Table depicting the  eight patients and the eight known candidate 
variants utilised for the validation of the IT-specific next generation sequencing 
panel. A heterozygous status with a low frequency mutant allele was observed 
in patient 20.I by Sanger sequencing as was deemed a partial heterozygote 
variation. 
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5.6. Candidate variants observed and variant prevalence in 26 
new patients 
In total 26 new patients were analysed by an IT-specific next generation sequencing 
panel. All patients, with the exception of 64.I, were single affected cases lack 
additional recruited affected family members. Following post-sequencing 
bioinformatics analysis as detailed in section 5.3, variants were observed in 77% of 
individuals (Table 5.6.1). This equates to 20 patients who were observed to harbour 
a genetic variant within a gene previously known or likely to be associated with IT.  
In total, 31 variants were noted in the 20 patients observed with a genetic variant in a 
gene previously known to cause IT. Seven patients were observed with two variants 
in two alternate genes and two patients were noted with three variants. No patients 
were noted with two variants occurring within the same gene and all variants were 
observed in a heterozygous state. One variant; GP5; c.867G>C, p.Met289Ile, was 
noted in two unrelated patients, 57.I and 58.I. 
The majority of variants identified were missense variants affecting a single amino 
acid. This equated to 87% of the variants observed. In addition; one 5’UTR start gain 
was noted in patient 48.I (TUBB1; c.-88G>C), one frameshift causing deletion was 
noted in patient 50.I (GP1BB; c.del120-142, p.Arg42Cysfs*14), one stop loss variant 
was noted in patient 54.I (GATA1; c.1240T>C, p.*414Arg+41), and one nonsense 
causing SNV was observed in patient 60.I (ITGA2B; c.2176A>T, p.Lys726*).
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Family Patient Gene(s) 
Genomic 
variation 
Protein effect 
Variation 
type 
Prevalence PhyloP 
Phast
cons 
Mutatio
n taster 
Poly
Phen
-2 
SIFT Provean ACMG criteria Classification 
48 I 
ABCG5 c.293C>G p.Ala98Gly Missense 
0.005 
(rs145154937) 
5.277 1 D D D D PP3 
Uncertain 
significance 
ABCG8 c.1667T>C p.Phe556Ser Missense 
0.0009 
(rs548098742) 
2.914 1 D D D D PP3 
Uncertain 
significance 
TUBB1 c.-88G>C   
5'UTR 
start gain 
0.004 
(1000G)(rs150
072434) 
              
Uncertain 
significance 
49 I 
ABCG5 c.1864A>G p.Met622Val Missense 
0.00541 
(rs140374206) 
-0.748 0 P B T N BP4 
Uncertain 
significance 
NBEAL2 c.6631G>A p.Asp2211Asn Missense Novel 5.515 0.997 D D D D PM2, PP3 
Uncertain 
significance 
50 I 
CYCS c.155C>T p.Ala52Val Missense Novel 5.962 1 D B D D PM2 
Uncertain 
significance 
GP1BB c.del120-142 
p.Arg42Cys 
fs*14 
Frameshif
t deletion 
Novel     D       
PM2, PP3, 
PM4, PP4 
Likely 
pathogenic 
51 I 
FLI1 c.812G>A p.Arg271Gln Missense Novel 5.983 1 D D D D PM2, PP3 
Uncertain 
significance 
MYH9 c.2872G>A p.Ala958Thr Missense 
0.0009 
(rs151036570) 
6.088 1 D B T N 
 
Uncertain 
significance 
52 I FLNA c.5948C>T p.Ser1983Leu Missense 
0.0026 
(rs187029309) 
5.952 1 P D D D   
Uncertain 
significance 
53 I 
FLNA c.7583A>T p.Asp2528Val Missense Novel 4.858 1 D D D D PM2, PP3, 
Uncertain 
significance 
MYH9 c.7C>G p.Gln3Glu Missense 
0.0015 
(rs56200894) 
4.643 0.998 D B D N 
 
Uncertain 
significance 
TUBB1 c.1199G>A p.Ser400Asn Missense Novel 5.88 0.972 D B D N PM2 
Uncertain 
significance 
54 I GATA1 c.1240T>C p.*414Arg+41 Stop loss  Known 2.408 0.572 P       PM4, PS1,  PP5 
Likely 
pathogenic 
55 I GP1BA c.206C>T p.Pro69Leu Missense 
0.001872 
(rs138825640) 
-1.407 0 P B D D 
 
Uncertain 
significance 
56 I GP1BB c.242T>G p.Leu81Arg Missense Novel -0.162 0.175 P D D D PM2, PP4 
Uncertain 
significance 
57 I GP5 c.867G>C p.Met289Ile Missense 
0.003101 
(rs142440028) 
2.516 0.55 P B D D 
 
Uncertain 
significance 
58 I GP5 c.867G>C p.Met289Ile Missense 
0.003101 
(rs142440028) 
2.516 0.55 P B D D   
Uncertain 
significance 
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STIM1 c.182A>G p.Glu61Gly Missense 
0.00004941 
(rs202160755) 
2.851 1 D B D D   
Uncertain 
significance 
59 I 
ITGA2B c.886G>A p.Gly296Arg Missense Novel 3.205 0.999 D B D D PM2 
Uncertain 
significance 
RUNX1 c.386C>A p.Ala129Glu Missense 
Known 
(rs267607026) 
6.077 1 D D D D PP3, PS1, PS3 Pathogenic 
60 I ITGA2B c.2176A>T p.Lys726* Nonsense Novel 1.419 0.957 D       
PM2, PM4, 
PVS1, PP4 
Pathogenic 
61 I 
ITGA2B c.2417G>A p.Ser806Asn Missense Novel 0.148 0.286 P B T N PM2 
Uncertain 
significance 
WAS c.995T>C p.Val332Ala Missense 
0.0051 
(rs2737799) 
0.096 0 P B T N BP4 
Uncertain 
significance 
62 I MKL1 c.569C>T p.Pro190Leu Missense 
0.00016 
(rs200309955) 
3.693 0.987 D B T D   
Uncertain 
significance 
63 I MKL1 c.1492G>C p.Val498Leu Missense 
0.000008638 
(rs199750225) 
2.138 0.998 D B T N 
 
Uncertain 
significance 
64 I MYH9 c.2152C>T p.Arg718Trp Missense Known 2.044 1 D D D D 
PP3, PS1, PS3,  
PM 
(segregation), 
PP4 
Pathogenic 
65 I MYH9 c.5074G>A p.Ala1692Thr Missense Novel 4.087 1 D B T N PM2 
Uncertain 
significance 
66 I 
MYH10 c.2987C>T p.Ala965Val Missense 0.0079 4.822 1 D B D D   
Uncertain 
significance 
NBEAL2 c.4361C>T p.Thr1454Met Missense 0.0001 3.227 0.999 D B T N   
Uncertain 
significance 
67 I TUBB1 c.421G>A p.Gly141Arg Missense 
0.00003295 
(rs778975827) 
5.803 1 D D D D PP3 
Uncertain 
significance 
68 I Unknown                         
69 I Unknown 
            
70 I Unknown                         
71 I Unknown 
            
72 I Unknown                         
73 I Unknown 
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Table 5.6.1 Variants identified by analysis of the IT-specific next generation sequencing panel. Prevelance is shown in 
the ExAC consortium if not specified otherwise. PhyloP and Phastcons scores are shown following the cut offs 
displayed in Table 4.3.2. Variants are noted as D – Disease causing and P – Polymorphism in MutationTaster, D – 
Damaging and T – Tolerated in SIFT, D – Deleterious and N – Neutral in Provean, D – Damaging and B – Benign in 
PolyPhen-2 in silico pathogenicity prediction software.  
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Of the 31 variants, 11 (35%) were novel and not previously identified in any of the 
databases scrutinised. 17 variants have been observed previously and the 
prevalence of these variants in the ExAC database, unless otherwise stated, is 
displayed in Table 5.6.1. When comparing all previously observed variants, an 
average MAF of 0.004 is noted. All variants were observed at a frequency of less 
than 0.0051 and all previously identified variants, with the exception of two, were 
present within the latest build of dbSNP. 
Three variants were identified that are previously known to cause IT. These were 
found in patients; 54.I (GATA1; c.1240T>C, p.*414Arg+41), 59.I (RUNX1; c.386C>A, 
p.Ala129Glu), and 64.I (MYH9; c.2152C>T, p.Arg718Trp).  
Two variants previously identified by WES analysis of 69 patients were also identified 
in patients analysed by the IT specific panel sequencing. These variants; CYCS; 
c.155C>T, p.Ala52Val, and ITGA2B; c.2176A>T, p.Lys726* were identified in 
patients 50.I and 60.I, respectively. Previously, the associated variants had been 
identified in 4.I (and additional family members) and 13.I, respectively by WES 
analysis. 
5.7. Conservation, pathogenicity prediction and variant 
classification 
Conservation at the site of variation was determined by PhyloP and PhastCons in 
silico software. Conservation scores for all variants occurring within known IT causing 
genes in the 20 patients are shown in Table 5.6.1. Conservation scores were 
unavailable for the 5’UTR variant observed in TUBB1 in patient 48.I and the 
frameshift causing deletion in GP1BB observed in patient 50.I. Average scores of 
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3.372 and 0.7945 were observed across all variants in PhyloP and PhastCon 
analysis, respectively. The majority of variants occurred at sites of high conservation 
and the two methodologies used were in agreement in all instances. 
Pathogenicity was predicted using in silico prediction software as preformed in 
chapter 4 and the results of each test are displayed in Table 5.6.1. Classification 
often varied amongst the software used for each variant indicating the benign 
potential of the variants observed.  
In total, of the 32 variants noted across all patients analysed, three variants were 
classified as “pathogenic” and two “likely pathogenic” when considering the ACMG 
consensus guidelines. Three of the five variants deemed to have a positive prediction 
of pathogenicity were variants previously identified in alternate studies as disease 
causing. The two remaining variants were those predicted to be detrimental to the 
length of the expressed protein. The remaining 27 variants without a positive 
prediction of pathogenicity were classified as of “unknown significance”. Only two 
variants displayed supporting evidence of a benign classification of the variant. 
5.8. Discussion 
An IT gene specific next generation sequencing panel was developed in order to pre-
screen patients prior to WES. The aim was to efficiently filter out patients with 
variants in known IT causing genes allowing for a rapid genetic diagnosis and 
subsequent focus on WES for patients who may harbour variants in novel genes. In 
addition, the cost implications were an important consideration given that the WES 
was more than 4 times (£800 vs ~£200) as expensive compared to the targeted 
panel sequencing. 
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All sequencing passed QC at all points throughout sample preparation and QC, 
cluster density and overall sequencing data was sufficient when compared to routine 
sequencing using alternate capture methods performed within the laboratory of 
analysis at the West Midlands Regional DNA laboratory at Birmingham Women’s 
Hospital. Although considered a rapid capture method, Agilent SureSelectQXT sample 
preparation does not quite reach optimum depth of coverage, evenness and target 
enrichment when compared to alternate methods of capture including Agilent 
SureSelectXT (Shigemizu, Momozawa et al. 2015; Garcia-Garcia, Baux et al. 2016). 
When applied to our custom designed panel; average coverage easily exceeded a 
universally accepted minimum 20x coverage for efficiently calling variants and an 
average read depth of 380 was identified at the points of variation (Lelieveld, 
Spielmann et al. 2015).  
In comparative tests it has been noted that SureSelectQXT performs well in GC rich 
areas. This may explain the increase in variants identified in GP1BB when compared 
to WES analysis. With a GC content of 73%, GP1BB often suffers from a reduction in 
coverage, which is why in WES analysis the gene was manually analysed. Utilising 
the next generation sequencing panel there was no drop in coverage within GP1BB 
for all patients analysed and two variants, in patient 50.I and 56.I, were identified 
which may be causative of disease which could be potentially missed by other 
sequencing methodologies. 
One of the additional benefits of using next generation sequencing panels and a 
capture method such as Agilent SureSelectQXT is the relatively low amount of starting 
material required. A starting quantity of 50ng of DNA from each individual was 
utilised for sample preparation. Previous studies have shown effective sample 
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preparation and subsequent sequencing to achieve a depth of coverage sufficient for 
variant calling is possible from as little as 6.25ng with an adapted technique (Chung, 
Son et al. 2016). When compared to a required quantity of ~1µg of DNA for WES, the 
application of an IT specific panel has the potential to aid in cases where little 
genomic content is available.  
In total, candidate variants were identified in 77% of individuals analysed by the IT 
specific panel. This detection rate far exceeds previous large-scale targeted panel 
sequencing studies and the application of WES to patients with IT of unknown 
aetiology discussed in chapter 4. One possible explanation of this is due to the 
relative increase in average read coverage when compared to WES analysis, 
especially at the point of variation. When comparing prevalence, however, next 
generation panel sequencing identifies a large number of variants that have been 
previously identified with a low MAF. This may be an indication that the variants are 
tolerated within the population and are not causative of disease. The most 
comprehensive database of genetic variation is noted to be the ExAC database, 
which may include data from affected individuals as part of separate studies. It is 
plausible, therefore, that although the variants have previously been noted, they are 
causative of a mild reduction in platelet count that has, or has not, been previously 
diagnosed in all other patients with the shared variant. To determine the reality of this 
would require further conformational work. 
Comparing pathogenicity prediction and variant classification of the variants 
determined by WES analysis, a larger percentage of variants were deemed to be of 
unknown significance. This may reflect on a reduced rate of sensitivity and a higher 
proportion of false negative variants identified. However, it is worth considering that 
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the majority of variants, 56% (18/32), displayed supporting evidence of pathogenicity 
but lacked sufficient evidence to be classified as such. This could potentially be an 
indication of the lack of related affected individuals recruited to the study, for these 
patients, negatively affecting classification because of a lack of segregation analysis. 
Three patients, following analysis, were noted with the presence of a variant 
previously known to cause IT. Patient 54.I, a 12 year old male with a history of 
cutaneous bleeding and a mild reduction in platelet count (101x109/L) was noted with 
a stop loss variant in GATA1; c.1240T>C, p.*414Arg+41. The predicted effect of 
variation is a loss of the wild type stop codon and extension of the protein by 41 
amino acids. Most reported variants within GATA1 occur within the N-terminal zinc 
finger domain, leading to a disruption of the binding of GATA1 to FOG1. The stop 
loss variant noted in patient 54.I was first identified in a 67 year old male proband 
who suffers from easy bruising (Singleton, Roxby et al. 2013). The patient’s platelet 
counts varied between 86-94x109/L at different times of testing and no other 
differences in haematological cell numbers were noted. The patient was initially 
sequenced due to the presence of a rare X-linked blood group Lu(a-b-) phenotype 
which results in the marked decrease in expression of Lutheran glycoprotein on the 
erythrocyte cell surface. To date, serological analysis using flow cytometry to analyse 
the presence of Lutheran on the erythrocyte cell surface has not been undertaken in 
patient 54.I. Also the presence of giant occasional macrothrombocytes, a marker of 
the published phenotype, have not been observed in patient 54.I.  
A previously identified causative variant was noted in RUNX1 in patient 59.I. The 
missense variant, c.386C>A, p.Ala129Glu, was found in addition to a missense 
variant in ITGA2B. The variant has previously been reported to be causative of 
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FPD/AML. in three patients from a single pedigree (Preudhomme, Renneville et al. 
2009). All three patients were identified with the p.Ala129Glu germline mutation 
causative of FPD/AML. All patients developed AML as a result of a secondary 
somatic event occurring within RUNX1 progressing to patient death in all cases. 
Patient 59.I is a male with a mild reduction in platelet count to 94x109/L. Following 
platelet function testing, no reduction in platelet secretion (a hallmark of variants 
within RUNX1) was noted. However, it is highly likely that the variant observed in 
RUNX1 is causative of the haemostatic phenotype observed. Whether the variant 
within ITGA2B is additive to the phenotype is unlikely as the platelet count is 
considered mild in severity but may warrant further investigation. 
Patient 64.I, is the only patient analysed by the IT specific panel with affected family 
members also recruited to the study. The patient forms part of a pedigree of four 
affected family members with a shared phenotype and clinical symptoms. Following 
analysis of the IT specific panel sequencing, a missense variant was identified in 
MYH9; c.2152C>T, p.Arg718Trp. This variant has been noted once previously in a 
patient initially diagnosed with Sebastian syndrome (Pecci, Panza et al. 2008). The 
variant occurs within the motor domain of MYH9 and is associated with an increased 
risk of deafness and nephritis, however, no secondary symptoms have previously 
been reported in patient 64.I or any of the affected family members also recruited to 
the UK-GAPP study.  
The presence of a variant in MYH9 in patient 64.I is surprising due to the routine pre-
screening for disorders such as BSS and MYH9-related disease in haemophilia care 
centres before recruitment to the UK-GAPP study. This abnormality of identifying 
patients with variants in genes negatively selected for inclusion is shared when 
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analysing patients by WES. Analysing patients using the IT-specific panel has 
elucidated variants in genes known to cause BSS and MYH9-related disease in 
seven patients. With the exception of patients 50.I and 65.I, who present with the 
characteristic increase in MPV to the magnitude of observable giant platelets, the 
remaining patients show an unaltered MPV. No Döhle like body leukocyte inclusions 
were noted on peripheral blood smears of patients 64.I and 65.I and no patients 
presented with secondary symptoms relating to specific IT disorders. It is most likely, 
therefore, that the variants in these genes are either causative of an atypical 
presentation of BSS and MYH9-related disease or are tolerated and not the genetic 
aetiology of disease in these patients. 
A phenotype-genotype correlation is often utilised in aiding in the diagnosis of a 
patient’s disease. Patient 61.I presented with a marked reduction in the cell surface 
levels of CD41, the integrin alpha IIb, to around 50% of the levels observed within the 
travel control tested simultaneously. When analysed by the IT-specific next 
generation sequencing panel, a missense variant was identified in ITGA2B. This 
variant, c.2417G>A, p.Ser806Asn, is novel within all databases but predicted benign 
and not well conserved at the site of variation. The variant occurs within the 
extracellular domain and the integrin alpha IIb heavy chain. Although not predicted 
to, the reduction in cell surface CD41 is indicative of the possibility that the variant in 
ITGA2B affects either protein levels or cellular localisation potentially leading to the 
observed platelet-based bleeding phenotype. This is the only occurrence of a 
genotype-phenotype correlation in all patients analysed by the IT-specific next 
generation sequencing panel. Although three variants were identified in ITGA2B and 
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one variant was identified in GP1BA, none of the patients, with the exception of 61.I, 
were observed with a reduction in the corresponding cell surface receptor levels. 
Interestingly a reduction in CD42b, encoded by GP1BA, was noted in patient 50.I, 
who harbours a potentially deleterious large deletion of GP1BB that spans two 
previously reported disease-causing variants (Moran, Morateck et al. 2000; 
Kunishima, Naoe et al. 2001). Although not occurring in the encoded gene, the 
variant, due to the detrimental effect of a frameshift causing deletion, may have 
propensity to disrupt the stability of the receptor complex leading to a reduction in cell 
surface expression. 
As mentioned previously in chapter 4, one patient, 47.I, was initially analysed by the 
IT specific next generation sequencing panel and subsequently analysed by WES. 
Following sequencing using the IT specific next generation sequencing panel, 
analysis determined that no plausible variants were identified in the known IT causing 
genes within the panel. It was therefore decided that the patient should undergo 
WES as the genetic aetiology of disease most likely occurs within a gene not known 
to previously cause thrombocytopenia. Currently, due to absence of related affected 
family members and the absence of variants in genes with a haemostatic relevance, 
no likely candidate variants have been identified that may be associated with the 
haemostatic phenotype observed within the patient. 
One of the main drawbacks of panel sequencing is the static amount of genes that 
can be analysed. Without a change in the bait design or the inclusion of baits ‘spiked’ 
into the capture library, the panel can only sequence the genes that it was designed 
for. This is a caveat that is apparent within the IT-specific next generation sequencing 
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panel designed in this chapter. The panel was designed to include 27 genes known 
previously to cause IT, in addition to three likely candidates as a result of WES 
analysis prior to the formation of the panel as part of the UK-GAPP study and 
extensive literature searching. Currently the panel therefore absent of the capture 
baits for eight genes that are reported to cause inherited thrombocytopenia. Although 
advantageous in providing a rapid insight into the genetic aetiology of IT in patients 
with unknown cause prior to WES, it is incomplete unless continuously updated. This 
problem is faced by all current panel-based sequencing platforms including the large 
multi-disorder ThromboGenomics platform (Simeoni, Stephens et al. 2016). Although 
more encompassing in its design, it suffers from the same limitations. Spiking baits 
into a pre-existing capture library is possible, especially if the pre-designed capture 
library is small in size, however, this is not practical in a clinical setting, suggesting 
that WES may be a more well-rounded method in determining the genetic aetiology 
of disease. 
5.9. Further work 
As with variants determined by WES analysis, the variants observed following the 
application of the IT-specific next generation sequencing panel requires further 
confirmational work to be determined disease causing. Further work would focus 
around this point mainly, utilising many of the biomarkers of disease attributed to 
variants in certain genes.  
A lack of genotype-phenotype correlation shown in patients harbouring variants in 
ITGA2B, GP1BA and MYH9 in particular is an interesting observation. The possibility 
that these variants are disease-causing rests on the functional confirmation of the 
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effect of variation. However, if causative, the patients represent a unique subset of 
each individual disease that does not share the typical phenotypic presentation of 
previous cases. The likelihood that patients exist without the secondary symptoms 
and qualitative defects in platelet function attributed to these disorders is therefore 
relatively high. Further work would benefit by expanding the patient cohort to recruit 
patients that may potentially harbour variants in the genes associated with GT, BSS 
and MYH9-related disease.  
Six patients in total were observed without any variants in genes of the IT specific 
panel. Following the UK-GAPP patient workflow that was applied to patient 47.I, 
further work would focus on analysing all patients by WES. Due to the absence of 
variants within the panel of 30 genes, there is a high chance that the genetic 
aetiology of disease is due to variants in novel genes not previously implicated in IT. 
Analysis of these patients in particular may progress our current knowledge of IT 
through the determination of novel causative genes.  
5.10. Key findings 
 Analysis of 26 patients using an IT specific next generation sequencing panel 
has identified candidate variants in 77% of individuals.  
 Variants include three variations previously associated with IT. 
 The IT-specific next generation sequencing panel is therefore an efficient 
method of pre-screening patients for variants in known IT causing genes prior 
to WES. 
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6. Determining the functional effects of sequencing variants 
6.1. Summary of background to this research 
With the progressive use of next generation sequencing and genotyping in research 
and clinical diagnosis, an increasing number of sequence variants are being 
identified. One of the main problems facing this field now is interrogating variants 
uncovered by sequencing to determine their physiological effects and disease 
outcomes.  
In the two previous chapters, WES and an IT specific next generation sequencing 
panel have identified a number of variants that are likely pathogenic for the 
phenotypic presentation of IT. Thus far, classification of these variants has focused 
on a number of in silico prediction software. Indeed, prediction software can aid in the 
prioritisation of variants but the results should often be interpreted with caution. 
Although showing a relatively high level of sensitivity (the “true positive” rate) a low 
specificity (“true negative” rate) is often observed and previously known disease 
causing variants can be misclassified (Tchernitchko, Goossens et al. 2004; 
Flanagan, Patch et al. 2010).  
Many of the variants identified within this work occur in genes known to previously 
cause IT and some have been previously identified as pathogenic in alternate 
studies. Often phenotypic variance is noted between individuals with the same 
disease and even in cases when the same genetic variant is observed. In addition, 
growing evidence suggests that many disorders are not simple in their presentation. 
Indeed, in this study alone a number of patients have been identified with potentially 
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causative variants in known IT causing genes but a lack of phenotypic similarity when 
compared to previously reported patients. Because of this heterogeneity confirmation 
of the functional effect of genetic variation is a necessity for a complete and accurate 
diagnosis.  
Many disorders are accompanied by phenotypic biomarkers characteristic of genetic 
variation. Previously the presentation of a number of these biomarkers has been 
harnessed in order to determine the functional effect of variation. This is often an 
effective and efficient method to determine the relevance of genetic variation. 
However, in cases of variants in novel genes, extensive accompanying study is 
required firstly to link the gene to a role within haemostatic control before determining 
the functional relevance of genetic variation. 
6.2. Aims of this chapter 
This chapter will work on previous results from a combination of WES and an IT 
specific next generation sequencing panel to try and elucidate the functional effect of 
the genetic variations observed. The chapter will focus firstly on the large number of 
patients observed with a genetic variant in RUNX1 and FLI1 utilising the biomarker 
presence of MYH10 expression. Lastly, the chapter will aim to categorise a novel 
variant within TTF2; c.3265C>G, in a single kindred, focusing initially on the work 
prior to prioritisation of the variant in TTF2 as the most likely candidate of disease.  
6.3. MYH10 expression in patients with genetic variants in 
RUNX1 and FLI1 
Sixteen patients were noted with variants in RUNX1 by the two next generation 
sequencing methods utilised. In addition, five patients also displayed variants in FLI1. 
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In total, stored platelet protein was available for 14 patients. Protein lysate from 
digested muscle tissue was available for one patient, 22.I. The patients analysed by 
WB included 11 patients with RUNX1 variants and 3 with variants within FLI1. 
MYH10 expression was determined using a goat polyclonal IgG antibody mapping 
near the N-terminus of MYH10 (MYH10 antibody N-17) (SantaCruz, UK, #sc-47204). 
Primary antibody was used at a 1:500 concentration in 5% skimmed milk powder in 
TBS-T. Patient platelet protein and protein lysates were analysed in tandem with 
three cell line lysates; DAMI, HEK293T and HEL. GAPDH was used as a loading 
control. A range of exposure times were used to determine expression. Shown in 
Figure 6.3.1 is scanned picture of the WB of MYH10 expression. 
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Figure 6.3.1 Western blot to determine MYH10 expression in patients with RUNX1 and FLI1 genetic variants as well as 
DAMI, HEK293T and HEL cell lysates. MYH10 expression compared to a loading control of GAPDH. No visible 
expression of MYH10 was noted in any patient and only within the HEL cell lysate. 
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6.4. Determining a likely candidate variant in a kindred with 
three affected family members 
Three family members, patients 36.I, 36.II and 36.III were recruited to the UK-GAPP 
study with a shared phenotype of a mild reduction in platelet count. Clinical 
manifestation including easy cutaneous bruising and bleeding in non-traumatic 
instances was shared among all three family members. Following initial phenotypic 
and genotypic investigation four additional unaffected family members with no history 
of bleeding were also recruited to the study. The family pedigree for all members is 
shown in Figure 6.4.1. Included are the patients and unaffected individuals most 
recent platelet counts. 
6.4.1. Identification of 14 novel variants shared among all three 
affected family members following WES 
Whole exome sequencing was performed on the three affected family members prior 
to the recruitment of the additional family members. Analysis depicted 14 novel SNV 
and small insertion/deletion variants shared among the individuals which are shown 
in Table 6.4.1. With the exception of a SNV in WAS; c.1456G>A, p.Glu486Lys, none 
of the remaining variants were identified in genes previously associated with 
haemostasis. When assessing the pathogenicity, the variant in WAS was predicted to 
disrupt the splice acceptor motif of exon 12 of the coding region due to occurring 3 
bases into the exon, c.1456G>A. The three affected individuals presented with no 
secondary symptoms of recurrent infection usually attributed to WAS. A likely 
diagnosis of XLT was therefore predicted and the variant in WAS prioritised for 
further investigation. 
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Figure 6.4.1 Family pedigree of the three affected family members of family 36 
and the four recruited unaffected family member controls. Inluded are whole 
blood platelet counts (x109/L)  
 
36.I 
137 
36.II 
186 
36.III 
80 
Died of SAM 
post fall 
Unaffected I 
        206 
Unaffected II 
264 
Unaffected III 
   213 
Unaffected IV 
294 
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Gene Genomic variation Protein effect Variation type 
MARCH1 c.368G>A p.Arg123Gln Missense 
ALDOB c.964G>T p.Glu322* Nonsense 
BAI2 c.4430C>G  p.Thr1477Ser Missense 
CAMKK2 c.1600_1601insAAA p.534insLys Non-frameshift insertion  
CNGB1 c.2060A>G p.Asn687Ser Missense 
GSC2 c.263C>T p.Ala88Val Missense 
MOB3B c.214A>C p.Asn72His Missense 
MYBPHL c.862C>T p. Pro288Ser Missense 
MYCL1 c.672C>A p.Asp224Glu Missense 
PADI2 c.1496A>G p.Lys499Arg Missense 
PEX1 c.3623G>A p.Arg1208Gln Missense 
RAD21 c.1433G>A p.Arg478Gln Missense 
TTF2 c.3265C>G p.His1089Asp Missense 
WAS c.1456G>A p.Glu486Lys Missense 
 
Table 6.4.1 Table showing Sanger sequencing results of all 14 shared novel variants among the three affected family 
members.
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6.4.2. Skewed X-inactivation assay 
X-inactivation was assessed to determine the likelihood that presentation of XLT is 
possible in the two heterozygous female patients due to skewed X-inactivation 
favouring retention of the mutant allele. When comparing the digested trace 
(unmethylated active X chromosome) to the undigested trace (methylated and 
inactive X chromosome) a normal random distribution between the frequency of 
maternal and paternal CAG lengths is noted in both patients ( 
Figure 6.4.2). This indicates that X-inactivation is not skewed favouring retention of 
one allele over the other. 
6.4.3. Assessing WASp expression by Western blot 
WB analysis was used to determine whether the expression of WASp encoded by 
WAS was disrupted by the genetic variant in the last coding exon. Protein lysates 
prepared from washed platelets were available for all three patients. A total quantified 
amount of 7µg of protein was available for patient 36.III therefore 7µg was loaded for 
all three patients in tandem with the same quantity of protein lysate from an 
unaffected unrelated individual. In addition, 18µg of protein was also assessed in 
patients 36.I and 36.II in tandem with the same quantity of unaffected unrelated 
protein lysate. A mouse monoclonal primary antibody (B-9) targeted to amino acids 
1-250 of the human protein was used to determine WASp expression (SantaCruz, 
UK, #sc-13139). The primary antibody was used at a concentration of 1:500 and a 
loading control of anti-GAPDH was also blotted for separately as detailed in the 
methods section 2.17. Western blots are shown in Figure 6.4.3 and quantification of 
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the anti-WASp WB using the LI-COR® Odyssey® Fc imaging system is shown in 
Figure 6.4.3. 
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Patient 36.I 
Patient 36.II 
Digested 
Undigested 
Digested 
Undigested 
 
 
 
 
 
 
 
 
 
 
Figure 6.4.2 Skewed X-inactivation assay of patients 36.I and 36.II. Peaks at 223 and 272 CAG repeats in patient 36.I 
and 223 and 266 in patient 36.II are noted in both the digested and undigested traces indicating normal distribution of 
X-inactivation.   
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Figure 6.4.3 A. Western blot of WASp expression in patient platelet lysates. 
WASp expression is compared to a loading control of GAPDH. No difference in 
the expression of WASp is noted between affected individuals and controls. B. 
Quantification of expression normalised to the loading control. No difference in 
quantified expression is noted. 
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6.4.4. Platelet spreading to determine the effect of WAS variation 
on the actin cytoskeleton 
Spreading of washed platelets from the three affected individuals was used to 
determine any effect on actin cytoskeleton remodelling upon activation. Platelets 
were spread as detailed in section 2.18. Patient platelets were spread in tandem with 
platelets from an unrelated unaffected control following the same procedure. Five 
images were taken per patient/control and 50 cells were counted per image in a 
predefined region to quantify the average platelet size when spread. Representative 
images of platelet spreading are shown in Figure 6.4.4, average platelet diameter 
over all cells counted is shown in Figure 6.4.4. No difference was noted in the 
number of platelets defined as fully spread, currently spreading or un-spread when 
comparing the three affected individuals to the unrelated control.  
6.4.5. Sanger sequencing of the 14 shared novel variants in four 
unaffected related family members 
Following functional investigation of the prioritised variant in WAS, four unaffected 
related family members were recruited to the UK-GAPP study to investigate 
segregation of all candidate variants. All four unaffected individuals reported no 
symptoms relating to haemostasis and platelet counts exceeded 200x109/L. All 
variants were sequenced by Sanger sequencing as detailed in section 2.15 in all 
affected and unaffected individuals. Results of sanger sequencing are displayed in 
Table 6.4.2. Only two variants; PADI2; c.1496A>G, p.Lys499Arg and TTF2; 
c.3265C>G, p.His1089Asp, segregated with disease and were only present in the 
affected individuals of family 36. 
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Figure 6.4.4 A. Platelet spreading on fibrinogen coated glass slides. No 
difference in observable levels of spreading is noted between all patients and 
the control. B. Average platelet diameter of all cells counted. No difference is 
noted in average platlet diameter between affected individuals and control. 
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Gene/Individual 36.I 36.II 36.III Unaffected I Unaffected II Unaffected III 
Unaffected 
IV 
MARCH1 c.368G>A c.368G>A c.368G>A c.368G>A c.368G>A WT WT 
ALDOB c.964G>T c.964G>T c.964G>T c.964G>T c.964G>T WT WT 
BAI2 c.4430C>G  c.4430C>G  c.4430C>G  c.4430C>G  WT c.4430C>G  c.4430C>G  
CAMKK2 
c.1600_160
1insAAA 
c.1600_1601ins
AAA 
c.1600_1601ins
AAA 
c.1600_1601ins
AAA 
c.1600_1601ins
AAA 
c.1600_1601in
sAAA 
WT 
CNGB1 c.2060A>G c.2060A>G c.2060A>G c.2060A>G c.2060A>G WT WT 
GSC2 c.263C>T c.263C>T c.263C>T c.263C>T c.263C>T WT WT 
MOB3B c.214A>C c.214A>C c.214A>C WT c.214A>C c.214A>C WT 
MYBPHL c.862C>T c.862C>T c.862C>T WT WT c.862C>T c.862C>T 
MYCL1 c.672C>A c.672C>A c.672C>A c.672C>A WT c.672C>A c.672C>A 
PADI2 c.1496A>G c.1496A>G c.1496A>G WT WT WT WT 
PEX1 c.3623G>A c.3623G>A c.3623G>A c.3623G>A WT c.G3623A c.G3623A 
RAD21 c.1433G>A c.1433G>A c.1433G>A c.1433G>A WT WT WT 
TTF2 c.3265C>G c.3265C>G c.3265C>G WT WT WT WT 
WAS c.1456G>A c.1456G>A c.1456G>A WT c.1456G>A WT WT 
 
Table 6.4.2 Sanger sequencing of all 14 novel shared variants in the three affected family members and four 
unaffected family members of family 36. Only variants in PADI2; c.1496A>G and TTF2; c.3265C>G are present only 
within the three affected family members and absent from all unaffected family members. 
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6.4.6. In silico expression of PADI2 and TTF2 in cells of the 
haematological lineage 
Expression of PADI2 and TTF2 was determined using Blueprint epigenome data 
(Chen, Kostadima et al. 2014). RNAseq data showed weak to no expression of 
PADI2 throughout the progenitors leading to megakaryocytes where as TTF2 was 
expressed in all progenitor populations of the haematopoietic lineage (Figure 6.4.5). 
In particular, expression of the full length 1162 amino acid encoding RNA, transcript 
ID – ENST00000369466, is high among megakaryocyte and erythroblast cell 
populations.
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Figure 6.4.5 In silico expression analysis of TTF2 and PADI2 in cells of the 
haematopoietic cell lineage. Expression of TTF2 is noted in all cells of the 
haematopoietic lineage as opposed to no expression of PADI2. HSC – 
Haematopoietic stem cell, MPP – Mulitpotent progenitor, CMP – Common 
myeloid progenitor, MEP – Myelo-erythroid progenitor, EB – Erythroblast, and 
MK – Megakaryocyte.  
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6.4.7. Western blot to determine expression of TTF2 in platelets 
Platelet protein prepared as detailed in section 2.9 and platelet lysates prepared as 
detailed in section 2.10 were available for patients 36.I and 36.II. Both preparations 
of protein in both patients were run in tandem with unaffected unrelated control 
samples prepared in the same way. 18µg of quantified protein in protein lysate 
samples was added for both patients and control. Samples were also run in tandem 
with cell lysates from HEL cells as a positive control. WB were probed with anti-TTF2 
rabbit monoclonal antibody targeted to amino acids 50-150 of the human protein 
sequence [ERP12756] (Abcam, UK, #ab181116) and an anti-GAPDH as a loading 
control. Anti-TTF2 primary antibody was diluted 1:500 in 5% skimmed milk powder in 
TBS-T. WBs were visualised using ECL and an example is shown in Figure 6.4.6. 
WB analysis depicted that no observable expression of TTF2 was identified in either 
patient or control prepared platelet protein. Due to a limited preparation of both 
protein sources, no material was available for patient 36.III. A band was noted at 
52kD in the anti-GAPDH expression blot. As the antibody is specific to a 36kD 
GAPDH this is predicted to be non-specific binding of the antibody. 
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Figure 6.4.6 Western blot to determine the expression of TTF2 in patient cell 
lysates and HEL cell lysates as a positive control. TTF2 expression compared 
to a loading control of GAPDH expression. No observable expression of TTF2 
was noted in either affected individuals or the control sample and was only 
present in the positive control. 
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6.4.8. Utilising the CRISPR-Cas9 system to analyse the in vitro 
effect of variations within TTF2 
CRISPR-Cas9 allows for highly efficient and specific gene editing in a variety of cell 
types. To further investigate the effects of the TTF2 variants reported herein, a 
CRISPR-Cas9 workflow introducing a fluorescent tag into the C-terminal coding 
region of the protein was applied. Four guide sequences within 25 base pairs of the 
STOP codon were designed and cloned into the small guide RNA encoding vector 
BPK1520. A donor template carrying the mEos 3.2 fluorescent tag flanked by 
homology arms approximately 700 base pairs in length was designed and cloned into 
a pGem-T easy backbone. All four sequences exceeded a quality cut-off of 50 and 
had minimal off-target effects especially those confined to the target sequence. To 
date, all four guide sequences and mEos 3.2 donor clones have been successfully 
cloned, amplified and sequence verified. DNA has been prepared for transfection into 
cell lines to determine transfection efficiency as well as initial impact of genetic 
variation in TTF2 once a stable cell line is established. 
6.5. Discussion 
Functional confirmation of sequencing variants focused on two main areas; 
determining the presence of MYH10 expression as a biomarker of RUNX1 and FLI1 
mutations and elucidating the genetic cause of disease in a kindred of three affected 
individuals. Due to time constraints, many of the functional assays to be able to 
determine the effect of genetic variation were unfinished and in progress. 
Western blot analysis of MYH10 expression in patients with RUNX1 and FLI1 
variants identified a lack of expression in all patients analysed. This may indicate two 
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possibilities; that the genetic variations within the two aforementioned genes are 
benign and do not alter the function of their encoding proteins leading to an absence 
of aberrant MYH10 expression. Alternatively, a lack of MYH10 expression may be a 
result of an inaccurate assay. Two cell lysates were utilised as positive controls, 
variance was observed between the expression in both lysates with clear expression 
noted in lysates of HEL cells but a lack of expression in HEK293T cells. Both cell 
lines are noted to express MYH10 at significant levels for detection by WB within the 
Human Protein Atlas (http://www.proteinatlas.org/ Last accessed October 2016). In 
addition, nine of the patient derived platelet protein samples were prepared in excess 
of four years ago, at the time of patient recruitment. Samples have undergone 
multiple free-thaw cycles suggesting that the protein content of each sample may be 
degraded in quality leading to an inability to determine expression upon WB analysis.  
The second part of this chapter focuses around a kindred with three affected 
individuals. All three individuals shared phenotypic symptoms relating to easy 
bruising, however, a slight variation in platelet count and secondary qualitative 
defects in platelet function was noted. Due to the similarities in clinical presentation 
this is most likely interpersonal variation.  
Following WES, 14 novel shared variants were noted among the three affected 
individuals. A SNV in WAS was prioritised due to previous implications of the gene 
within IT. Due to the location of WAS on the X-chromosome, presentation of XLT and 
WAS in female patients is often rare and as a result of skewed X-inactivation 
(Andreu, Matamoros et al. 2007). X-inactivation was assessed in the two female 
patients, 36.I and 36.II, by methylation sensitive PCR of the CAG repeat within the 
androgen receptor. No skewing towards the retention of an active mutant allele was 
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noted in either patient indicating a normal heterozygous state of variation, different to 
the hemizygous state noted in the male patient 36.III.  
Overall the functional categorisation of the variant within WAS suggests that the 
variant is benign and not causative of disease. As no difference in the expression of 
the encoded WASp was noted, it may be argued that a full length protein is retained 
but is impaired in its ability to impact the actin cytoskeleton. However, cytoskeleton 
remodelling upon activation leading to platelet spreading was unaffected suggesting 
its role within platelets was normal. 
The attention was therefore shifted to the alternate 13 shared novel variants in genes 
of no haemostatic relevance. Sanger sequencing to determine segregation of 
variants with disease in the three affected family members and four unaffected 
related family members was undertaken to narrow down candidate variants. Two 
variants, occurring within PADI2 and TTF2, were only present in the affected family 
members of family 36. When categorised as part of chapter 4 both variants were 
classified as of “uncertain significance”. However, expression of TTF2 was far more 
significant in cells of the haemopoietic lineage, in particular within megakaryocyte cell 
populations.   
TTF2 is predicted to be weakly expressed in platelets when scrutinised in expression 
databases, however no expression was noted in any of the patients or unrelated 
unaffected control samples analysed. This may indicate a lack of sensitivity of the 
assay or expression confined to progenitor cells of the megakaryocytic lineage. Work 
utilising the CRISPR-Cas9 gene editing system is ongoing, however sequence 
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verified guides and clones were identified and following subsequent transfection may 
provide insight into the role of TTF2 upstream of platelet production.  
6.6. Further work 
As the majority of the results within this chapter are ongoing, due to time constraints, 
further work will focus around completion of outstanding experiments. MYH10 
expression in platelets is a well-established biomarker of genetic variance in RUNX1 
and FLI1 (Antony-Debre, Bluteau et al. 2012; Lordier, Bluteau et al. 2012). Further 
work will initially aim to repeat this assay to determine whether the lack of expression 
is due to a benign effect of variation or a lack of sensitivity of the assay to determine 
expression, especially in samples prone to degradation. Variants in RUNX1 are also 
often associated with a secondary qualitative defect in dense granule secretion. 
Indeed, a large proportion of our patients with variants within RUNX1 phenocopy this 
trait in platelet function testing. Whole mount electron microscopy has previously 
been utilised to determine a reduction in dense granule number in patients with 
variants within SLFN14 (Fletcher, Johnson et al. 2015). This method could be 
adopted for patients with variants in RUNX1, in particular to determine whether the 
reduction in dense granule secretion is due to a diminishment in number. However, 
although further categorising the phenotype of the affected patients this will not aid in 
tying the genetic variations within RUNX1 to disease and further in vitro work would 
be required to do this. 
Priority in family 36 lies with the variant within TTF2 as the most likely candidate of 
disease due to its uniform expression throughout megakaryopoiesis. However, genes 
with little to no expression within platelets and cells of the megakaryocytic lineage 
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have been previously implicated in disease through variants within ABCG5 and 
ABCG8. 
Initial further work though would aim to continue to determine the in vitro effect of 
variants within TTF2 before analysing the impact of variations within PADI2. Although 
a lack of expression was noted in patient-derived platelet protein, TTF2 is expressed 
throughout the megakaryocytic lineage in in vitro cell population RNAseq analysis. 
Determining the expression in CD34+ cells isolated from donated cord blood and 
cultured to allow megakaryocyte differentiation and maturation would be beneficial in 
determining whether genetic variation may impact thrombopoiesis (Robert, Cortin et 
al. 2012).  
The next step utilising the CRISPR-Cas9 system would be to co transfect guide, 
donor and Cas9 expressing vectors into clonal cell lines prior to clonal expansion and 
determination of the effect of variation. Further work would then aim to apply this 
methodology to megakaryocytes derived from induced pluripotent stem cells (iPS 
cells) (Takayama and Eto 2012). This powerful approach is currently being applied to 
a number of IT causing genes and may provide novel insight into the functional role 
of TTF2 in megakarypoiesis.  
6.7. Key findings 
 A lack of MYH10 expression in platelet protein in patients with variants in 
RUNX1 and FLI1. 
 Elimination of a variant within WAS, through functional characterisation of the 
effect of variation, as disease-causing in a kindred with three affected 
individuals. 
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 Determination of variants within PADI2 and TTF2 as potential candidate 
variants of disease through Sanger sequencing-derived segregation analysis. 
 Lack of TTF2 expression with prepared platelet protein. 
 Initial steps to analyse the in vitro effect of variants within TTF2 in cells of the 
haematopoietic lineage through the CRISPR-Cas9 system have been 
completed. 
 212 
 
7. Overall Discussion and Conclusions 
IT represents a heterogeneous group of disorders characterised by a reduction in the 
circulating platelet count. Indeed, when considering all patients entered into the UK-
GAPP study with IT of presumed unknown genetic aetiology to date, a wide 
variability is observed among the physical characteristics measured. Age and sex 
distribution among the 95 patients was consistent with other large-scale studies into 
IT and bleeding diathesis, as previously mentioned. This can also be said for the 
platelet characteristics including platelet count and size, which vary from severe to 
borderline normal. One unique attribute of this study is the inclusion of patients with a 
platelet count exceeding the normal cut-off of 150x109/L. These patients were 
included due to the likelihood that the effect of genetic variation has reduced their 
platelet count but not significantly below a standardly recognised threshold. 
Considering that many of these patients would have been overlooked if the usual cut-
off was applied, they represent an interesting sub-set which may offer a unique 
insight into the genetic aetiology of disease. Interestingly, variants were noted in a 
wide variety of known IT-causing genes in this subset of patients indicating that the 
reduction in platelet count may be consistent with other patients but these patients 
have a higher overall circulating level of platelets. 
Phenotypically analysing all patients recruited to the study gives the UK-GAPP study 
group a novel stance in the field of IT research. By understanding, in depth, the 
potential functional effect of disease it can help with narrowing candidate variants in 
subsequent genetic analysis. It also provides crucial information to support any 
candidate variants in genes previously known to cause disease. This is the case in 
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patients with a number of variants within RUNX1, who share the phenotypic attribute 
of a reduction in measurable platelet secretion, as well as patient 61.I who showed a 
reduction in surface CD41, which was supported by subsequent identification of a 
variant in ITGA2B. 
Platelet function testing, however, is not without its limitations. As mentioned 
previously there is a lack of an industry gold standard for determining all ranges of 
platelet function defects. This may explain the lack of any observable defect in 29% 
of patients analysed. These patients could potentially harbour defects in platelet 
cytoskeleton remodelling, platelet adhesion or a number of platelet functions that are 
not covered by the platelet function tests utilised within the study. Alternatively the 
bleeding associated with these patients could be attributed directly and solely to the 
reduction in platelet count. 
Utilising WES analysis is a novel approach to determining the causality of IT. In this 
study WES has also been applied to a different subset of patients than what was 
previously tested in alternative studies. As such, the genetic picture of disease 
portrayed in this work is not comparable to previous large-scale studies into the 
disease. However, detection rates, when considering those predicted to be likely 
disease causing, are comparable to both previous large-scale studies into IT and 
other WES based approaches to Mendelian disease proving the effectiveness of 
WES in this disease subtype.  
When compared to previous studies utilising targeted sequencing, a superior overall 
detection rate for all variants was noted. However, no likely causative variants in 
genes previously known to cause IT or novel genes were found in 13 index cases. 
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With the exception of one index case, 37.I, all individuals were single affected cases. 
All individuals displayed a sustained reduction in platelet count or the presence of 
affected family members that were unavailable for recruitment to the study indicating 
the genetic origins of disease. There are therefore two plausible explanations for the 
lack of variants identified. One explanation is that the genetic variant(s) causative of 
disease occur in novel genes and the post-sequencing bioinformatics pipeline utilised 
is not sensitive enough to detect the variants. The other explanation is that variants 
occur in genomic regions beyond the coding exome. To date, excluding variants that 
occur within the 5’UTR of ANKRD26 causative of THC2, only one variant has been 
previously identified in a regulatory region outside of the coding sequence. This 
variant is the low frequency SNP in RBM8A co-inherited with a null allele in patients 
with TAR (Albers, Paul et al. 2012). There is a possibility that variants in regulatory 
regions may explain the cause of disease in patients without a likely candidate 
variant of disease identified by WES.  
Focusing on variants in genes previously known to cause IT initially showed, most 
interestingly, a large proportion of patients with variants in RUNX1. Causative of 
FPD/AML, variants were previously determined to be relatively rare in frequency with 
only a handful of variants known in published literature and mutation databases. 
However, WES analysis has revealed that its prevalence, when excluding patients 
with an already established causative variant of disease, is more inclined to more 
prevalent disorders such as BSS and MYH9-related disease. This information carries 
a strong clinical implication, suggesting that FPD/AML should be considered upon 
initial diagnosis of IT.  
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Focusing our initial post-sequencing analysis of variants within genes known to 
previously be associated with IT lead to design and application of a IT-specific next 
generation sequencing panel as a pre-screening tool prior to WES. An Agilent 
SureSelectQXT platform was chosen for library preparation as an efficiently and 
accurately optimum method. In validation testing, a slight lack of sensitivity was 
noted, however, QC, coverage and the presence of false-positive results all 
exceeded quality cut-offs upon application of the sequencing panel to the subset of 
selected patients. As a pre-screening tool prior to WES, the IT-specific next 
generation sequencing panel provided a potential candidate variant of disease in 
77% of patients analysed. Although requiring functional categorisation to determine 
the effect of variation it is an effective tool to minimise the time and costs taken to 
analyse the genetic aetiology of patients with IT. 
The ability to determine the genetic aetiology of IT is often bound to be problematic, 
in part due to the heterogeneity of disease but also due to the likelihood that 
identified variants are benign. Functional characterisation of variants is therefore 
required to conclusively determine whether the variants are disease causing or not. 
Indeed a number of variants within the ExAC database are believed to be benign, 
even those previously thought to be associated with disease (Song, Gardner et al. 
2016). In this study, follow-up functional work is ongoing but is fundamental to 
determine the mutation status of all variants identified, in particular those in genes 
not known previously to cause IT. 
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7.1. Future work arising from this study 
There are several hypotheses arising from the work described in this thesis: 
Hypothesis 1 
Patients with a borderline platelet count between 150-200x109/L, that exceed 
previously recognised thresholds of thrombocytopenia, represent an interesting 
subset of IT previously unassessed. 
Suggested work 
Fully analyse all patients with a platelet count between 150-200x109/L using the UK-
GAPP patient workflow to determine if these patients harbour previously unidentified 
genetic variants that are causative of a very mild reduction in platelet count. 
Hypothesis 2 
A high proportion of patients identified with variants in RUNX1 indicate a clinical 
relevance of the gene in IT. 
Suggested work 
Extend the recruitment of patients to include those that are potentially pre-screened 
routinely for BSS and MYH9-related disease in haemophilia referral centres to 
determine the true prevalence of RUNX1 variants in IT. This can be followed 
subsequently by the development of a genetic pre-screening protocol for clinical use 
that can be combined with genetic counselling following a positive result.  
Hypothesis 3 
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Patients with no plausible candidate variants identified by WES analysis are likely to 
harbour variants in novel genes or outside of the coding exome. 
Suggested work 
Recruitment of additional affected and unaffected family members, where applicable, 
to help define candidate variants by determining genetic segregation of variants with 
disease. Application of WGS to patients with no likely candidate variants causative of 
IT to consider potential variants occurring in regulatory regions.  
Hypothesis 4 
Variants in TTF2 are causative of IT in a kindred with three affected individuals. 
Suggested work 
Progress with functional characterisation of the effect of variation through the 
utilisation of the CRISPR-Cas9 genome editing technology. Null alleles will first be 
analysed in relevant cell lines to determine the effect of a complete lack of 
expression. Cell lines and iPSC derived megakaryocytes will be further used to 
determine the effect of the variant identified within family 36 on haemostasis and the 
production, function and lifespan of platelets. 
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RASGRP2, which encodes CalDAG-GEFI, abrogate Rap1 activation, causing 
platelet dysfunction”. Blood. 128(9 
3. Johnson, B., Lowe, G.C., Futterer, J., et al., (2016) “Whole exome 
sequencing identifies genetic variants in inherited thrombocytopenia with 
secondary qualitative function defects.” Haematologica.  
4. Fletcher, S.J., Johnson, B., Lowe, G.C., et al., (2015) “SLFN14 mutations 
underlie thrombocytopenia with excessive bleeding and platelet defects.” J 
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Toronto, Canada. 
2. “Whole exome sequencing as a tool for detection of the genetic basis of 
inherited thombocytopenias.” Johnson, B., Lowe, G.C., Drake, S., et al. 
47th European Human Genetics Conference, 2014, Milan, Italy. 
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Appendix 
Table A. Database of 358 platelet related disease and the percentage coverage 20x 
Gene 
Percentage covered 
20x 
ABCA12 95.78903846 
ABCB4 91.87596154 
ABCC4 94.33057692 
ABCG5 94.33923077 
ABCG8 94.58923077 
ACSL4 89.83423077 
ACTN1 95.97653846 
ACVRL1 86.78846154 
ADAMTS13 82.55192308 
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ADCY3 94.18192308 
ADCY6 96.89115385 
ADCY7 93.01884615 
ADORA2B 99.71942308 
ADRA2A 88.06634615 
ADRA2B 99.77769231 
ADRBK1 96.19711538 
AK3 55.78346154 
AKT1 96.86942308 
AKT2 95.20153846 
ALOX12    93.64807692 
ANKRD12 93.75903846 
ANKRD18A 33.42519231 
ANKRD18B 33.72769231 
ANKRD26 88.99711538 
ANKRD33 99.03942308 
AP3B1 94.50730769 
AP3D1 91.79173077 
AP3M1 96.0675 
AP3S1 52.58692308 
APC 98.35365385 
ARHGAP1 92.67423077 
ARHGAP17 90.04076923 
ARHGAP32 97.34884615 
ARHGAP6 90.92846154 
ARHGDIA 99.87653846 
ARHGDIB 94.91942308 
ARHGEF12 94.94096154 
ARHGEF3 92.61442308 
ARRB1 96.75096154 
ASPN 95.82096154 
BAK1 84.71307692 
BCL2L1 95.73134615 
BCOR 95.31596154 
BET1L 88.50326923 
BLOC1S1 87.50596154 
BLOC1S2 84.00711538 
BLOC1S3 64.64711538 
BLOC1S4 0 
BLOC1S5 0 
BLOC1S6 0 
BMP4 99.61769231 
BTBD9 88.92961538 
BTK 90.95365385 
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C14orf133 93.49211538 
C19orf55 95.45673077 
C20orf42  98.17076923 
C6orf25 94.98673077 
CD226 96.20423077 
CD36 95.57326923 
CHD3 87.89211538 
CLEC1B 84.17692308 
CLEC4F 96.99903846 
CNO 68.97596154 
CSK 91.53903846 
CTTN 92.78730769 
CYCS 76.61653846 
DAAM1 91.85519231 
DIAPH1 90.83076923 
DIAPH2 88.93423077 
DIAPH3 90.49826923 
DNAH11 94.54923077 
DNM1L 90.95442308 
DNM2 90.57903846 
DNM3 93.96403846 
DTNBP1 97.78865385 
EFNB1 94.40038462 
EPHA4 96.95403846 
EPHB1 92.37596154 
ERG 96.33038462 
ETS1 96.40730769 
ETV6 95.02826923 
EXOC1 93.74442308 
F2R  98.79557692 
F2RL3  94.01692308 
FARP2  95.73269231 
FCER1G 83.29288462 
FCGR2A 67.57211538 
FERMT1 91.73211538 
FERMT3 95.51115385 
FGD3 94.28884615 
FGR 98.005 
FHOD1 96.28326923 
FLI1 94.73076923 
FLII 93.37019231 
FLNA 97.00788462 
FMNL1 81.43192308 
FMNL3 92.46903846 
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FYN 95.37461538 
GATA1 92.99692308 
GDI2 85.11634615 
GFI1 95.03865385 
GFI1B 94.83923077 
GNA12 91.09903846 
GNA13 99.22730769 
GNAI1 83.15596154 
GNAI2 97.37134615 
GNAQ 82.19326923 
GNAZ 99.58403846 
GNB2 95.55461538 
GNB3 98.4325 
GNG11 95.51576923 
GNG12 99.955 
GNG13 82.95346154 
GNG5 57.10211538 
GP1BA 98.47846154 
GP1BB 48.24865385 
GP5  94.20826923 
GP6 87.45961538 
GP9 85.64980769 
GRAP2 92.87307692 
GRB2 96.925 
GRK5 93.96980769 
GRK6 93.00576923 
GUCY1A3 99.19346154 
GUCY1B3 94.70807692 
HBB 100 
HOOK3 90.58788462 
HOXA11 98.39903846 
HPS1 90.14211538 
HPS4 97.02096154 
HTR2A 98.28846154 
INPP5D 96.43903846 
ITGA2 94.87115385 
ITGA2B 90.47326923 
ITGA5 92.47230769 
ITGB1 91.83923077 
ITGB3 91.50692308 
ITPR1 94.55153846 
JAK2 91.67096154 
JMJD1C 96.59538462 
KIAA1109 96.005 
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KIAA2018 99.5275 
LAIR1 92.38615385 
LAT 96.34288462 
LCP2  90.20923077 
LPAR1 98.79923077 
LTBP1 93.08288462 
LY6G6F 98.07923077 
LYN 90.19884615 
LYST 95.22557692 
MAP2K2 94.87903846 
MAP2K4 71.90673077 
MAP3K9 93.925 
MAPK1 96.88 
MAPK13 98.06653846 
MAPK14 98.94038462 
MAPK8 96.26557692 
MDS1 0 
MECOM 97.42153846 
MKL1 92.5525 
MLK1 0 
MLPH 83.94865385 
MMP17 83.83634615 
MNX1 64.92788462 
MPL 95.89403846 
MRPS34 96.49923077 
MUC16 98.12096154 
MUC2 92.51884615 
MUTED 95.05711538 
MYB 92.59384615 
MYH10 95.62423077 
MYH13 88.64865385 
MYH9 96.80057692 
MYL9 90.89884615 
MYLK 95.07519231 
MYLK2 93.62173077 
MYO18B 89.13384615 
MYO3A 93.55019231 
MYO5A 94.82423077 
MYO5B 87.30557692 
NAPA 95.39730769 
NAPG 92.46403846 
NBEA 86.9125 
NBEAL2 97.56807692 
NFE2 99.05153846 
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NIPSNAP3A 90.91269231 
NOTCH1 89.38865385 
NOX1 88.43692308 
NRG3 96.13076923 
NSF 37.36192308 
NXF1 94.20769231 
ORAI1 92.00634615 
P2RX1 96.11173077 
P2RY1 99.26365385 
P2RY12 100 
P2RY13 100 
PDE2A 90.25076923 
PDE3A 90.60538462 
PDE4D 93.30769231 
PDE5A 95.16384615 
PDPK1 36.81807692 
PDZD3 95.2925 
PDZK1 15.58576923 
PEAR1 96.45153846 
PECAM1 100 
PGM3 94.78634615 
PHOX2A 54.54903846 
PIK3CA 90.36384615 
PIK3CB 94.71692308 
PIK3CD 87.63288462 
PIK3CG 98.25461538 
PIK3R1 95.99730769 
PIK3R3 96.83307692 
PIK3R5 96.96980769 
PLA2G4A 96.91615385 
PLA2G4C 93.49153846 
PLCB2 97.0875 
PLCB3 92.18576923 
PLCG2 94.48692308 
PLDN 75.15980769 
PPP1CA 99.00038462 
PPP1CB 97.86730769 
PPP1CC 98.79423077 
PPP1R12A 91.18615385 
PPP1R12C 78.43576923 
PPP1R14A 85.47346154 
PPP1R2 45.66384615 
PRKACA 96.39538462 
PRKACB 92.21788462 
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PRKACG 100 
PRKAR1A 77.49673077 
PRKAR2A 94.83557692 
PRKCA 92.09307692 
PRKCB 94.39903846 
PRKCD 96.76076923 
PRKCQ 91.7475 
PRKD1 98.66307692 
PRKG1 91.3625 
PRKG2 95.72442308 
PTEN 83.83673077 
PTGIR 92.86269231 
PTGS1 99.03711538 
PTK2 93.98653846 
PTPN1 93.99519231 
PTPN11  55.94115385 
PTPN12 95.05057692 
PTPN18 91.53596154 
PTPN2 70.88884615 
PTPN6 94.96384615 
PTPN7 88.78 
PTPN9 92.46019231 
PTPRA 97.68 
PTPRC 91.14269231 
PTPRJ 92.07307692 
RAB27A 99.31019231 
RAB27B 97.62057692 
RAB38 99.27326923 
RAB4A 90.98846154 
RABGGTA 90.39365385 
RAC1 56.83538462 
RAF1 93.3425 
RAI1 98.35096154 
RAP1B 58.62884615 
RAP1GAP 92.23673077 
RAP1GAP2 94.07826923 
RAP1GDS1 85.94403846 
RASGRP2 90.82 
RBM8A 85.60326923 
RGS10 90.32192308 
RGS18 94.02134615 
RGS19 96.77903846 
RGS20 91.42634615 
RGS9 92.94538462 
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RHOA 95.28730769 
RHOC 96.63519231 
RHOF 92.28615385 
ROCK1 86.35980769 
ROCK2 94.94538462 
RUNX1 89.41538462 
SCAMP2 87.93230769 
SCAMP5 85.06346154 
SCFD1 94.55307692 
SELP 94.06769231 
SERPINE2 93.29230769 
SH2B3 87.26384615 
SIRPA 74.93711538 
SLC35D3 90.26326923 
SLC9A3R1 94.555 
SLC9A3R2 75.83384615 
SLFN14 95.47711538 
SMAD1 97.22134615 
SMAD6 79.03769231 
SNAP23 89.95788462 
SNAP25 89.25403846 
SNAP29 99.19 
SNAPIN 93.63538462 
SNX1 88.6075 
SRA1 94.33307692 
SRC 88.58730769 
SRF 91.81730769 
STIM1 90.21519231 
STOM 91.51615385 
STX11 99.55711538 
STX12 96.40942308 
STX2 90.69057692 
STX4 93.61519231 
STX6 96.60596154 
STX7 98.15153846 
STXBP1 95.39442308 
STXBP2 96.60769231 
STXBP3 93.66923077 
STXBP4 93.48961538 
STXBP5L 95.54057692 
STXBP6 88.68615385 
SUZ12 70.34346154 
SYK 97.63346154 
SYTL3 91.77326923 
 242 
 
SYTL4 93.77846154 
TAL1 76.37923077 
TAOK1 93.57307692 
TBXA2R 82.61076923 
TEC 91.73115385 
TGFBR3 94.92346154 
THPO 90.60980769 
TLN1 97.19653846 
TLR2 98.30980769 
TMCC2 90.78711538 
TPM1 96.63076923 
TPM4 77.58057692 
TRAF4 95.36480769 
TREML1 98.26788462 
TRPM7 94.52211538 
TTC37 97.67211538 
TUBA3C 76.80365385 
TUBB1 99.98019231 
UNC13A 94.45807692 
UNC13B 97.44692308 
VAMP2 99.25480769 
VAMP3 98.30519231 
VAMP7  16.34615385 
VAMP8 84.83596154 
VAV1 91.29730769 
VAV2 95.41961538 
VAV3 94.33903846 
VPS11 98.45057692 
VPS16 94.97403846 
VPS18 98.01461538 
VPS33A 95.89807692 
VPS33B 95.43365385 
VPS39 94.17423077 
VPS41 91.65442308 
VPS4B 97.05673077 
VPS52 92.45634615 
VPS8 90.68557692 
VWF 75.24192308 
WAS 82.84884615 
WDR66 92.87173077 
ZFPMI 66.54634615 
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Participant Information Sheet on ‘Mild Platelet Disorders’ 
 
PART 1  
 
1. Study title: Mild bleeding disorders caused by platelet defects 
 
2. Invitation paragraph:   
You are being invited to take part in a study. Before you decide it is important for you 
to understand why the research is being done and what it will involve. Please take 
time to read the following information carefully and discuss it with friends, relatives, 
your GP and your Consultant if you wish. Ask us if there is anything that is not clear 
or if you would like more information. Take time to decide whether or not you wish to 
take part. 
The UK Clinical Research Collaboration (UK CRC) publishes a leaflet entitled 
"Understanding Clinical Trials”. This leaflet gives more information about medical 
research and looks at some questions you may wish to ask. A copy may be obtained 
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from the internet at http://www.ukcrc.org/publications/informationbooklets.  If you do 
not have access to the Internet, please let us know and we will print a copy off for 
you. 
 
3. What is the purpose of the study? 
This study aims to understand why some patients bleed excessively.  We are going 
to look at the following groups of patients: 
 
1. Patients with mild bleeding who have been seen by a blood specialist who 
feels their symptoms could be due to a problem in the platelets (“clinically 
diagnosed platelet defects”)  
2. Patients who have unexpectedly heavy periods with no obvious cause 
3. Patients with lifelong low platelet counts in the blood with no known cause 
 
In addition, we will also include some “control” individuals who do not suffer from the 
above problems and are important to allow us to compare responses between those 
who bleed excessively and those who do not.  If we only examined affected patients 
it would be difficult to tell how their response compared to that expected in a normal 
individual. 
 
You will be included in the highlighted group above, if you choose to participate in 
this study. 
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For all populations except the control group, we suspect that you have a problem in 
small cells in the blood, known as platelets, but we are not certain that this is the 
case.    This study will use new and more specialist tests in an attempt to confirm that 
there is a problem in your platelets and to use this information to help identify the 
gene or genes that cause this problem.  More information on platelets and what the 
study aims to achieve is given below: 
What are platelets? 
Platelets are small cells within the blood that are involved in the clotting mechanism. 
Following injury, platelets ‘stick’ to each other and block (or plug) the site of injury.  
Patients with too few platelets or with platelets that are less sticky may bleed more 
than we would expect, and in combination with other factors such as medications or 
injury may cause the loss of a great deal of blood.  By carrying out certain tests on 
platelets, it is possible to find out whether somebody has a problem with their 
platelets and whether this is likely to explain their bleeding problem. 
 
The testing of platelet function 
Platelet tests are routinely performed in the Haematology Clinic to investigate 
whether a patient has a platelet problem.  In many cases, however, the tests do not 
give a clear answer on whether the patient has a platelet problem or on the cause of 
the problem.  The present study will use a range of more specialist platelet tests to 
establish whether the patient has a platelet problem and to gain further information 
on the nature of the defect.  This will require analysis of platelet function in freshly 
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donated blood.  Work will be carried out by the Birmingham Platelet Group who have 
a large amount of experience in this field. 
 
The search for defects in genes that could cause the platelet problem 
The most likely explanation for a platelet problem is a defect (or problem) in one or 
more of the genes that you have been passed down (or inherited) from your mother 
and/or father.  Genes can be described as the set of “instructions” that tell the body 
how to develop and work.  A problem in one or more genes could cause the bleeding 
problem. 
 
The results from the study of platelet function will have provided important clues on 
genes that may have caused the bleeding problem. The present study will look for 
errors in these genes using techniques that have been developed to identify gene 
defects.   These studies require a small amount of blood that can be stored frozen for 
many years. 
 
Is it possible that the gene defect will not be identified? 
Yes. There is no guarantee that we will detect a change in either the platelet tests or 
in your gene. If we are unable to find a problem, we will tell you. If we fail to identify a 
problem, it does not mean you do not have a platelet or gene disorder – it is just that 
we have not been able to identify a problem with the techniques that we have used. 
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Are my family members likely to have the same gene defects and will they participate 
in the study? 
Your mother, father and other family members may have a bleeding problem caused 
by a defect in the same gene or genes.  Alternatively, your mother, father and other 
family members may have (or ‘carry’) one or more of the genes that is responsible for 
the bleeding problem, but may not have a bleeding problem.   
 
If we are able to identify one or more gene defects that cause your platelet problem, 
we may wish to investigate, with their consent, other members of your family to see if 
they have a problem with their platelets and whether they have a defect in the same 
gene or genes.  A separate information sheet is available for members of your family 
explaining these studies.  
Will my blood be analysed for gene defects other than those which could cause the 
bleeding problem? 
No.  We are only interested in identifying defects that could cause your bleeding 
problem and we will target our search for abnormal genes to those involved in the 
way that platelets work under normal circumstances. 
 
In patients with low platelet counts, we will need your consent to also look for 
mutations in the RUNX1 gene.  Mutations in this gene have been shown to cause low 
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platelet numbers and may also predispose to several types of leukemia.  You are 
free to decline your permission for this testing without compromising your 
participation in this study.  This testing will not be carried out in the other participants 
in this study. 
 
4. Why have I been chosen? 
You have been chosen due to one of the following factors: 
 
1. Your hospital doctor suspects that you have a problem with your platelets, but 
does not know the cause of the problem. 
 
2. You have been identified as a suitable “control” or healthy volunteer. 
 
5. Do I have to take part? 
It is up to you to decide whether or not to take part.  If you decide to take part you will 
be given this information sheet to keep and be asked to sign an agreement (or 
consent) form.  By signing the consent form you are saying that you are happy to 
take part in the study and that you understand what has been explained to you. 
If you choose not to take part, the clinical care you receive will not be affected 
in any way. 
 
6. What will happen to me if I take part? 
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If you agree to take part you will be asked some questions about your medical 
history including questions to complete a bleeding questionnaire. 
You will also be asked to give a sample of blood (between 10–50 ml, which is about 
the same volume as that of 2–10 teaspoonfuls).  The blood will usually be taken at a 
local Haematology Clinic at a time that is suitable for your yourself and the 
Haematology Clinic, ideally early in the day so that the analyses can be carried out 
on the same day. 
 
Depending on the results of the tests, we may ask you to give blood on up to 
three further occasions.  This is to enable us to carry out different types of tests on 
your platelets and therefore find out more information on the problem.  We will again 
ask for between 10–50 ml of blood, and this again can be taken either during a 
‘regular’ visit to the Haematology Clinic / surgery or through a specific appointment.   
There will be a minimum of one month between the dates that the blood is taken and 
no upper time limit on the gap between the donations. 
 
What will happen to my blood? 
Your blood samples will be sent to research laboratories in Birmingham, Bristol 
and/or Sheffield for analysis of your platelets. We will also keep a frozen sample for a 
maximum of 10 years, which may be used to look for gene defects that could cause 
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the platelet problem or changes in blood proteins that may increase your chance of 
bleeding.  The sample will be destroyed at this time, or earlier if you request.    
We may wish to keep the sample for this length of time in the event that we 
are unable to find a problem with your genes in our first set of investigations.  It is 
possible that, as we gain more knowledge, that we will wish to investigate the sample 
at later times to see if we can find a gene defect that may be the cause of the 
bleeding problem. 
 
Please note that a frozen sample will not be stored for “control” 
individuals. 
 
7. What are the possible disadvantages and risks of taking part? 
You may experience a little pain and bruising around the vein where the blood 
sample is taken from.  The needle used to take the blood will be identical to what has 
been used on you previously to take blood samples. 
 
8. What are the possible benefits of taking part? 
The study will generate important information on possible defects in your platelets 
and may also identify the genes that are responsible for the defects.   The 
identification of a defect in your platelets may influence your clinical treatment. 
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If a gene defect is found, it will be possible to investigate whether one or more 
members of your family have the same gene defect, should they wish. 
 You will not receive any money for taking part in this study. 
 
9. When will the study be completed? 
Recruitment of patients will end in February 2015.  Because we anticipate receiving 
many samples from throughout the UK, it may be many months before we can let 
you know if we have found a gene defect in your blood.  
The nature of the gene defect will not be identified in all patients. However, 
developments may take place over the next few years that will provide important, 
new information on the likely cause of platelet bleeding disorders.  We will therefore 
continue to follow developments in the field and, if appropriate, use this information to 
direct our efforts to identify the defective gene(s) in your frozen blood sample, which 
will be kept frozen for up to ten years, unless you ask for it to be destroyed.  We will 
contact you as soon as we have identified a genetic defect in the sample. 
 
10. Will my taking part in this study be kept confidential? 
Yes.  All information which is collected about you during the course of the research 
will be kept strictly confidential. 
 
11. What will happen if I don’t want to carry on with the study? 
 252 
 
If you decide that you do not want to be in the study at any time after you have had 
your blood sample taken, you can ask for us to destroy your stored sample. 
 
12. Further information on genetic testing 
If we find a genetic defect related to bleeding, we will let you know of this.  You will 
have the right to choose not to access this information.   We may refer you for 
retesting by genetic services outside of this study for confirmation of the gene 
analysis. 
We will discuss the full implications of the genetic studies with you with regard 
to your own children, having children in the future, insurance status and available 
counselling, as appropriate.  Stored samples will not be used for other genetic 
studies without additional consent and presentation to an ethics committee for 
consideration.   
 
13.  Further tests that may be undertaken on your blood sample 
In some circumstances, we will pursue more detailed testing of your blood samples.  
The types of detailed tests include, for example, using the stem cells from your blood 
sample to look at platelet production or examining the proteins in your platelets.  Only 
tests for which permission has been formally granted to the Birmingham Platelet 
Group from the Research Ethics Committee (REC) will be performed.  The purpose 
of the REC is to protect the rights, safety, dignity and well-being of research 
 253 
 
participants, and to facilitate and promote ethical research that is of potential benefit 
to participants, science and society. 
 
14. Contact for further information 
Further information about this study can be obtained by contacting one of our group 
on telephone number 0121 415 8680.  You will be able to leave a message if there is 
no-one in the office and we will get back to you.  The members of the group are Mrs 
Gayle Halford (general enquires), Dr Marie Lordkipanidzé, Dr Gillian Lowe and Ms 
Rachael Taylor. 
The study co-ordinator is a British Heart Foundation Professor, Stephen 
Watson (Centre for Cardiovascular Sciences, School of Clinical and Experimental 
Medicine, Institute of Biomedical Research, College of Medical and Dental Sciences, 
Wolfson Drive, University of Birmingham, Edgbaston, Birmingham, B15 2TT). 
 
This completes Part 1 of the information sheet.  If the information in Part 1 has 
interested you and you are considering participation, please continue to read the 
additional information in Part 2 before making any decisions. 
 
PART 2 
 
15. Who is funding this study? 
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The work is supported by the British Heart Foundation Research Charity. 
 
16. Will I get paid for taking part? 
You will not be paid for taking part. 
  
17. Who has reviewed this study? 
This study has been reviewed and approved by the West Midlands Multi-Centre 
Research Ethics Committee and by the Local Research Ethics Committee for your 
hospital.   
 
18. What if something goes wrong? 
If you are hurt by taking part in this research project, there are no special 
compensation arrangements.   
If you are harmed due to someone’s negligence, then you may have grounds 
for a legal action but you may have to pay for it.  Regardless of this, if you wish to 
complain, or have any concerns about any aspect of the way you have been 
approached or treated during the course of this study, the normal National Health 
Service complaints mechanisms should be available to you.  At present this would be 
via PALS (Patient Advice and Liaison Service) at your local hospital, or 
www.pals.nhs.uk 
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19. What will happen to the results of this study? 
Your results will be passed on to your haematology doctor who will be asked to give 
them to you and to answer any questions you may have.   
The collective results from all of the patients in the study may be presented in 
a scientific report to help other doctors who are treating patients with these bleeding 
disorders.  No patient names will be used and it will not be possible to identify you 
from any report of the results of the study. 
 
20. What if I wish to complain about the way in which the study has been 
conducted? 
If you have any cause to complain about any aspect of the way in which you have 
been approached or treated during the course of the study, the normal National 
Health Service complaints mechanisms are available to you and are not 
compromised in any way because you have taken part in a research study.  
Complaints should be dealt with by an independent body such as PALS.   To use the 
normal hospital complaints procedure, you should contact the PALS officer at your 
hospital or get more information at www.pals.nhs.uk 
 
 
Thank you very much for reading through this information sheet. 
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INFORMED CONSENT FORM 
7.2. PATIENT / FAMILY MEMBER 
 
Thank you for reading the information about our research project.  If you would like to take 
part, please read and sign this form. 
 
Patient Identification Code for this study: 
 
Title of Project:  Mild bleeding disorders caused by platelet defects 
 
Contact details for research team:  
 
Your referring doctor / research nurse      ……………………………………………….. 
 
or 
 
 257 
 
The study team: Mrs Gayle Halford (general enquiries), Dr Marie Lordkipanidzé and Dr 
Gillian Lowe  
 
Birmingham Platelet Group, Institute for Biomedical Research, School of Clinical and 
Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, 
Birmingham B15 2TT,  0121 415 8680.  Please leave a message if no-one is in the office 
and we will get back to you. 
 
Please initial all boxes 
 
1.  I have read the attached information sheet on this project, and have been given a copy to keep.  I 
have been able to ask questions about the project and I understand why the research is being done 
and any risks involved. 
 
 
2.  I agree to give a sample of blood for research in this project.  I understand how the sample will be 
collected, that giving a sample for this research is voluntary and that I am free to withdraw my approval 
for the use of the sample at any time without giving a reason and without my medical treatment or 
legal rights being affected. 
 
 
3.  I give permission for someone from the local research team to look at my medical records to get 
information on my bleeding history.  I understand that the information will be kept confidential. 
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4.  I agree to answering some questions about my medical history including those needed to complete 
a bleeding assessment by questionnaire. 
 
 
5.  I understand that my referring doctor and I will be informed if any of the results of the medical tests 
done as a part of the research are important for my health. 
 
 
6.  I understand that I will not benefit financially if this research leads to the development of a new 
treatment or medical test. 
 
 
7.  I know how to contact the research team if I need to, and how to get information about the results 
of the research. 
 
 
8.  Consent for storage of sample  
I agree that the sample I have given and the information gathered about me can be stored in the 
Medical Schools of the Universities of Birmingham, Bristol and Sheffield for the purpose of analysing 
platelets, bleeding tendency and detection of the gene change responsible for the platelet disorder in 
myself or a family member, for a maximum of 10 years, after which it will be destroyed.   
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If I wish I may request the return of the sample after analysis has been completed. 
 
 
9.    Consent for genetic research.  
I give permission for genetic analysis to be carried out on the sample I give, as part of this project.  I 
have received written information about this test and I understand what the result could mean to me 
and/or members of my family.  
 
 
10.    Consent for stem cell studies 
I give permission for the stem cells in my blood sample to be used to understand how my platelets are 
produced. 
          YES 
          NO 
 
11.    Consent for RUNX1 mutation testing (ONLY FOR PARTICIPANTS WITH LOW PLATELET 
COUNTS).  
I give permission for genetic analysis to be carried out on the sample I give to specifically look at the 
RUNX1 gene.  I understand that this mutation is associated with low platelet counts and can in some 
cases predispose to certain types of leukemia.  
          YES 
          NO 
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12.   I want to be told the results of the tests undertaken in this study.  I understand I can change my 
mind about this later. 
          YES 
          NO 
 
 
 
………………………………………… ……………………… …………………………………… 
Name of patient     Date   Signature 
(BLOCK CAPITALS) 
 
 
……………………………………….  …………………… …………………………………… 
Name of person taking consent   Date   Signature 
(if different from researcher) 
 
 
……………………………………..  …………………… …………………………………. 
Name of researcher    Date   Signature 
 
 
 
 261 
 
 
Thank you for agreeing to participate in this research  
1 copy for patient, 1 for hospital notes, 1 for researcher 
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8. 11. Annexe 1: ISTH/SSC Bleeding Assessment Tool 
 
The clinical appreciation of the presence and severity of bleeding symptoms is a 
fundamental step in the evaluation of patients referred for a possible bleeding 
disorder.  In an attempt to improve the collection and reproducibility of the bleeding 
history, several Bleeding Assessment Tools (BAT) have been proposed and used.  
Currently available BAT have some limitations, particularly regarding the lack of 
pediatric-specific symptoms in some of them and the predominance of the severity of 
bleeding symptoms over other potentially clinically important features, such as the 
frequency of symptoms. 
 
To overcome the above-mentioned limitations and to promote the standardization of 
the available BATs, a Working Group was established within the framework of the 
ISTH/SSC Subcommittees on VWF and on Perinatal/Pediatric Hemostasis 
(ISTH/SSC-BAT) during the 53rd SSC Annual Meeting held in Geneva in 2007. 
Members of the group first met in Toronto on January 2008 and then regularly at 
each subsequent SSC meeting. This paper presents a structured questionnaire and 
its clinical use agreed on by the ISTH/SSC-BAT together with a proposal for a new 
BS system to undergo validity and reliability testing in future studies.This new BAT is 
intended for inherited bleeding disorders in children and adults. The questionnaire 
should be collected by a physician or another adequately trained health-professional. 
Only symptoms and related treatments, if any, before and/or at diagnosis should be 
reported. Refer to the full text for additional instructions (Rodeghiero, Tosetto et al. 
2010). 
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Minimal criteria defining a significant bleeding 
For each specific bleeding symptom, the ISTH/SSC joint working group proposed 
minimal criteria in order to classify a symptom as significant and thus receive a score 
of 1 or more (see also Table 1): 
 
1. Epistaxis: Any nosebleed, especially occuring after puberty, that causes patient 
concern (e.g., interference or distress with daily or social activities) is considered 
significant. In general, epistaxis should not be considered significant when it lasts 
less than 10 minutes, has a frequency of < 5 episodes/year, has a seasonal 
occurence, or is associated with infections of the upper respiratory tract or other 
identifiable cause (e.g., dusty dry air). 
 
2. Cutaneous bleeding: Bruises are considered significant when 5 or more (> 1cm) in 
exposed areas; petechiae when adequately described by the patient or relatives; or 
hematomas when occurring without trauma. 
 
3. Minor cutaneous wound: Any bleeding episode caused by superficial cuts (e.g., by 
shaving razor, knife, or scissors) or that requires frequent bandage changes is 
considered significant. Insignificant bleeding from wounds includes those of duration 
< 10 minutes and lesions that usually require stitches in normal subjects (e.g., under 
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the chin). Symptoms should also be manifest on more than one occasion to be 
considered significant. 
 
4. Oral cavity bleeding: Gum bleeding should be considered significant when it 
causes frankly bloody sputum and lasts for 10 minutes or longer on more than one 
occasion. Tooth eruption or spontaneous tooth loss bleeding should be considered 
significant when it requires assistance or supervision by a physician, or lasts at least 
10 minutes (bleeding associated with tooth extraction is considered separately). 
Bleeding occurring after bites to lips, cheek, and tongue should be considered 
significant when it lasts at least 10 minutes or causes a swollen tongue or mouth. 
 
5. Hematemesis, melena, and hematochezia: Any gastrointestinal bleeding that is 
not explained by the presence of a specific disease should be considered significant. 
 
6. Hematuria: Only macroscopic hematuria (from red to pale-pink urine) that is not 
explained by the presence of a specific urologic disease should be considered 
significant. 
 
7. Tooth extraction: Any bleeding occurring after leaving the dentist’s office and 
requiring a new, unscheduled visit or prolonged bleeding at the dentist’s office 
causing a delay in the procedure or discharge should be considered significant. 
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8. Surgical bleeding: Any bleeding judged by the surgeon to be abnormally 
prolonged, that causes a delay in discharge, or requires some supportive treatment 
is considered significant. 
 
9. Menorrhagia: Any bleeding that interferes with daily activities such as work, 
housework, exercise or social activities during most menstrual periods should be 
considered significant. Criteria for significant bleeding may include any of the 
following: changing pads more frequently than every 2 hours; menstrual bleeding 
lasting 7 or more days; and the presence of clots > 1 cm combined with a history of 
flooding. If a patient has previously made a record of her menstrual loss using a 
pictorial blood loss assessment chart (PBAC), a PBAC score higher than 100 also 
qualifies for a score of 1. 
 
10. Post-partum bleeding. Vaginal bleeding or uterine discharge (lochia) that lasts for 
more than 6 weeks. Any bleeding of lesser duration that is judged by the obstetrician 
as abnormally heavy or prolonged, that causes a delay in discharge, requires some 
supportive treatment, requires changing pads or tampons more frequently than every 
2 hours, or causes progressive anemia is also considered significant. 
 
11. Muscle hematomas or hemarthrosis. Any spontaneous joint / muscle bleeding 
(not related to traumatic injuries) is considered significant. 
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12. CNS bleeding. Any subdural or intracerebral hemorrhage requiring diagnostic or 
therapeutic intervention is scored 3 or 4, respectively. 
 
13. Other bleeding symptoms. When these bleeding symptoms occur during infancy, 
they are scored 1 or more. Their presence when reported by either the patient or a 
family member should always prompt detailed laboratory investigation. 
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Only symptoms and treatment BEFORE and AT diagnosis should be considered  
1. Epistaxis 
 
  
  
 
 
1.1 Have you ever had spontaneous 
epistaxis? 
  Yes  No or trivial (skip to 2)  
1.2 Have the symptom ever required 
medical attention ? 
  Yes   No (resolve 
spontaneously; skip to 
1.6) 
 
 
 
1.3 
 
 
     
 
  
If answer to 1.2 is yes, please 
specify 
  Consultation only 
 
 
  Cauterization/ Packing 
 
  Treatment with desmopressin / antifibrinolytics/ iron 
therapy 
 
  Treatment  with plasma, platelet or factor 
concentrates 
      
  Blood (RBC) transfusion 
 
1.4      How many times in your life did 
you receive any of the above 
treatments (# 1.3)? 
  1 - 2 
 3 to 5 
 6 to 10  
 more than 10 
 
1.5      At what age did you first have 
symptoms? 
 
 Before 1 year 
 Between 1-5 years of age 
 Between 6-12 years of age 
 Between 13-25 years of age 
 After 25 years of age 
    
 
1.6     Approximate number of episodes 
NOT requiring medical attention  
  less than 1 per year 
 1 per year 
 1-5 every six month 
 1-3 every month 
 1 every week 
 
 
1.7     Duration of average single 
episode (min.) NOT requiring 
medical attention 
  1 minute or less 
 1 - 10 minutes 
 more than 10 minutes 
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2. Cutaneous bleeding (Bruising, ecchymoses, purpura, subcutanueos hematomas) 
  
 
 
2.1 Have you ever had any of the above 
cutaneous bleeding? 
  Yes  No or trivial skip to 3  
2.2 Have the symptom ever required 
medical attention? 
  Yes No   skip to 2.6 
 
 
2.3 
 
 
  
If answer to 2.2 is yes, please 
specify 
  Consultation only 
 
 
 
 Treatment with desmopressin 
 
  Treatment  with plasma, platelets or factor 
concentrates 
      
 
 Blood (RBC) transfusion 
2
2.4 
     How many times in your life did 
you receive any of the above 
treatments (# 2.3)? 
  1 - 2 
 3 to 5 
 6 to 10  
 more than 10 
 
2.5      At what age did you first have 
symptoms?  
 
 Before 1 year 
 Between 1-5 years of age 
 Between 6-12 years of age 
 Between 13-25 years of age 
 After 25 years of age 
 
2.6     Approximate number of episodes 
NOT requiring medical attention  
  less than 1 per year 
 1 per year 
 1-5 every six month 
 1-3 every month 
 1 every week 
 
2.7     Type of bleeding   Petechiae 
 Bruises  
 Hematomas 
 
2.8     Location    Exposed sites 
 Unexposed sites 
 Both 
 
2.9     Common size    ≤ 1 cm  
 >1 cm 
 Extensive (palm sized or 
larger) 
 
 
2.10      How many bruises >1 cm in 
exposed areas in the most severe 
manifestation? 
  ≤ 5 
 > 5 
 
2.11      Location of petechiae   Limited to lower limbs 
 Diffuse 
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3. Bleeding from minor wounds (not requiring stitches in the average patient) 
  
 
 
3.1 Have you ever had prolonged  
bleeding from minor wounds? 
  Yes  No or trivial skip to 4 
3.2 Have the symptom ever required 
medical attention ? 
  Yes   No skip to 3.6 
 
 
 
3.3 
   
 
 
If answer to 3.2 is yes, please 
specify 
  Consultation only  
 
 
 Surgical hemostasis 
 
 
 Treatment with desmopressin 
      
  Treatment  with plasma, platelet or factor 
concentrates 
 
 
 Blood (RBC) transfusion 
3.4      How many times in your life did 
you received any of the above 
treatments (# 3.3)? 
  1 - 2 
 3 to 5 
 6 to 10  
 more than 10 
 
3.5      At what age did you first have 
symptoms? 
 
 Before 1 year 
 Between 1-5 years of age 
 Between 6-12 years of age 
 Between 13-25 years of age 
 After 25 years of age 
    
 
3.6     Approximate number of episodes 
NOT requiring medical attention  
  less than 1 per year 
 1 per year 
 1-5 every six month 
 1-3 every month 
 1 every week 
 
 
3.7     Duration of average single 
episode (min.) 
  1 to 10 minutes 
 more than 10 minutes 
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4. Hematuria 
  
 
 
4.1 Have you ever had hematuria ?   Yes  No skip to 5 
4.2 If answer to 4.1 is yes, please 
specify   
   
    Presence of associated 
urologic disease 
 
 
Yes   (skip to 5) 
Specify: 
 Stones 
 Infection 
 Kidney/ bladder 
   disease 
 
No  
Please answer the following questions only for SPONTANEOUS symptoms (answer No to 4.1) 
4.3 Have the symptom ever required 
medical attention ? 
 Yes  No   skip to 4.7 
 
 
4.4 
 
 
 
 
 
If answer to 4.3 is yes, please 
specify 
 
 Consultation only  
 
 
 Surgery 
 
 
 Treatment with desmopressin 
      
  Treatment  with plasma, platelet or factor 
concentrates 
 
 
 Blood (RBC) transfusion 
4.5      How many times in your life did 
you received any of the above 
treatments (# 4.4)? 
  1 - 2 
 3 to 5 
 6 to 10  
 more than 10 
 
4.6 At what age did you first have 
symptoms? 
 
 Before 1 year 
 Between 1-5 years of age 
 Between 6-12 years of age 
 Between 13-25 years of age 
 After 25 years of age 
    
 
4.7     Approximate number of episodes 
NOT requiring medical attention  
  less than 1 per year 
 1 per year 
 1-5 every six month 
 1-3 every month 
 1 every week 
 
 
 
 273 
 
  
 274 
 
5. Gastrointestinal  bleeding (Hematemesis, Melena, Hematochezia) 
  
 
 
5.1 Have you ever had gastrointestinal  
bleeding ? 
  Yes  No skip to 6 
5.2 If answer to 5.1 is yes, please 
specify   
 
  
    Type of bleeding 
 
 Hematemesis 
 Melena 
 Hematochezia 
 
 
    Presence of associated 
GI disease 
 
 
Yes  
Specify: 
 Ulcer 
 Portal hypertension 
 Angiodysplasia 
No  
Please answer to the following questions only for SPONTANEOUS symptoms 
5.3 Have the symptom ever required 
medical attention ? 
 Yes  No   skip to 5.7 
5.4 If answer to 5.3 is yes, please 
specify 
 
 Consultation only 
 
 
 
 
 Surgical haemostasis  
 
 
 Treatment with desmopressin 
 
  Treatment  with plasma, platelet or factor 
concentrates 
      
 
 Blood (RBC) transfusion 
5.5 How many times in your life did 
you received any of the above 
treatments (# 5.4)? 
  1 - 2 
 3 to 5 
 6 to 10  
 more than 10 
 
5.6  At what age did you first have 
symptoms? 
 
 Before 1 year 
 Between 1-5 years of age 
 Between 6-12 years of age 
 Between 13-25 years of age 
 After 25 years of age 
    
 
5.7  Approximate number of episodes 
NOT requiring medical attention  
  less than 1 per year 
 1 per year 
 1-5 every six month 
 1-3 every month 
 1 every week 
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6. Oral cavity bleeding (Tooth eruption, spontaneous or after brushing/flossing, gum bleeding, 
bleeding after bites to lip & tongue) 
  
 
 
6.1 Have you ever had oral cavity 
bleeding ? 
  Yes  No or trivial skip to 7 
6.2 Have the symptom ever required 
medical attention ? 
 Yes  No   skip to 6.6 
6.3 If answer to 6.2 is yes, please 
specify 
 
 Consultation only  
 
 
 Surgery (dental packing, suture, cauterization) 
 
 
 Treatment with desmopressin / iron therapy 
 
  Treatment  with plasma, platelet or factor 
concentrates 
 
 
 Blood (RBC) transfusion 
6.4      How many times in your life did 
you received any of the above 
treatments (# 6.3)? 
  1 - 2 
 3 to 5 
 6 to 10  
 more than 10 
 
6.5      At what age did you first have 
symptoms? 
 
 Before 1 year 
 Between 1-5 years of age 
 Between 6-12 years of age 
 Between 13-25 years of age 
 After 25 years of age 
    
 
6.6     Approximate number of episodes 
NOT requiring medical attention  
  less than 1 per year 
 1 per year 
 1-5 every six month 
 1-3 every month 
 1 every week 
 
 
6.7     Duration of average single 
episode (min.) 
  1 to 10 minutes 
 more than 10 minutes 
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7. Bleeding after Tooth/ Teeth extraction 
  
 
 
7.1 Have you ever had bleeding after 
tooth (teeth) extraction ? 
  Yes  No skip to 8 
7.2 If answer to 7.1 is yes, please 
specify 
 
  Number of extractions 
  
 
 
     
Please fill in one of the following forms  for each tooth extraction 
 
 
 
Age at extraction  Type of extraction  Deciduous 
 Permanent 
 Molar 
Actions taken to prevent 
bleeding 
  None 
 Antifibrinolytics 
 Desmopressin 
 Plasma or clotting factor concentrates 
 Platelet infusion 
 
Bleeding after extraction?  Yes  No  
Actions taken to control 
bleeding 
  Resuturing 
 Packing  
 Antifibrinolytics 
 Desmopressin 
 Plasma or clotting factor concentrates 
 Platelet infusion 
 Blood (RBC) transfusion 
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8. Bleeding after Surgery  or Major Trauma 
  
 
 
8.1 Have you ever had bleeding after 
surgery or major trauma ? 
  Yes  No, skip to 9 
8.2 If answer to 8.1 is yes, please 
specify 
 
  Number of interventions 
  
 
 
     
Please fill in one of the following forms for each surgery  or major trauma episode 
 
 
 
Age at  intervention/trauma  Type of surgery 
 
 Tonsillectomy/Adenoids 
 Pharynx/Nose 
 Major-abdominal 
 Major-thoracic 
 Major-gynecology 
 Other 
Actions taken to prevent 
bleeding 
  None 
 Antifibrinolytics 
 Desmopressin 
 Plasma or clotting factor concentrates 
 Platelet infusion 
 
Bleeding after intervention?  Yes  No  
Actions taken to control 
bleeding 
  None 
 Resuturing 
 Packing  
 Antifibrinolytics 
 Desmopressin 
 Plasma or clotting factor concentrates 
 Platelet infusion 
 Blood (RBC) transfusion   
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9. Menorrhagia 
  
 
 
9.1 Have you ever had very heavy 
menstrual bleeding (menorrhagia)? 
  Yes  No or trivial skip to 10 
     If answer to 9.1 is yes, please 
     specify 
  Changing pads/tampons more frequently than 
every 2 hours 
    Bleeding more than 7 days  
   
 Clot and flooding 
   
Impairment of daily 
activities (work, 
housework, exercise, 
social activities): 
      Never or rarely 
      Most menses 
9.2 Have the symptom ever required 
medical attention ? 
  Yes  No   skip to 9.6 
9.3 If answer to 9.2 is yes, please 
specify 
a  Consultation only  
 b  Pictorial Bleeding 
       Assessment 
Score ___________ 
 c  Antifibrinolytic therapy 
 d  Iron therapy 
 e  Hormonal therapy 
 f  Combined antifibrinolytics & Hormonal therapy 
 g  Hysterectomy / endometrial ablation / D & C 
 h  Treatment with desmopressin, plasma or factor 
concentrates, platelet transfusion  
  i  Blood (RBC) transfusion 
  l  Hospital admission and emergency treatment  
9.4      How many times in your life did 
you received any of the above 
treatments (# 9.3 a-l)? 
 
 1 - 2 
 3 to 5 
 6 to 10  
 more than 10 
 
9.5      At what age did you first have 
symptoms? 
  At menarche  
 Between 14-25 years of age 
 After  25 years of age 
9.6      Have you had time off 
work/school for menorrhagia? 
 
 < twice a year 
 > twice a year 
 
9.7      Duration of menorrhagia  
  Since menarche  
 > 12 months  
 < 12 months  
 
9.8      Have you had acute menorrhagia 
requiring emergency 
treatment/hospital admission 
 
 Yes    
How many times:  ____ 
 No 
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10. Post-partum hemorrhage 
  
 
 
10.1 Number of successful pregnancies 
(live births) 
  
 
10.2 Have you ever had post-partum 
haemorrhage? 
  Yes  No or trivial skip to 11 
10.3 Did it occur   In the first 24 hours after delivery (Primary) 
   
 Between 24 hours and 6 weeks postpartum 
(Secondary) 
    Both Primary and Secondary  
10.4 How long did vaginal discharge 
(lochia) last? 
  < 6 weeks 
 > 6 weeks 
 
10.5 Did it require changing 
pads/tampons  more frequently 
than every 2 hours? 
  Yes   No 
10.6 Did this bleeding cause delay of 
hospital discharge/ readmission to 
hospital? 
  Yes   No 
10.7 Have the symptom ever required 
medical treatment? 
  Yes   No 
10.8 If answer to 10.7 is yes, please 
specify 
 
 Consultation only /oxytocin i.v. infusion 
   Additional uterotonic medications 
 
 
 Iron therapy 
 
 
 Antifibrinolytic therapy 
 
 
 Treatment with plasma or factor concentrates, 
platelet transfusion 
        Blood (RBC) transfusion 
 
 
 
 
 Any procedure requiring examination under 
anaesthesia 
 Uterine balloon/package to tamponade the 
uterus  
 Any procedure requiring critical care or surgical 
intervention (includes: hysterectomy, internal iliac 
artery legation, uterine artery embolization, uterine 
brace  sutures) 
10.9      Number of deliveries that 
required any of the above 
treatments (# 10.8)? 
  
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11. Muscle hematomas or hemarthrosis (spontaneous) 
  
 
 
11.1 Have you ever had muscle 
hematomas or hemarthrosis ? 
 
 Yes  No or trivial skip to 12  
11.2 Have the symptom ever required 
medical attention ? 
  Yes   No skip to 11.6 
11.3 If answer to 11.2 is yes, please 
specify 
  Consultation only  
 
 
 Surgical draining  
 
 
 Treatment with desmopressin 
 
  Treatment  with plasma, platelet or factor 
concentrates 
 
 
 Blood transfusion 
11.4      How many times in your life did 
you receive any of the above 
treatments (# 11.3)? 
  1 - 2 
 3 to 5 
 6 to 10  
 more than 10 
 
11.5      At what age did you first have 
symptoms? 
 
 Before 1 year 
 Between 1-5 years of age 
 Between 6-12 years of age 
 Between 13-25 years of age 
 After 25 years of age 
    
 
11.6 Approximate number of episodes 
NOT requiring medical attention  
  less than 1 per year 
 1 per year 
 1-5 every six month 
 1-3 every month 
 1 every week 
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12 Other bleedings 
  
 
 
12.1 Have you ever had one of the following?  
 Excessive umbilical stump bleeding   Yes  No  
 Cephalohematoma   Yes  No  
 Bleeding at circumcision   Yes  No  
 Venipuncture bleeding   Yes  No  
 Suction Bleeding    Yes  No  
 Ovulation bleeding(in women)    Yes  No 
12.2 Have one of these symptoms ever 
required medical attention? 
  Yes   No  
12.3 If answer to 12.2 is yes, please 
specify 
 
 Consultation only  
 
 
 Surgery  
 
 
 Treatment with desmopressin 
 
  Treatment  with plasma, platelet or factor 
concentrates 
 
 
 Blood (RBC) transfusion 
12.4      How many times in your life did 
you receive any of the above 
treatments (# 12.3) for this 
symptom? 
  1 - 2 
 3 to 5 
 6 to 10  
 more than 10 
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Table 1. Bleeding score 
SYMPTOMS 
(up to the time of 
diagnosis) 
8.1.1.1.1. SCORE 
8.1.1.2.  
 0
§
 1
§
 2 3 4 
EPISTAXIS  No/trivial  - > 5/year 
or 
- more than 10 
minutes 
CONSULTATION 
ONLY* 
Packing or cauterization or 
antifibrinolytic 
Blood transfusion or replacement 
therapy (use of hemostatic blood 
components and rFVIIa)  or 
desmopressin 
      
Cutaneous  No/trivial For bruises 5 or 
more (> 1cm) in 
exposed areas  
 
Consultation only* Extensive  Spontaneous hematoma requiring 
blood transfusion  
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Bleeding from minor 
wounds 
 No/trivial  - > 5/year  
or 
- more than 10 
minutes 
CONSULTATION 
ONLY* 
Surgical hemostasis Blood transfusion, replacement 
therapy, or desmopressin 
      
Oral cavity  No/trivial Present CONSULTATION 
ONLY* 
Surgical hemostasis or 
antifibrinolytic 
Blood transfusion, replacement 
therapy or desmopressin 
      
GI bleeding  No/trivial Present (not 
associated with 
ulcer, portal 
hypertension, 
hemorrhoids, 
angiodysplasia) 
Consultation only* Surgical hemostasis, 
antifibrinolytic 
Blood transfusion, replacement 
therapy or desmopressin 
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Hematuria  No/trivial Present 
(macroscopic) 
CONSULTATION 
ONLY* 
Surgical hemostasis,  
iron therapy 
Blood transfusion, replacement 
therapy or desmopressin 
      
Tooth extraction  No/trivial or 
none  done  
Reported in <25% 
of all procedures, no 
intervention** 
REPORTED IN 
>25% OF ALL 
PROCEDURES, 
NO 
INTERVENTION*
* 
Resuturing or packing Blood transfusion, replacement 
therapy or desmopressin 
      
Surgery  No/trivial or 
none done 
Reported in <25% 
of all procedures, no 
intervention** 
REPORTED IN 
>25% OF ALL 
PROCEDURES, 
NO 
INTERVENTION*
* 
Surgical hemostasis or 
antifibrinolytic 
Blood transfusion, replacement 
therapy or desmopressin 
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Menorrhagia  No/trivial Consultation only* 
or 
- Changing pads 
more frequently 
than every 2 hours 
or  
- Clot and flooding 
or 
- PBAC score>100
#
 
 
- TIME OFF 
WORK/SCHOOL 
> 2/YEAR OR 
- REQUIRING 
ANTIFIBRINOLY
TICS OR 
HORMONAL OR 
IRON THERAPY 
- Requiring combined 
treatment with 
antifibrinolytics and hormonal 
therapy 
or 
- Present since menarche 
and > 12 months 
- Acute menorrhagia requiring 
hospital admission and 
emergency treatment  
or 
- Requiring blood transfusion, 
Replacement therapy, 
Desmopressin,  
or 
- Requiring dilatation & curretage 
or endometrial ablation or 
hysterectomy) 
      
Post-partum 
hemorrhage 
 No/trivial or 
no deliveries  
Consultation only* 
or 
 - Use of syntocin 
or 
- Lochia > 6 weeks 
 - Iron therapy 
or 
- Antifibrinolytics 
- Requiring blood transfusion, 
replacement therapy, 
desmopressin 
or 
- Requiring examination 
- Any procedure requiring critical 
care or surgical intervention (e.g. 
hysterectomy, internal iliac artery 
legation, uterine artery 
embolization, uterine brace  
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under anaesthesia and/or the 
use of uterin balloon/package 
to tamponade the uterus 
sutures)  
 
 
 
    
Muscle hematomas  
Never Post trauma, no 
therapy 
SPONTANEOUS
, NO THERAPY  
Spontaneous or traumatic, 
requiring desmopressin or 
replacement therapy  
Spontaneous or traumatic, 
requiring surgical intervention or 
blood transfusion 
 
 
    
Hemarthrosis  
Never Post trauma, no 
therapy 
SPONTANEOUS
, NO THERAPY 
Spontaneous or traumatic, 
requiring desmopressin or 
replacement therapy 
Spontaneous or traumatic, 
requiring surgical intervention or 
blood transfusion 
 
     
CNS bleeding  
Never - - Subdural, any intervention Intracerebral, any intervention 
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Other bleedings^  
No/trivial Present 
 
CONSULTATION 
ONLY* 
Surgical hemostasis, 
antifibrinolytics 
Blood transfusion or replacement 
therapy or desmopressin 
 
  
   
 
In addition to the guidance offered by the table, it is mandatory to refer to the text for more detailed instructions. 
§ 
Distinction between 0 and 1 is of critical importance. Score 1 means that the symptom is judged as present in the patient’s history by the interviewer 
but does not qualify for a score 2 or more 
* Consultation only: the patient sought medical evaluation and was either referred to a specialist or offered detailed laboratory investigation  
** Example: 1 extraction/surgery resulting in bleeding (100%): the score to be assigned is 2; 2 extractions/surgeries, 1 resulting in bleeding (50%): the 
score to be assigned is 2; 3 extractions/surgeries, 1 resulting in bleeding (33%): the score to be assigned is 2; 4 extractions/surgeries, 1 resulting in 
bleeding (25%): the score to be assigned is 1 
#
 If already available at the time of collection  
^ Include: umbilical stump bleeding, cephalohematoma, cheek hematoma caused by sucking during breast/bottle feeding, conjunctival hemorrhage or 
excessive bleeding following circumcision or venipuncture. Their presence in infancy requires detailed investigation independently from the overall 
score  
 
 
